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Natural products (NPs) are compounds isolated from any living organisms and continue to 
be a rich source of medicines, especially chemotherapeutics. In order to develop new anticancer 
compounds, this work aimed to synthesize two NPs, reniochalistatin E and lagunamide C, shown 
below. Reniochalistatin E is a cyclic octapeptide with anticancer activity in a variety of cancer cell 
lines; including, myeloma (RPMI-8226: IC50 = 4.9 µM), gastric (MGC-803: IC50 = 9.7 µM), and 
cervical (HeLa: IC50 = 24.4 µM). To this end, the first total synthesis of reniochalistatin E has been 
completed in 15 steps with an overall 5% yield. Analog synthesis and biological testing identified 
the tryptophan amino acid (shown in red) as a site for drug conjugation. Future work will harness 
the synthetic route to generate a cysteine analog in order to conjugate the FDA approved 
chemotherapeutic, 6-thiopurine (6TP), though a disulfide linkage. Lagunamide C is a cyclic 
depsipeptide with potent cytotoxic activity in a number of cell lines including lymphoma (P388: 
IC50 = 24.4 nM), lung (A549: IC50 = 2.4 nM), colon (PC3: IC50 = 2.1 nM), and ovarian (SK-OV3: 
IC50 = 4.5 nM). This work highlights a module-based approach to access the diastereoselective 
polyketide fragment (shown in blue). Key stereogenic steps include an aldol reaction with an N-
acetylated Crimmins auxiliary, an asymmetric cyclopropanation with tandem ring-opening, and 
an iridium catalyzed allylation. Future 
work will look to complete the first total 
synthesis of lagunamide C and identify 
the importance of each subunit of the NP 
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Chapter 1: History of Medicinal Natural Products 
1.1 Cancer, Treatments, and Chemotherapeutics  
1.1.1 Cancer Types 
Cancer is defined as unregulated cell growth leading to the development of tumors, which 
if untreated, can spread throughout the body in a process called metathesis. With 1.9 million new 
cases and nearly 10 million deaths in 2020, cancer remains the second leading cause of death in 
the United States (US) following only heart disease.1 There are over 100 different types of cancers 
based on organ system including, but not limited to; eye & orbit, bones & joints, endocrine system, 
soft tissue (including heart), oral cavity and pharynx, skin (excluding basal & squamous), 
myeloma, brain and other nervous system, lymphoma, leukemia, urinary system, breast, genital 
system, respiratory system, and digestive system.2 Shown in Table 1 are the new cases and deaths 
for a collection of cancer types in the US for 2020.3 Each of these classes provide unique challenges 
with respect to diagnosis, treatment, and recovery; however, early identification is critical for 
remission regardless of the cancer type.  
Table 1: New cases of cancer and deaths in the US for 2020. 
Cancer Site # of New Cases % of all Cases # of Deaths % of Total Deaths
Breast 253,465 11% 42,617 7%
Lung 227,875 10% 138,225 23%
Prostate 209,512 9% 32,438 5%
Colon 101,809 4% 37,930 6%
Melanoma of skin 96,445 4% 7,201 1%
Bladder 80,617 4% 18,130 3%
Kidney 69,569 3% 14,589 2%
﻿Leukemia 61,152 3% 23,753 4%
Pancreas 56,654 2% 47,683 8%
Thyroid 52,912 2% 2,161 0%
Liver 42,284 2% 31,078 5%
Stomach 26,259 1% 11,413 2%
Brain, central nervous system 24,538 1% 18,133 3%
Lip, oral cavity 24,470 1% 4,285 1%
Ovary 23,820 1% 14,359 2%
Oesophagus 18,309 1% 16,209 3%
Total 2,281,658      612,390     
New Cancer Cases and Deaths by Class in the US for 2020
2 
1.1.2 Cancer Stages and Survival 
A cancer diagnosis is assigned a stage that indicates the severity and progression of the 
disease. The stage of the cancer is used to determine optimal treatment options and survival 
likelihood. Table 2 shows the 5-year survival rate for a collection of tumorous cancer types based 
on the location in the body which can be local, regional, or distant.4 Local is an invasive growing 
cancer that is confined to the original organ.2 Regional cancers are known to invade surrounding 
tissue and can also affect the nearby lymph nodes. Distant cancers have spread to remote parts of 
the body away from the primary tumor site either by direct extension or via metathesis. The stage 
of the cancer is determined by a variety of tests depending on the type and location; but include 
physical examination and tests such as mammography, X-rays, MRI, CT scan, PET scans, 
ultrasound, endoscopy, colonoscopy, blood tests, and biopsy. The general trend of the data in Table 
2 identifies a significant decrease in survival rates based on more advanced stage of diagnosis. For 
Five-year Relative Survival Rates (%) by Stage at Diagnosis, US, 2010-2016
All stages Local Regional Distant
Breast (female) 90 99 86 28
Colon 63 91 72 14
Rectum 67 89 72 16
Esophagus 20 47 25 5
Kidney 75 93 70 13
Larynx 61 78 45 34
Liver 20 34 12 3
Lung & bronchus 21 59 32 6
Skin melanoma 93 99 66 27
Oral cavity & pharynx 66 85 67 40
Ovary 49 93 75 30
Pancreas 10 39 13 3
Prostate 98 >99 >99 30
Stomach 32 70 32 6
Testis 95 99 96 73
Thyroid 98 >99 98 55
Urinary bladder 77 69 37 6
Uterine cervix 66 92 58 17
Uterine corpus 81 95 69 17
Table 2: 5-year survival rate for solid tumor cancers based on stage 
of diagnosis. (Taken from the American Cancer Society) 
3 
example, the survival rate of breast cancer patient when diagnosed as local is 99%; however, if the 
cancer spreads to the regional or distant stage, the survival odds decrease significantly to 86% and 
28%, respectively. Other cancer types have a similar result, as with the case of distant spread 
pancreatic cancer where only 3% of patents are expected to survive 5 years. This data stresses the 
need for improved detection methods, and the need for enhanced treatment options for advanced 
cancers. Regular diagnostic testing, such as the Papanicolaou test has been used for early 
identification of cervical cancer for the past 70 years and as a result there has been a 70% decrease 
in cervical cancer related deaths since 1950.5 While early identification is ideal for enhanced 
treatment outcomes, many cancer types, such as blood cancers, present unique challenges for 
diagnosis and treatment. 
Diagnosing blood cancer requires a comprehensive blood test to measure levels of 
individual cell types that comprise the blood; including plasma, red blood cells, white blood cells, 
and platelets.6 To date, no simple diagnostic tests have been developed to identify irregularity in 
the blood and most blood cancers patients are unaware they have cancer until symptoms such as 
anemia, shortness of breath, fever, bone pain, and confusion. The disfunction of each of these types 
of cells type identifies the type of blood cancer including leukemia, lymphoma, and myeloma. 
Leukemia is the dysfunction of white blood cells and is the most common form of blood cancer in 
children under 15.7 Lymphoma is a malfunction of the lymphatic system that affects the 
lymphocytes carried by white blood cells. Myeloma is the dysfunction of plasma which carries 
antibodies and nutrients thought the body. The relative survival rates for these cancer types from 
1975 to 2016 is illustrated in Figure 1. While the remission rates for all blood cancer types has 
improved, myeloma remains the deadliest with only 54% of patients surviving longer than 5 years.6 
4 
This data shows a need for new treatment options to help reduce the mortality of blood-based 
cancers.  
1.1.3 Treatment options  
Depending on the type of cancer, stage, and aggressiveness, treatment options are generally 
a combination of localized and systematic approaches. Localized cancer treatments include 
surgery, radiation, and cryotherapy by targeting an area of cancerous tissue. Surgical removal of 
the cancerous tissue was the predominant form of cancer treatment until the 1960’s when remission 
rates plateaued at ~33%.8 Unknown at the time, attempts to surgically remove the tumorous cells 
left behind small portions of the cancer, called micrometastases, leading to cancer recurrence. 
Together the inability to treat metathesized cancers, the invasive procedures, and the inability to 
treat non-tumorous cancer types such as blood cancers, continues to limit localized therapeutic 
options. To improve remission rates, systematic treatments were envisioned to be used in tandem 
Trends in 5-year Survival Rates (%), US
1975-77 1987-89 2010-16
Hodgkin lymphoma 72 79 87
Non-Hodgkin lymphoma 47 51 73
Leukemia 34 43 64




























Figure 1: Trends in 5-year survival rates for blood cancers based on 
stage of diagnosis. 
5 
to treat the remaining cancer cells. Systematic treatments circulate the bloodstream acting on all 
cells and can include; immune therapy, hormone therapy, and chemotherapy. Chemotherapy has 
become the predominant form of treatment with approximately 650,000 of all cancer patients per 
year receiving chemotherapy in the US. 
 
1.1.3.1 Chemotherapeutics  
Of the numerous cancer treatment strategies, this work highlights the use of 
chemotherapeutic approaches, which are principally composed of small molecules. One example 
in the development of small molecule chemotherapeutics was designed by Gertrude B. Eliot and 
Dr. George H. Hitchings in 1950, who drew inspiration from the recently discovered structure of 
DNA. Their efforts were aimed 
at developing nucleic acid 
analogs for cancer treatment. To 
this end, they synthesized 6-
mercatopurine (6TP, 1) which is 
biosynthetically transformed into 6-thioguanine (2) and incorporates into DNA acting as a guanine 
mimic, as shown in Figure 2. Compound 2 is incorporated into DNA after ribosylation and 
phosphorylation and activates the natural DNA mismatch repair mechanisms to induce apoptosis. 
These sulfur analogs have shown success for treatment of hematological cancers and continues to 
be used for the treatment of acute lymphocytic leukemia (ALL).8 Through their work in the 
construction of nucleotide analogs Eliot and Hitchings were awarded the Nobel Prize in Medicine 
in 1988. Rapid distribution and use of 6TP in the 1950’s helped to spur the foundation of 
Figure 2: Chemotherapeutics 6-thioguanine (1), 6-
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chemotherapeutics. However, today’s drug approval process has become extensive and lengthy 
due scrutinized regulations set forth by the US Food and Drug Administration (FDA).  
 
1.1.4 FDA Drug Approval Process 
The process of developing new therapeutics is both time and cost 
intensive, requiring on average 10 years and approximately $2.6 billion USD.9 
The strict drug regulations set forth by the FDA is a result of the 1962 drug crisis 
caused by thalidomide (3, Figure 3). Thalidomide was developed for treatment of 
morning sickness for pregnant woman and was originally sold as a racemic 
mixture; however, both enantiomers were not rigorously tested independently. 
Upon widespread European distribution, the drug was identified to cause sever birth defects 
impacting approximately 10,000 embryos with a 40% fatality rate.10 Contrary to the European 
market where a majority of the cases occurred, the FDA’s Dr. Frances Kelsey declined the drug 
approval for sale in the US. Dr. Kelsey’s decision to refuse the approval of the drug not only saved 
many American lives but also inspired a wave of new regulations that scrutinize the FDA drug 
approval process. It was later discovered that the (R)-enantiomer was responsible for the 
therapeutic effects, while the (S)-enantiomer caused the toxic side-effects. The thalidomide crisis 





















The FDA drug approval process is highly restrictive; on average one of 10,000 potential 
small molecule candidates acquires approval. The 4 stages of the drug approval process are 
depicted in Figure 4. The process starts with 5,000-10,000 lead compounds which are tested for 
biological activity. In this stage, the mechanism of action is identified in efforts to optimize the 
observed activity. Once a potential drug is identified, the pre-clinical investigation determines 
drug-like characteristics and bioavailability including traditional absorption, distribution, 
metabolism, excretion and transport (ADMET) evaluations. After the drugs characteristics are 
identified, clinical trials are undertaken to investigate the safety for human use. Each phase of 
clinical trials works with increasing populations of volunteer patients to identify drug safety and 
efficacy. Finally, the FDA reviews the data collected through the process and determines the 
approval status. The approval of the drug by the FDA does not end the agencies involvement. The 
FDA continuously monitors the status through post-market surveillance and if deemed necessary 
they can retract approval at any time.  
5,000-10,000 
compounds
- Lead compound 
synthesis
- Analog synthesis











- Phase 1, 2, and 3
1 new drug
3-5 years 1-2 years 6-7 years 1-2 years
Post-m
arket Surveillance
Figure 4: The drug discovery pipeline for new FDA approved compounds. 
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Rightfully, the process of developing new drugs for diseases, like cancer, is closely 
monitored and regulated. To develop a new cancer drug is time and costs intensive, so comparing 
the origin of the drug can help indicate which compounds are likely to be successful. Historically, 
a majority of the compounds that have led to FDA approved drugs are, or have been inspired by, 
naturally occurring compounds known as natural products (NPs). These naturally occurring 
compounds have dominated the field of small molecule therapies either as sole agents, hybrids, or 
as points of synthetic inspiration (vide infra).  
 
1.2  Natural Products as Therapeutics 
NPs are molecules isolated from 
any living organisms including aquatic 
and terrestrial species. A vast majority 
of all NPs are secondary metabolites, 
meaning their production is for non-
essential functions such as cell 
signaling, defense, or mating. From 
1946 to 2019, a majority of the drugs 
approved by the FDA have been based 
on NPs (Figure 5); including, unaltered 
NPs (N = 35), NP derivatives (ND = 
65), synthetic drugs as NP mimics 
(S/NM = 38), synthetic drugs with a 





























Type of Cancer Treatment Abbreviation # of FDA Approved
Biological Macromolecules B 52
Botanical Drug NB 1
Synthetic Drug S 53
Vaccines V 10
Unaltered Natural Products N 35
Natural Product Derivatives ND 65
Synthetic Natural Product Mimic S/NM 38
Synthetic drugs (NP pharmacophore) S* 22
Synthetic/ Natural product mimic S*/NM 45
Total 321
Based on NPs 205
% of NP Drugs 64%
Figure 5: Prevalence of natural products in FDA 
approved chemotherapeutics. 
9 
synthetic drugs acting as NP pharmacophore mimics (S*/NM = 45). Other FDA approved 
treatments include biological macromolecules, botanical drugs, synthetic drugs, vaccines, but 
combined have not yet surpassed the utility of NPs as medicines. Moreover, with respect to the 
development of cancer treatments, 40 of the 75 small molecule approved by the FDA from 1946 
to 1980, were based on NPs and despite advances in high throughput screening and computer aided 
drug design, this has continued from 1981 to 2019, with 120 of the 185 cancer treatments deriving 
from NPs.11  
 The use of NPs in drug development continues to be critical. Illustrated in Figure 6 is a 
representative sample of NPs that have been approved, or are under investigation by the FDA, this 
list is not inclusive. Included in 
this list are anticancer 
compounds, including arglabin 
(4), masoprocol (5), vinblastine 
(7), pentostatin (8), doxorubicin 
(10). In addition, some NPs 
have immunosuppressive 
activity like myfortic acid (6), 
antibacterial activity as in the 
case of penicillin G (11), 
cognitive enhancing abilities; 
as with galantamine (9), and 
pain management compounds such as morphine (12). However, the use of NPs from isolation is 
limited by the finite amount present within the original organism. For example, the isolation of 













































































vinblastine (7) requires 1 liter of cultured fungi from the leaves of Catharanthus roseus to produce 
76 µg of the drug.12 There are several ways of producing NPs including fermentation and 
extraction, semi-synthesis, and total synthesis.   
 
1.2.1 Methods of Accessing NPs 
There are three main methods for accessing NPs including extraction or fermentation, 
semi-synthesis, and total synthesis. Advances in NP biosynthetic pathways has enabled sustainable 
production of various drugs through fermentation and extraction. Penicillin G (11) remains the 
predominant method of treating bacterial infections with more 3 x 107 kg/year being produced 
through fermentation.13 Production of pharmaceuticals from microorganisms has had an 
overwhelming contribution in the last 80 years, and with 99% of bacteria and 95% of fungi having 
never been cultivated in a labs, the potential of cultivated NPs is optimistic. However, low 
quantities of the NPs can be demanding to some organisms and can negatively impact their 
ecosystems. In these cases, a biosynthetic intermediate can be isolated, and a semi-synthetic route 
can be developed to access to the drug in large-scale. The semi-synthetic method has been 
particularly useful for the production of Paclitaxel (known as Taxol, 13, Figure 7). Taxol was 
originally isolated from the bark of the pacific yew (Taxus brevifolia) and is a widely used 
Figure 7: Natural products can be produced by fermentation like 
Penicillin G (11), from semi-synthesis such as Paclitaxel (13) arising 






















Isolated from Penicillium notatum 13. PaclitaxelOriginally isolated from 













chemotherapeutic to treat breast, lung, and ovarian cancer; however, harvesting from the bark of 
the tree is fatal and provides limited quantities of the drug. Luckily, a biosynthetic intermediate, 
10-Deacetylbaccatin (14), was discovered to be abundant in the pine needles allowing for non-
toxic harvesting and a semi-synthetic route was developed to access 13 for commercial use. 
Accessing NPs through total synthesis continues to be a rich source of knowledge. In addition to 
allowing scalable access to the drug, total synthesis routes also expand our knowledge of the 
biosynthetic pathways used to produce the compound and leads to the development of new 
chemical reactions. Additionally, total synthesis can enable testing of synthetic intermediates to 
determine structure activity relationship (SAR) and can generate new analogs of the NP for further 
testing. Overall, total synthesis is a powerful tool to access NPs but can also serve as a technique 
to learn about the therapeutic mode of action.  
 
1.3 Types of Natural Products  
NP are grouped into classes based on their structural features. There are many types of NPs 
including, but not limited to, alkaloids, peptides, terpenes, and chalcones. The focus of this work 
is on peptide NPs, including both cyclic peptides and depsipeptides. Peptide-based NPs have 
diverse biological activities and have led to several FDA approved drugs. This work will highlight 
our synthetic efforts towards two molecules in the class and will look to harness the peptide core 
to develop novel drug delivery platforms.  
 
1.3.1 Peptide Natural Products 
Peptide-based NPs, both linear and macrocyclic, have continued to be a rich source of 
bioactive compounds. Peptide NPs currently occupy ~2% of the drug market; however, with more 
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than 600 compounds under investigation in the preclinical stage, this class is likely to have an 
increasing impact in future of drug development.14 Currently there are 60-70 peptide drugs 
approved for the global market, including gramicidin S15 (15) tyrocidine (16), kurahyne B16 (17), 
and dolastatin1517 (18) (Figure 8), and more than 100 other molecules are currently under clinical 
investigation.18 Within the peptide family, proline-rich peptides show diverse biological activity 
including; antibacterial, antifungal, cytotoxic, immunosuppresive, anti-inflammatory, anti-HIV, 
and antiviral. Interestingly, the structural conformation of proline-rich cyclic peptides has been 
suggested to play a key role in the biological activity.19  
 
1.3.1.1 Proline-Rich Cyclic Peptides  
 Linear peptides with less than 10 amino acids are considered highly flexible; however, 
peptides with 10 to 20 amino acids can adopt secondary confirmations in the form of a-helices, 
and b-turns, and other conformations.19 In some cases, cyclized peptides are restricted to a limited 
number of molecular configurations which is suggested to enable more specific interactions within 
cells.20,21 Proline-rich cyclic peptides have been shown to possess diverse biological activities,19 
which is suggested to arise from the constrained geometries of the tertiary nitrogen of proline.21 
Figure 8: Chemical structure of FDA approved peptide natural products. Gramicidin S (15), 


















































































These cyclic proline-rich peptides have prolonged half-lives in biological systems due to the 
limited confirmational flexibility. This is suggested to promote additonal resistance to enzymatic 
degradation via proteases, more specific interaction with protein targets, and are more membrane 
permeable than their linear counterparts. One recently discovered proline-rich peptide are the 
reniochalistatin family of NPs.  
 
1.3.1.2 Reniochalistatin Family of Natural Products  
 The reniochalistatin family of NPs were isolated from Reniochalina stalagmitis by Lin and 
coworkers in 2014.22 The isolation of the family was a result of a screening campaign in the South 
China Sea aimed to identify new bioactive peptides. All of the reniochalistatin family are proline 
rich, with reniochalistatins A-D (19-22) being heptapeptides and reniochalistatin E (23) an 
octapeptide (Figure 9). Reniochalistatin E was shown to possess modest cytotoxicity in multiple 
Figure 9: The reniochalistatin family of natural products: reniochalistatin A 
(19), reniochalistatin B (20), reniochalistatin C (21), reniochalistatin D (22), 



















































































cancer cell lines including myeloma (RPMI-8226, IC50 = 4.9 μM), gastric (MGC-803, IC50 = 9.7 
μM), and cervical (HeLa, IC50 = 17.3 μM).  
 We speculate the modest cytotoxicity of reniochalistatin E is derivied from the enhanced 
cellular penetration associated with proline-rich cyclic peptides. In addition, we believe the 
cytotoxic activity in myeloma cells could be harnessed as a drug delievery vehicle. We hypothesize 
that conjugating reniochalistin E to potent theraputics could allow for enhanced penetration 
leading to new treatment strategies. To this end, we undertook the development of a total synthesis 
route to allow for additional biological evaluation and SAR investigations.   
 
1.3.2 Depsipeptide Natural Products 
Depsipeptides are defined as peptide containing NPs wherein one or more amide bonds are 
replaced by an ester(s) via a hydroxy acid moiety. Depsipeptides NPs have been shown to possess 
a variety of therapeutic properties, such as: anticancer, antifungal, antibacterial, cholesterol-
lowering, antiparasitic, insecticidal, and immunosuppressive.23,24 These types of NP have resulted 
in over 50 compounds investigated as potential drugs; however, only FK-228 has been approved 
by the FDA.25  
The depsipeptide FK-228 (24, Figure 10), also known as Romidepsin, is a NP 
chemotherapeutic 
approved by the FDA 
in 2009 for the 
treatment of cutaneous 
T-cell lymphoma. 
Originally accessed 
Figure 10: Activation of anticancer drug FK-228 (24) through reduction 






























HS26. Active form of 
Romidepsin, HDAC 
inhibitor
25. Inactive dithiol form
HO
15 
synthetically by Prof. Robert M. Williams at Colorado State University, 24 is used for the treatment 
of lymphoma through the inhibition of histone deacetylases (HDACs). HDACs are responsible for 
altering the histone coiling of DNA which affects protein expression. However, 24 is known to be 
inactive in the original form and must be activated to elicit a therapeutic effect. The activation 
starts with the reduction of the disulfide, producing a dithiol (25); however, the length of the carbon 
tether is too short to reach the zinc binding domain of the HDAC protein. Hydrolysis of the ester 
within 25 to the open chain form (26) allows the thiol to reach into the binding sight of HDAC and 
bind to the zinc center within. This biochemical transformation of romidepsin is an example of a 
prodrug (vide infra).  
 
1.3.2.1 Prodrug Chemotherapeutics 
Prodrugs are therapeutics that possess a labile bond allowing bioconversion in vivo to the 
medicinal active species. Prodrugs can occur naturally, as seen with FK-228, or can be designed 
to overcome pharmacokinetic limitations such as; poor solubility/absorption, rapid 
metabolism/excretion, or pharmacodynamic limitations such as side-effects, off-target toxicity, 
and poor efficiency. Aldoxorubicin (27, Figure 11) was designed with two functional moieties 
imparted to allow for cancer cell targeting through human serum albumin (HSA) conjugation. 
Efficient delivery of the doxorubicin (29) is acquired by the rapid uptake of HSA by cancer cells, 
Figure 11: Aldoxorubicin (27) is bio converted to the active form, doxorubicin (29) 
through two steps. First human serum albumin (HSA) adds into the maleimide moiety 


















































bound to HSA for 
enhanced drug delivery
16 
and cleavage of the hydrazone linker. The targeting of cancer cells via HSA is accomplished via 
covalent modification by the cysteine (C34) residue within HSA to the alkene moiety of the 
maleimide functional group (shown in blue on 27). Circulation of HSA leads to accumulation of 
the drug-conjugate near the tumor site where the hydrazone linker (shown in red) is cleaved by the 
acidic microenvironment of the tumor releasing doxorubicin (29) near the cancer site. This prodrug 
allows for enhances efficiency and decreased toxic side-effects associated with 27 treatment alone. 
While aldoxorubicin has shown success as a rationally designed prodrug, this strategy does 
not work in all cases. Altering the structure of a drug by adding prodrug moieties can affect the 
biological activity and render the molecule inactive. For this reason, it is important to understand 
the active portions of the drug, also known as the pharmacophore. To explore what portion of a 
new drug is active, SAR investigations are undertaken by synthesizing analogs and performing 
biological evaluation. In the synthetic works of FK-228, researchers identified that replacing the 
ester linkage with an amide prevented ring-opening and rendered the molecule inactive.26 Analog 
synthesis and SAR can help to understand the active pharmacophore of the molecule and help to 
identify how the molecule elicits a therapeutic effect, such as a ring-opening in the case of FK-
228. In the case of NPs, SAR investigations can be done during synthesis by performing biological 
testing on synthetic intermediates and structural analogs. This can illuminate key features of the 
molecule and provide evidence for the drugs mechanism of action. Naturally occurring prodrugs 
containing hydrolyzable bonds, such as esters, and disulfides are common in depsipeptide NPs. 
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1.3.2.2 Aurilide Natural Products  
Another family of bioactive depsispetide NPs is the aurlide 
family. Aurilide (30, Figure 12) was first issolated in 1996 by 
Suenaga and coworkers from the Japanese sea hare Dolabella 
Auricularia.27 Later, aurilide B (31) and aurilide C (32) were 
isolated by Gerwick and coworkers in 2006 from a sample of 
Lyngbya majuscula harvested in Papa New Guinea.28 The aurilide 
family were identified to consist of two subunits namely, a 
hexapeptide containing two a-hydroxy acid residues linked to a 
stereospecific dihydroxy acid polyketide, highlighted in blue. The 
structure of the peptide differ by single amino acids changes, shown in red in Figure 12. Cytotoxic 
evaluation of the class revealed potent toxicity in a number of cancer cell lines including; HeLa 
cells (30, IC50 = 1.2 µg/mL), NCI-H460 human lung tumor cells (31, LC50 = 0.04 µM, 32, LC50 = 
0.13 µM) and neuro-2a mouse neuroblastoma cells (31, LC50 = 0.01µM, 32, LC50 = 0.05µM). In 
addition, 31 was tested for activity in the NCI-60 cancer cell line panel showing a mean GI50 of 
less than 10 nM with potent activity in leukemia, renal, and prostate cancer cell lines.  
 
1.3.2.3 Lagunamide Family of Depsipeptides: Isolation and Characterization 
 In 2010 Tan and coworkers isolated the lagunamide family of NPs, new bioactive 
secondary metabolites from a sample of cyanobacteria Lyngbya majuscula from a lagoon in 
Singapore. Through their efforts, they reported the strucutral elucidation and biological evaluation 
of lagunamide A (33) and lagunamide B (34), shown in Figure 13.29 One year later, Tan and 
Figure 12: The Aurilide NP 
family: Aurilide (30), 
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coworkers reported the isolation of 
lagunamide C (35) from the same biological 
source.30 The lagunamide family grew in 2019 
when Luesch and coworkers isolated 
laguanmide D (36) from the same bacterium 
harvested near the Florida coast.31 Compounds 
33, 34, and 36 are 26-membered macrocyclic 
depsipeptides differing only by an exocyclic carbon chain, shown as R in Figure 13. In contrast, 
36 is the first 27-membered macrocycle of the class owing to the additional methylene carbon 
(C39) within the polyketide. Only 4.7 mg of 36 were obtained from the 169 grams (0.003% 
extraction yield) of the cyanobacterium. The stereochemistry of the polyketide was determined by 
adjacent proton coupling calculations (3JH,H) and 2D NOSEY correlations from which the 
following assignemnts were made: C37(S), C38(S), C40(R), and C41(S). However, the limited 
quantity of the NP prevented full confidence of the polyketide stereochemistry (vida infra). 
Biological testing of 36 revealed potent cytotoxicity in a number of cell lines including; murine 
leukemia (P388: IC50 = 24.4 nM,), lung carcinoma (A549: IC50 = 2.4 nM), prostate cancer (PC3: 
IC50 = 2.6 nM), ileocecal colorectal adenocarcinoma (HCT8, IC50 = 2.1 nM), and ovarian cancers 
(SK-OV3: IC50 = 4.5 nM). In addition, 36 was tested for antimalarial activity in Plasmodium 
falciparum with IC50 value of 0.29 µM, and showed weak anti-swarming acitivty against gram-
negative bacterial growth when tested at 100 ppm against Pseudomonas aeruginosa (PA01). The 
potent cytotoxicity and diverse biological activity of the aurilide class has drawn interest from 
several research labs; resulting in the total synthesis of lagunamide A;32–36 however, there have 
been no reports of synthetic efforts towards lagunamide B to date. 
Figure 13: The lagunamide family: lagunamide 
A (33), lagunamide B (34), lagunamide D (36), 
and lagunamide C (35). 






























1.3.3 Research Motivations 
With no previously reported total synthesis of either reniochalistatin E or lagunamide C, 
we set out to design a synthetic route to access each. Moreover, the anticancer activity and the 
limited understanding of these molecules drew our interest for acquiring a deeper understanding 
of their biological activity. We hypothesized these molecular frameworks could be used to develop 
new and potent drug delivery systems and as sole therapeutics agents. To this end, a conjugation 
strategy was envisioned to generate new prodrugs to repurpose currently approved 
chemotherapeutics. This work looks to use total synthesis as a tool to develop new and effective 
chemotherapeutics for the treatment of cancer.  
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Chapter 2- Previous Work Towards Peptide NPs and Biological 
Evaluation  
 
2.1 Research Motivations and Chapter Outline 
Reniochalistatin E and lagunamide C are peptide based NPs that have complex biological 
activity; however, no synthetic efforts have been made for further studies. The unique strcutral 
features of both molecules such as the proline rich cyclic peptide, or the stereoselective polyketide 
drew our interest to develop a total synthesis route to study their mechanism of toxicity. The 
previous works identifying the general cytotoxicity of the molecules encouraged the hypothesis 
that each has the ability to penetrate cancer cells to elicit a toxic effect. Moreover, devloping a 
total sysnthesis route would allow for exploration of these NPs as a new platforms for drug 
delievery systems. This chapter will focus on the general protocols for the formation of peptide 
based NPs and discuss the previous used routes to access the polyketide structure of the aurilide 
class of NPs. Finally, a comparison of the work will be done to rationalize each synthetic route 
and highlight the utility in developing a synthesis towards lagunamide C.  
 
2.1.1 Review of Synthetic Means to Access Peptide Natural Products 
 Linear and cyclic peptides have gained interest in the synthetic community due to their 
complex interactions with cells leading to diverse biological activity.37–39 To synthesize peptide 
NPs, there are two main techniques; solid phase peptide synthesis (SPSS) and solution phase 
peptide synthesis. SPSS uses resin-bound amino acids as starting blocks for peptide chain 
formation, this allows for solvent washes to remove unreacted starting material, unused coupling 
reagents, and by products. However, a drawback of SPSS is the use of strongly acidic reagents, 
21 
like TFA, which are needed to cleave the peptide from the resin and are known to cause 
epimerization in some cases. In contrast, solution phase peptide synthesis requires both aqueous 
workup and chrotomographic purification for each amino acid addition. While more time 
consuming, it allows for full characterization of the intermediates which can be tested for 
biological activity helping to identify 
potential SAR. Solution phase peptide 
synthesis employes an array of coupling 
reagents that assist in the formation of 
peptide bonds.  
 
2.2 Peptide Coupling Reagents 
Numerous methods allow for the formation of amide bonds through nucleophilic attack of 
an amine to an activated carboxylic acid, shown in Scheme 1. Activation the carbonyl carbon 
through electron withdrawing groups such as, 
but not limited to; acid halides, azides, esters, 
and anhydrides can be generated by activating 
reagents to favor aminolysis. In addition, there 
are coupling reagents that form transient 
intermediates including acyl urea, acyl 
phosponium, and acyl uronium that further 
activate the carboxylic acid and enhance the 
formation of new amide bonds. To be 
































Scheme 1: General amide bond formation. 
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22 
reagents to our synthetic efforts; including, carbodiimides, phosphonium salts, and 
aminium/uronium salts (shown in Figure 14). For a full list of peptide reagents there are several 
reviews.39–41 
 
2.2.1 Carbodiimide Method  
Carbodiimide methods employ reagents like DCC (37, dicyclohexylcarbodiimide), and 
EDC (38, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide) and are known as the traditional 
method for peptide coupling.42 Mechanistically, the basic 
nitrogen in the carbodiimide structure is enough to 
deprotonate the carboxylic acid to form the O-
acylisourea, as shown in Scheme 2; however, general 
reaction conditions include a base to assist in 
deprotonation. The activated O-acylisourea is highly 
reactive and aminolysis occurs rapidly. Carbodiiamide 
reagents can also facilitate by product formation in 
addition to standard urea displacement (Route I). 
Formation of the symetric anhydrides (Route II) can 
occur with the attack of a second moleclue of acid, but 
will enevitably be aminolyzed to the peptide product. Intramolecular attack by the nitrogen leads 
to formation of oxazolones (Route III), a lesser reactive intermediate, which limits the activation 
of the carbonyl carbon and increases steric bulk, therefore decreasing reactivity.43 Nucleophilic 
attack upon this intermediate can be from either face and will lead to racemization of the product. 

























































(Rapidly forms in DMF, but slowly in DCM)
N-acylurea
Scheme 2: Carbodiimide method of 
peptide formation. 
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prevents the formation of the desired peptide. Some solvents including dimethylformamide (DMF) 
favor N-acylurea formation leading to parcipitation and slows reaction progress; however, 
dichloromethane (DCM) has been shown to limit the formation of the N-acylurea and is the 
prefered solvent for carbodiimide reagents.42 One disadvantage of the carbodiimide reagents are 
the incapatability with fluorenylmethyloxycarbonyl (Fmoc) protecting groups. An advantage of 
these reagents is the ease of purification via aqueous work up because the urea by product is 
aqueous soluble in acidic conditions. Moreover, reactions run with N-hydroxy compounds like 1-
hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole (HOAt) can help to decrease by 
product formation and limit racemization.43  
 
2.2.2 Phosphonium salts 
Phosphonium salts such as BOP (39, 
(benzotriazol-1-yloxy)tris(dimethylamino)- 
phosphonium hexafluorophosphate), PyBOP 
(40, benzotriazol-1-
yloxytripyrrolidinophosphonium 
hexafluorophosphate), and HOAt (41, 1-
hydroxy-7-azabenzotriazole) are shown in 
Figure 14 (above). The mechanism of 
phosphonium salts starts with the 
deprotonation of the carboxylic acid followed 
by phosphonium addition. Mechanistically, 
there is debate over the activated species, but 
Scheme 3: Mechanism of peptide coupling 


























































the acyloxyphosphonium salt, shown in brackets in Scheme 3, is considered the key reactive 
intermediate. This activated species is then displaced by an N-hydroxy compound such as HOBt 
of HOAt further activating the carbonyl carbon and faciliatating amide bond formation. The 
acyloxyphosphonium salt can also undergo intramolecular cyclization to form the oxazolone, or 
attack from a second molecule of carboxylic acid to form an anhydride. In either case, either an 
N-hydroxy compound or amine attack will inevitably form the desired peptide. One advantage of 
the phosphonium salt is the lack of interaction with the amine which enables cyclization without 
excess reagent preventing coupling.  
 
2.2.3 Aminium/Uronium salts 
 While phosphonium reagents contain a positivly charged phosphonium, the 
aminium/uronium salts contain a iminium ion, shown in Scheme 4. One equivelent of base forms 
the activated ester species leading to the N-acyl or O-
acyl esters and favors amide bond formation at room 
temperature. Additional hydroxylamine derivatives 
allow for the displacement of the activating reagent 
and amide bond formation through nucleophilic 
amine attack. However, if the activation of the 
carboxylate is slow, the aminium/uronium salts can 
react with the amine functionality and terminate the 
peptide chain elongation. This limits the uronium 
salts applicability, as cyclization or fragment based Scheme 4: Mechanism of 























































coupling reagents. This obstacle can as overcome with the use of selective protecting groups to 
mask the amine functionality.  
 
2.2.3.1 Summary of Peptide Coupling Reagents 
In the last 200 years peptide bond formation has evolved from Emil Fisher’s original acid 
chloride formation to coupling reagents with high selectivity and broad substrate scope. While 
progress can still be made, peptide coupling reagents are a powerful tool for synthetizing new 
peptide-based NPs. The reactivity of the reagents discussed in this work are all viable options with 
distict advantages. For example, carbodiimide reagents when used in the proper solvent can allow 
for high yielding peptide bond formation and aqueous workup removes the urea by product of the 
reaction allowing for easier purification. Phosphonium salts are easy to use and do not react with 
the amine functionality making them highly usefull in cycilization conditions. Finally the 
aminium/uronium reagents are low cost and can be used on peptides with protecting groups 
enabling high yielding reactions. In summary, there are many reagents that can facilitate in peptide 
bond formation, and exploring each can allow for optimized yields to generate peptide NPs.   
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2.3  Previous Total Synthesis of Peptide Natural Products 
Employing peptide coupling reagents has led to 
the total synthesis of several NPs including but not 
limited to; Zizyphine A (44), Seongsnamide B (45), 
Dendroamide A (46), Dehydrodidemnin B (47), 
and GE2270 A (48), shown in Figure 15. Each of 
these routes harnessed peptide coupling reagents to 
access the NP structure. With some expoloration of 
reaction optimization, peptide bond fomration has 
become a managable hurdel in the total synthesis of 
NPs. The favorable conditions of forming peptide 
bonds has been disclosed herein, and the reminder 
of this work will focus on efforts made towards the 
polyketide of depsipeptide NPs. Exploration of 
reaction conditions in the following sections are 
usefull to understand chemical reactivity, in addition to the peptide chemistry discussed, to achieve 
the total synthesis of lagunamide C.  
 
2.4 Synthesis of Cyclodepsipeptides 
The depsipeptides discussed in this report are compounds of a polypeptide and polyketide 
components, which contains at least one ester in place of an amide bond. Biosynthetically, 
polyketides are synthesized via condensations of acetyl coenzyme A through malonyl coenzyme 
A, producing alternating carbonyl and methylene groups.38 Synthetically, there are many strategies 
Figure 15: Peptide NPs accessed via peptide 
























































































for constructing polyketides; however this report will focus on the synthetic efforts made towards 
the Aurilide class of NPs. In addition, the biological activity and SAR findings of previous works 
will be discussed. This work will summarize the key synthetic steps in the stereoselective 
formation of the polyketides and will emphasize the critical need of a stereoselective approach 
towards lagunamide C by highlighting previously disclosed SAR investigations.  
  
2.4.1 Aurilide Family of NPs  
 NPs are grouped into classes based 
on common structural features. One class of 
cyclodepsipeptides containing a polyketide 
and hexapeptide backbone are the aurilide 
family. The complete family of Aurilide 
NPs is shown in Figure 16. This class of 
NPs includes the aurilides (30-33), 
Odoamide (49), Kulokekahilide (50), 
palau’amide (51), and the lagunamides A-D 
(33-36) and have been shown to possess an 
array of biological activities including; 
antifungal, antibacterial, and anticancer. A 
key feature of this class is the 26-membered 
macrocyclic structure in all members except 
palau’amide, which is a 24-membered epimer, and lagunamide C (35) which has an added 
methylene (C37) in the polyketide making it the first 27-membered macrocycle of the family. The 

























































































































additional methylene requires a unique synthetic route to access the polyketide, but the previous 
works outlined herein, serve as a tool in developing a route to the first total synthesis of lagunamide 
C. 
 
2.4.2 Synthesis of Aurilide Polyketide Fragment  
Aurilide (30) was isolated in from the Japanese sea hare D. Auricularia in 1996 by Suenaga 
and coworkers.27 To determine the absolute stereochemistry of the polyketide, 30 was reduced by 
LiAlH4 and acylated using p-BrC6H4COCl to give 52, shown in Scheme 5. However, they were 
unable to identify the absolute configuration of the 3 stereocenters in the polyketide fragment and 
proposed the structure 52. To validate the stereochemistry, a synthetic route was designed to access 



















56 X=OH, Y=H (58%)
57 X=H, Y=OH (40%)53 54 55
1. Me2AlN(Me)OMe, 
THF, toluene, 0 oC;
2. TESCI, imidazole, 
DMF, 23 °C;
3. DIBAl-H, THF, 




58 X=OTES, Y=H (59%)
59 X=H, Y=OTES (64%)
1. TESCI, imidazole, DMF, 
23 °C;
2. DIBAl-H, THF, hexane, 
-23 oC;
3. DMSO, (COCl)2, Et3N, 
CH2Cl2, -78 to 0 oC
4. (EtO)2P(O)CH(Me)CO2Et, 
NaH, DME, -20 oC
1. HF·pyridine, pyridine, 
THF, 23 oC;
2. MnO2, CH2Cl2;
3. TESCI, imidazole, DMF, 
23 °C
1. DIBAl-H, THF, hexane, -78 oC;

























60 X=OTES, Y=H (57%)
61 X=H, Y=OTES (55%)
1. NaBH4, CeCl3·7H2O, EtOH, -23 oC
2. HF·pyridine, pyridine, THF, 23 oC;




the four possible stereoisomers about C35 and C37 to be compared with the natural 52. The 
synthesis, shown in Scheme 5, begins with a boron mediated aldol reaction with the N-propyl 
oxazolidinone (53) to give the Evan’s syn product (54) in 80% yield. The Weinreb amide was 
generated followed by protection of the hydroxyl via triethylsilane (TES), and finally DIBAl-H 
reduction afforded aldehyde 55 in 91% over 3 steps. Nucleophilic attack by an organolithium 
containing the tBu-ester provided both diastereomers about C35 to form 56 and 57 in 58% and 
40% yield, respectively. The newly formed hydroxyl was protected with TES, followed by full 
reduction to the alcohol. Subsequent oxidation via Swern conditions provided an aldehyde which 
was subjected to Horner-Wadsworth-Emmons (HWE) olefination conditions to afford 58 and 59 
in 59% and 64% yields, respectively. Each diastereomer was subjected to reduction under DIBAl-
H conditions followed by a global deprotection of the TES groups and finally acylation to afford 
the 52 and 62 in 88% and 91% respectively. In order to access the C37(S) diastereomer, 
deprotection of 58 and 59 followed by MnO2 oxidation afforded ketones 60 and 61 in 57% and 
55% yield, respectively. The ketones were reduced to the 1,3-syn-diol and deprotected to afford 
the allylic alcohols 63 and 64 in 57% and 53% yield, respectively. This 9-step reaction sequence 
allowed for the synthesis of the 4 diastereomers (52, 62, 63, 64) to be compared with 52 generated 
from 30. The 4 diastereomers were analyzed by H1 NMR and CD to assign the stereocenter 
polyketide as C35(S), C36(S), and C37(S).   
30 
In 1997 Mutou and coworkers used a similar route to achieve the enantioselective total 
synthesis of 30.44 Analogous to previous reports, a boron mediated enolate was generated from the 
N-propyl oxazolidinone (65) providing the Evan’s anti product (66) setting the C37(S) hydroxyl 
(Scheme 6). In an analogous approach to the previous report, Weinreb amide formation followed 
by protection via tert-butyldimethylsilyl chloride (TBSCl) and DIBAl-H reduction to afford the 
aldehyde 67 in 3 steps in 93% yield. Compound 67 was subjected to Mukaiyama aldol conditions 
with the TMS-enol ether (2-methyl-1-trimethylsiloxy-1,3-butadiene) (59% yield) and subsequent 
treatment with diazomethane afforded 68 in quantitative yields over 2 steps. However, these 
conditions afforded the C35(R) hydroxyl which was undesired. To overcome this, oxidation to the 
ketone via DMP produced 69 in 99% yield and was treated with NaBH4 to afford the 1,3-syn-diol, 
successfully inverting the stereochemistry about C35 to the desired (S) configuration. The 
selectivity of this reaction can be understood by the 6-membered 
ring transitions state of the reaction, show in Scheme 7. Lithium 
coordination with the 1,3-diol forms a 6 membered ring which 
allows for facially selective reduction favoring the formation of the 
















Me3Al, THF, 50 oC, 
84%;
2. TBSCI, imidazole, 
DMF, 23 °C quant.;
3. DIBAl-H, THF, 
hexane, -78 oC 93%
O OTBS 1. BF3·OEt, CH2Cl2, 












68: X = OH, Y = H
69: X = Y = O







1. DMSO, Ac2O, 
AcOH, 40 oC, 100%






















Scheme 6: Selectivity of 
1,3-syn-diol formation. 
31 
ether (MTM), followed by saponification afforded the carboxylic acid 71 in 92% yield. From there, 
peptide couplings with the peptide portion allowed for the total synthesis of 30.  
In 2003, Takahashi and coworkers harnessed a similar route to access the polyketide 
fragment and explored the effects of peptide analogs.45 A library of compounds based on the 
C37(R) diastereomer 52 was coupled to various pentapeptides described in Table 3.46 The purity 
of each analog produced was determined by reverse-phase HPLC; however, the biological activity 
of these analogs has not been reported. To date, there have been no reported synthetic works 
towards 31, or 32, likely due to the high homology with 30. 
2.5 Summary of Aurilide Polyketide Syntheses 
In summary, the synthetic work towards aurilide has been an inspiration for the 
development of a route towards lagunamide C and are summarized in Figure 17. The key 
stereogenic steps in the 1997 Suenaga synthesis include a boron mediated Evan’s aldol, a 
Table 3: Peptide analogs of Aurilide and observed purity.  
32 
nucleophilic addition via organolithium, and an HWE olefination to 
grant access to diastereomers of the polyketide in 18% over 9 steps. 
In 1997 Mutou achieved the total synthesis of 30 featuring key 
stereogenic steps such as; a boron mediated Evan’s aldol reaction, 
TMS-enol ether addition, and a selective 1,3-syn-diol formation 
using NaBH4. This route afforded the enantioselective synthesis of 
30 with access to the polyketide subunit in 9-steps with an overall 
25% yield. The Takahashi synthetic route featured analogous 
stereogenic steps to access the diastereoselective polyketide in 9-
steps with an overall 26% yield. A library of compounds with various 
peptide moieties was described, but the biological activity was not 
reported.  
The additional methylene within the polyketide (C37) of lagunamide C limits the above 
mention routes for the following reasons. Each of the above reaction sequences begin with an 
Evan’s type aldol reaction with the N-
acetyl variant of the chiral auxiliary. 
This aldol reaction sets both the C37 
alcohol and the directly adjacent C36 
methyl (shown in red, Figure 18). 
However, the additional methylene in 
lagunamide C requires the aldol 
reaction be with an N-propyl auxiliary, which have much lower enantioselectivity and reactivates 
(vida infra). Moreover, these routes previously described produce a mixture of diastereomers about 
EtO
O OTES OTES






















Figure 17: Summary of 
Aurilide polyketide 
strategies 
Figure 18: Highlights of the aurilide polyketide routes and the 





































the C35 alcohol; or are dependent on a facially selective reduction that is observed in 1,3-syn-diol 
formation. In contrast, the polyketide of lagunamide C contains a 1,4-diol; meaning the controlled 
reduction induced by the 6-membered ring transition state is voided. However, the utility of these 
routes cannot be understated and was taken in high regard when developing the route towards 
lagunamide C.  
 
2.6 Aurilide SAR Investigations 
With synthetic access to aurilide via the routes discussed above, several groups aimed to 
identify the SAR of the molecule. In 2008 Suenaga and coworkers generated several analogs to be 
of 30 and examined the cytotoxicity in HeLa cells (Table 4).47 Through their SAR investigations, 
they found that reduction of the alcohol at C35 (72) had little effect on the cytotoxicity (IC50 = 17 
ng/mL) when compared to 30. Further studies revealed that inversion of the valine from L to D (73) 
resulted in a loss of all cytotoxicity (IC50 = >4000 ng/mL). The addition of a Boc-protected amine 
via a carbon tether (CH2)4 at position C2 (74), C6 (75), or C20 (76) all significantly reduced 























Table 4: Analogs of 30 generated for SAR.  
R1 R2 R3 X Y IC50 (ng/mL)
30 Aurilide OH Me i Pr i Pr H 2.4-11
72 H Me i Pr i Pr H 17
73 OH Me i Pr i Pr i Pr >4000
74 OH (CH2)4NHBoc i Pr i Pr H 20
75 OH Me i Pr (CH2)4NHBoc H 260
76 OH Me (CH2)4NHBoc i Pr H 32
34 
the importance of specific configuration of the amino acid residues in the peptide portion, and the 
need for further SAR investigations 
 
2.7 Aurilide Mode of Action Investigations 
In 2011, Sato and coworkers were able to isolate the protein target of 30 by using a 
polyproline linker at 
the C35 hydroxyl, as 
shown in Figure 19.48 
Identifying the C35 
hydroxyl has limited 
effect on the biological 
activity from the work 
by Suenaga, the 
researchers attached a 
polyproline linker 
with a biotin moiety to identify the protein target of the NP. The analog was treated in cells and 
purified through gel electrophoresis showing a strong interaction with a 30-kDa protein band 
which was identified as prohibitin 1 (PHB1). Interestingly, the C6-epimer of 30 (77) was used to 
generate the linker molecule 79, which showed a >1000-fold decreased interaction with PHB1. 
Several other biochemical and visualization experiments revealed 30 binds to prohibitin (PHB1) 
and disrupts mitochondrial fragmentation by effecting the optic atrophy 1 (OPA1) protein. The 
OPA1 protein has been previously reported to effect mitochondrial-mediated apoptosis49,50, and 


















































78. R1= iPr, R2= H
79. R1= H, R2= iPr
30. R1= iPr, R2= H




for more information regarding the PHB1 and OPA1 proteins and their cellular interactions, please 
refer to the review by Scorrano and coworkers.51  
In 2017, Takase and coworkers developed a barcoded genome-wide RNA interference 
(RNAi) library to determine the mode of action for 31.52 In conclusion, the gene expression of a  
Na+/K+ ATPase complex protein (ATP1A1) is downregulate upon treatment with 31. However, 
there is no evidence of direct ATP1A1 inhibition, as there may be some other inhibition leading to 
decreased gene expression. In summary, how aurilide induces cell death is still unclear, but further 
studies will hopefully reveal its cellular interactions and mechanism of toxicity.   
 
2.8  Synthesis and Stereochemical Determination of Kulokekahilide-2 
 Nakao and coworkers isolated kulokekahilide-2 (50 in Figure 15) in 2004.53 Their work on 
the structure elucidation revealed their newly isolated compound was composed of a heptapeptide 
and a polyketide similar to the architecture of 30. To determine the correct structure of the NP, 50 
was reduced to the polyketide and peptide fragments; however, there were still unable to identify 
the absolute stereochemistry of C35, C36, and C37 within the polyketide. In order to determine 
the stereochemistry about C35 and C37, a synthetic route was developed to access the 4 possible 
diastereomers shown in Scheme 8. The synthesis commenced with an Evan’s aldol reaction 
between the N-propionyl oxazolidinone (80) and (E)-2-methylbut-2-enal (81). Equivalent control 
of the coordinating reagent Bu2BOTf allowed for control of the C36 stereochemistry to afford the 
aldol products 82 and 83 in 94% and 60% yields, respectively. This reaction proceeds through a 
6-membered ring transition state and is controlled by coordination to the oxazolidinone. More 
details regarding the transition state of the aldol reaction will be discussed in chapter 3. 
Analogously, oxazolidinone (84) was used in a similar fashion to afford the C37(S) compounds 85 
36 
and 86 in an unreported yield. Orthogonal chemistry to the work towards aurilide afforded the 
methyl ester compounds 87-90. Silyl deprotection conditions afforded the triols 91, 92, 93, and 94 
to be used for NMR comparison to the polyketide derived from the NP. As a result, compound 94 
correlated closely to the NP assigning the stereochemistry of the polyketide as C35(S), C36(S), 
and C37(S). However, limited supply of the NP also made identify the peptide portion difficult. 
Efforts towards the total synthesis in 2007 were reported, but were only able to identify possible 
structural misassignments of the NP.54 Their follow up report in 2007 synthesized the possible 
confirmation of the peptide portion in question and identified the absolute stereochemistry as 21-
L-Ala, 24-D-MePhe and the 43-D-Ala, as shown in Figure 16.55 
In 2014, Han and coworkers published their synthetic efforts towards a 11C-labeled 
polyketide of 50 that was envisioned for future applications as a positron emission tomography 
(PET) tracer.56 Probes designed as PET tracers are radiolabeled with short-life positron-emitting 
nucleotides such as 11C, 13N, 15O, or 18F to name a few. This technique can be used as a non-




























































































Scheme 8: Route used to access to the polyketide of 50 and possible C35 and C37 
diastereomers.   
37 
In this work, Han and coworkers envisioned a late stage Suzuki cross-coupling with a [11C]methyl 
iodide source, as shown in Scheme 9. Referring to previous reports by Nakao and coworkers, 
methacrylaldehyde (81) was reacted with the Evan’s oxazolidinone 84 in the presence of 
nBu2BOTf with DIPEA to afford 95 in 47% yield setting the C37(S) alcohol. Standard reactions 
afforded the TBS protected aldehyde 96 which was subjected to vinylogous Mukaiyama aldol 
reaction (VMAR) conditions with the TBS-enol ether (97) to provide compound 98 in 69% yield 
as a mixture of diastereomers. These diastereomers of the C35 alcohol were oxidized via a 
Pfitzner–Moffatt oxidation employing N,N'-dicyclohexylcarbodiimide (DCC) and was reduced 
under NaBH4 conditions to afford the 1,3-syn-diol 99 selectively. Compound 99 was further 
elaborated onto the para-methoxybenzyl (PMB) ethers to protect the alcohol (100) in 49% yield, 
and the TBS group was deprotected with HF in pyridine to afford the olefin 101 was generated in 
74% yield. Compound 101 was then exposed to the Hoveyda-Grubbs second-generation catalyst 
to afford the (E)-organoboron compound 102 in 14% yield. Finally the Pd0-mediated Suzuki 
conditions using radiolabeled [11C]methyl iodide afforded the polyketide derivative 103 in 72% 
yield. In conclusion, Han and coworkers were able to identify a synthetic route to access a 11C-
O N
O O 81, nBu2BOTf, 
DIPEA, CH2Cl2, -





1. i) MeNH(OMe)HCl, 
Me3Al, 0˚C-RT
ii) TBSCl, Imidazole, 
DMF, 94% (2 steps)














2. NaBH4, MeOH, 





PMBTCA, Et2O, -78˚C, 










O HG-II, toluene, 






























Scheme 9: Synthetic route to access the 11C-PET tracer analog of 50. 
38 
labeled polyketide fragment of 50; however, future work will identify the utility of this strategy, 
as no biological data has been reported at this time.  
 
2.8.1 SAR Investigations of Kulokekahilide-2 
The work done by Nakao generated a library of compounds based on 50, that were tested 
for cytotoxic activity shown in Table 5. This library examined the effects of the polypeptide of the 
NP (104), the effect of epimers about C2, C11, and C14, protecting groups on C23 alcohol, and 
Table 5: SAR investigation of 50. 





































































P388 HeLa A549 K562 MCF
IC50 (ug/mL) IC50 (nM)
0.004 - - - -
50 Me H H Bn H Me H H 0.016 0.0032 0.0021 0.0031 0.22
108 H Me Bn H Me H H H 10 >10 - - -
109 H Me Bn H H Me H H >10 >10 - - -
110 Me H Bn H H Me H H 0.4 0.039 - - -
111 Me H H Bn Me H H H 0.016 0.0053 - - -
112 H Me H Bn H Me H H 4.5 2 1045 584 1645
113 Me H H Bn Me H H MTM 0.08 0.016 - - -
114 Me H H Bn H Me H MTM 0.016 0.0072 0.00019 0.0063 6.3
115 Me H Bn H H Me H MTM 0.4 0.039 - - -
116 Me H H Bn H Me Me MTM 0.04 0.04 - - -
117 H Me H Bn H Me H MTM >10 >10 4336 1189 >10,000
118 Me H H pClBn H Me H H 0.0072 0.0014 0.00001 0.000011 0.003
119 Me H H pClBn H Me H MTM 0.016 0.0072 0.73 7.1 6.5
120 Me H H Bn H Me Me H 0.0072 0.0072 - - -
121 Me H Bn H H Bn H MTM 0.89 0.89 - - -
122 Me H H Bn H Me H Bz - - 0.00058 1.8 2.9
105 Me H H Bn H Me - - - - ﻿0.0014 ﻿0.012 0.29
106 H Me H Bn H Me - - - - 1077 1189 3692
107 Me H H pClBn H Me - - - - ﻿0.000020 0.000216 0.025
104 - - - - - - - - - - >10,000 ﻿>10,000 ﻿>10,000
!! !" !# !$ !% !& !' !(
39 
tested the 24-membered macrocyclic analogs (105, 106, and 107).57,58 In summary, the 24-
membered analog (105) retained cytotoxicity; however, inversion of stereochemistry about C14 
(108, 109, 112, 117, and 106) showed significant decrease in activity (IC50 values shown in Table 
4). Modest activity was retained from stereochemical changes about C11 (110, 115 and 121). 
Neither the inversion of C2 (111, and 113), nor protection of the C23 hydroxyl, via MTM or 
benzyl, had an effect on biological activity (114, 115, 116, and 122). Interestingly, addition of a 
halogen on the 24-D-MePhe in the para position at C11 increased toxicity (118, 119, and 107). 
Finally, the pentapeptide (104) showed a complete loss in cytotoxicity.  
  
2.8.2 Summary of Kulokekahilide-2 Polyketide Syntheses 
 In summary the polyketide portion of 50 was synthesized by 
Nakao and coworkers in 2004, and by Han and coworkers in 2014, both 
harnessing a similar route as used in the synthesis of 30, shown in Figure 
20. Key stereogenic steps include Evan’s mediated aldol reactions 
followed by Mukaiyama aldol addition. The utility of the TMS-enol ether 
addition is an efficient method to access the carbon framework of the 
polyketide; however, this non-selective addition lead to a mixture of 
diastereomers and 1,3-syn-diol formation was used to correct the 
stereochemistry. Nakao and coworkers were able to generate a library of compounds which 
allowed for biological testing and SAR showing the importance of the stereochemistry in both the 
polyketide and peptide portion of 50. Han and coworkers were able to introduce a radioactive 11C-






Nakao & coworkers: 2004
Evans Aldol
TMS-enol ether addn.





TBS-enol ether addn. Suzuki 
cross-coupling




2.9 Synthesis of Odoamide Polyketide  
 Odoamide (49) was isolated from the marine cyanobacterium Okeania sp. in 2016 by 
Sueyoshi and coworkers.59 To help determine the absolute stereochemistry of the NP, a synthetic 
route was devised to access the possible diastereomers about the C39 hydroxyl, and was inspired 
by the previous synthetic work by Mutou and coworkers, as shown in Scheme 10. Swern oxidation 
of 123 followed by Wittig olefination with ethyltriphenylphosphonium bromide (TEP) afforded 
124 in 71% yield over 2 steps in a Z/E ratio of 7:1. Deprotection of the benzyl group over Pd with 
H2 afforded the primary alcohol 125 with the reduced olefin. Again, the alcohol was oxidized via 
Swern conditions and subjected to Mukaiyama aldol conditions with the TMS-enol ether (126) to 
afford 127 in 85% yield over 2 steps. The methyl ester 127 was then oxidized to the ketone and 
the 1,3-syn-diol was generated using standard NaBH4 conditions to afford 128 in 83% yield over 
2 steps with a high degree of selectivity (dr > 97:3). Finally, the TBS deprotection with 
tetrabutylammonium fluoride (TBAF) afforded the methyl ester 129 in 81% yield. The diol was 
then converted to the acetonide for NMR characterization (not shown, 90% yield). Reduction with 
DIBAl-H followed by acetonide cleavage with HCl afforded the desired triol 130 to be compared 













i) (COCl)2, DMSO, 
DIPEA, CH2Cl2, 
-78 °C to 0 °C;
ii) TEP, n-BuLi, THF, 
72% (2 steps) 
(Z/E = 7 : 1)
10% Pd/C, H2, 
EtOH, rt, 85%
HO
OTBS (COCl)2, DMSO, DIPEA, CH2Cl2, -78 °C to 0 °C;
126, BF3·OEt2, CH2Cl2, 
Et2O, -78 °C, 
85% (2 steps)
MeO
O OH OTBS i) DMP, CH2Cl2, rt; 





TBAF, THF, rt, 81%
123 124 125
127 R=TBS 128










PPTS, CH2Cl2, rt, 90%; 
DIBAl-H, toluene, THF, 
-78 oC, 90%;




with the polyketide derived from the NP. Comparison to the NP revealed a C37(S), C38(S), 
C39(R), and C40(S) stereochemical relationship, however there remained some ambiguity of the 
stereochemistry about C40 (exocyclic methyl).  
In 2016 Sueyoshi and coworkers reported the total synthesis of odoamide (49).60 To further 
validate their previous reports, a synthetic route was designed to access the diastereomers about 
C40, shown in Scheme 11. The route began with an aldol reaction between (R)-4-benzyl-3-
propionyl-2-oxazolidinone (131) and the freshly generated aldehyde 132 affording 133 in 80% 
yield. The alcohol was protected via TBS (89% yield) and cleaved from the auxiliary using LiBH4 
(69% yield) to afford the primary alcohol 134. Swern oxidation conditions followed by Wittig 
olefination with TEP provided the alkene (135) in 69% yield over 2 steps with a Z/E mixture of 













nBu2BOTf, DIPEA, CH2Cl2, 
-78 °C to -10 °C, 80%
nBu2BOTf, DIPEA, CH2Cl2, 
-78 °C to -10 °C, 72%
1. TBSOTf, 2,6-lutidine, 
CH2Cl2, 0 °C to rt, 89%
2. LiBH4, MeOH, THF, 















i) (COCl)2, DMSO, DIPEA, 
CH2Cl2, 
-78 °C to 0 °C;
ii) TEP, n-BuLi, THF, rt, 
69% (2 steps) 
(Z/E = 7 : 1)
BnO
OTBS Pd/C, H2, EtOH, 
rt, 92% HO
OTBS (COCl)2, DMSO, DIPEA, 
CH2Cl2, -78 °C to 0 °C;
OX, BF3·OEt2, CH2Cl2, 










1. TBSOTf, 2,6-lutidine, 
CH2Cl2, 0 °C to rt, 87%
2. LiBH4, MeOH, THF, 




i) TsCl, Et3N, Me3N·HCl, 
CH2Cl2, rt; 
ii) LiAlH4, THF, 0 °C to rt, 
70% (2 steps)
BnO




(COCl)2, DMSO, DIPEA, 
CH2Cl2, -78 °C to 0 °C;
126, BF3·OEt2, CH2Cl2, 





















Confirmed structure of 49













Cytotoxicity in A549 cells: 540 nM
42 
7:1. Reduction of 135 with Pd/C and H2 afforded the primary alcohol 136 in 92% yield. Oxidation 
to the aldehyde followed by Mukaiyama aldol conditions afforded the methyl ester 137 in 54% 
yield. Standard peptide chemistry was used to construct 49 which was validated by NMR and 
showed a cytotoxicity comparable to the NP (IC50 = 2.1 nM in A549 cells). In addition, the C6-
epimer of the NP (144) was tested and showed a significant decrease in toxicity (IC50 = 540 nM). 
This work highlights the importance of the stereochemistry of the polyketide and stresses the need 
for a selective approach towards the polyketide of lagunamide C.  
2.9.1 SAR of Odoamide  
In 2018 the same lab reported the cytotoxicity of a set of odoamide analogs in A549 cell line, 
shown in Figure 21.61 Inversions of single amino acid residues at C25 (145, IC50 = 1554 nM), C15 
(146 IC50 = 48 nM), or C6 (147 IC50 = 645 nM) significantly decreased toxicity; however, inversion 
of the N-Me-L-Alanine at C2 position (148 IC50 = 1.9 nM) increased the cytotoxicity. Interestingly, 
the researchers also noticed the NP slowly converts to the 24-membered analog (149 IC50= 1.9 
nM) but retains toxicity. The addition of a methyl ether onto the C24 hydroxyl in both the 26 and 
24-membered macrocyclic structure (150 IC50 = 48 nM; 151 IC50 = 3383 nM) significantly 
decreased toxicity. Dehydration of the polyketide moiety (152) leads to a slight decrease in activity 
(IC50 = 28 nM). Finally, replacement of sarcosine with N-methyl-alanine (153), glycine (154), and 
D-Phe substitution (155) all slightly decreased toxicity (IC50 153 = 74 nM; IC50 154 = 31 nM; IC50 
155 = 5.4 nM). This work illustrates the chirality of the amino acids in the peptide portion play a 
critical role in the biological activity of the NP; further stressing the importance of a highly 
stereoselective approach in synthetic design towards the polyketide of lagunamide C.  
43 
  
Figure 21: SAR of odoamide through analog synthesis and cytotoxic 
evaluation. 













































































150: 48 ± 2.9 nM










149: 4.5 ± 1.4 nM



































































2.10 Synthetic Efforts Towards the Polyketide of Lagunamide A  
Following the isolation of lagunamide A (33, in Figure 15) in 2010, Dai and coworkers set out 
to achieve the first total synthesis leading to the reconfiguration of several stereocenters.34 Efforts 
towards the synthesis of the polyketide portion of 33 is shown in Scheme 12. The route began with 
an Evan’s mediated aldol reaction between 131 and freshly generated S-2-methylbutanal, followed 
by auxiliary cleavage with NaBH4. The resulting diol was protected with anisaldehyde in the 
presence of PPTS to provide the acetal 156 in an overall yield of 61% over 3 steps. Compound 
156 was subjected to DIBAl-H reduction with subsequent oxidation with Dess-Martin Periodate 
(DMP) to afford an aldehyde (not shown) which was subjected to the diastereoselective allylation 
using Keck’s protocol62 to afford the two diastereomers 157 and 158 in 27% and 67% yield, 
respectively. Protection with TES group on the newly formed hydroxyl followed by Johnson-
Lemieux oxidation allowed access to aldehyde 159 in 83% yield. Compound 159 was subjected to 
HWE olefination conditions with the phosphonate 160 to afford the α,β-unsaturated ester 161 in 
84% yield. Compound 161 was carried on producing compound 162; however, neither H1 nor C13 
NMR matched the NP. At this point, researchers hypothesized that several stereocenters of the 









i. BuBOTf, DIPEA, CH2Cl2, 
0 oC, then S-2-
methylbutanal, -78 oC
ii. NaBH4, Et2O-MeOH
iii. anisaldehyde dimethyl 
acetal, PPTS, DCM
61% (3-steps)
i. DIBAL-H, DCM, -78 to 
-10 oC;












































proposed structure may have incorrect 
stereochemical assignment. Comparing the 
proposed structure to the aurilide class of 
NPs, the C39 alcohol, the C40 methyl, and 
the C6 L-allo-isoleucine of 162 (shown in red 
in Scheme 12) were identified as possible 
sources of the error in the assignment of the 
original structure. To identify the correct 
structure, the possible diastereomers of the 
proposed NP were synthesized, shown in Figure 22. This work identified three stereochemical 
corrections wherein the C6 L-allo-isoleucine was exchanged with L-isoleucine, in addition to the 
inversions of C39 alcohol to (R) and C40 methyl to (S).  
Later in 2013 Huang and coworkers envisioned a new route involving a late stage cross-
metathesis to afford 33.63 The commercially available S-2-methylbutanol (166, Scheme 13) was 
oxidized via Swern conditions to the aldehyde (167) followed by subjection to Paterson anti-aldol 
conditions.64 Treatment of 168 with (c-hex)2BCl in addition to Me2NEt generated the trans enolate 
forming the aldol product 169 in 74% yield over 2 steps with high degree of diastereoselectivity 
(dr: 99:1). Protection of the C39 alcohol with TBS, followed by NaBH4 reduction produced a 
Figure 22: Isomers of lagunamide A synthesized 































































 dr > 99:1










1. TBSOTf, 2,6-lutidine, 0 °C, 
82%
2. i) NaBH4, MeOH/THF, 0 °C; 








1. AllylMgCl, THF, −78 °C, 
84% (dr 39:61)
- or -






166 167 168 169 170
171 172 173
46 
mixture of diastereomers of the diol 170 in 56% over 2 steps. Oxidative cleavage with NaIO4 
afforded the aldehyde 171 in 84% yield and was the synthetic handle needed for allylation. The 
addition of allyl magnesium bromide in THF at -78 oC gave an 84% yield with a dr of 39:61 in 
favor of the desired C37(S) configuration seen in compound 172. Conversely, treatment of 171 in 
the presence of ZnCl2 in THF at -78 oC gave 59% yield of the diastereomers with a 40:60 dr, in 
favor of the undesired diastereomer C37(R) shown as compound 173. The lack of desired 
selectivity caused the authors to reinvestigate a new route to get more selective allylation. 
Visualization of the Cram’s model, shown 
in Figure 23, identified the C3-OTBS group 
in the (R)-configuration (transition states A 
and B) has no steric bias and leads to a 
mixture of compounds. However, inversion 
of the C3-OTBS group to the (S)-
configuration (shown as C and D) allows for 
slower nucleophilic attack on the si-face 
(shown as disfavored) enabling increased 
formation of the C39(R) isomer. It is critical 
to mention this selectivity is strongly 
dependent upon the 1,3-diol chelation that produces a 6-membered ring transition state. With this 
new vision in mind, the authors set out the synthesize the C39(S) isomer with the intentions of 
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Figure 23: Transition state for selective allylation. 
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To this end a new route was developed that mimicked the previous reports towards 30, 
shown in Scheme 14. To start, N-propyl oxazolidine (131) was subjected to aldol conditions with 
167 to afford the C39(S) hydroxyl (174) in 93% yield reported as a single diastereomer. Alcohol 
protection with TBSCl (95% yield) followed by auxiliary cleavage and Swern oxidation provided 
compound 175 in an overall yield of 92% over 2 synthetic steps. With aldehyde 175 in hand, 
allylation conditions were explored leading to the desired C37(S) (176) hydroxyl in 90% yield 
with minor amounts of the undesired C37(R) (177: 10%). To invert the stereochemistry about C39, 
compound 176 was converted to 178 by removal of the TBS group on the C39 alcohol and selective 
TBS protection of the C37 alcohol. Compound 178 was then oxidized via DMP (92% yield) and 
reduced with lithium triethylborohydride (Et3BHLi) (94% yield) to afford the 1,3-syn-diol, 179. 
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The free hydroxyl at C39 was then coupled to the N-Me-Fmoc-D-Ala-OH (180) to afford the 
esterified product 181 in 55% yield. Compound 181 was advanced with standard peptide chemistry 
to afford compound 182 as the precursor for the ring-closing metathesis (RCM); however, all 
attempts to cyclize using Grubb’s second-generation catalyst failed to form 33. To overcome this 
limitation, compound 181 was exposed to Grubb’s second-generation catalyst in the presence of 
methacrylaldehyde to form compound 
184 in 87% yield with a E:Z ration of 
>99:1. Standard peptide chemistry 
was used to complete the total 
synthesis of 33 in addition to several 
analogs (shown in Figure 24) 
including; 39-epi-33 (185), 2-epi-33 
(186), 7,37,39-epi-33 (187), and 7,39-
epi-33 (188). A following report in 
2016 described the biological activity 
of these analogs, also show in Figure 
24.63 Interestingly, all analogs of 33 
showed significantly (>10x) 
decreased toxicity in all cell lines 
tested. Inversion of the C39 hydroxyl 
(185) inhibits all toxicity (IC50 range = 
191-950 nM), while inversion about 









































































Cell viability was detected using MTS assay after 48 h of treatment with serial dilutions
Figure 24: SAR of lagunamide A analogs and cytotoxic 
evaluation.  
Cell Line 33 185 186 187 188 189
A549 ﻿8.7 ± 0.3 273.9 ± 38.3 62.3 ± 11.5 3400.3 ± 567.3 >10000 >10000
HeLa 17.0 ± 1.7 191.6 ± 63.7 67.3 ± 20.3 1377.7 ± 313.5 >10000 >10000
U2OS ﻿8.6 ± 1.0 437.9 ± 58.0 59.3 ± 9.8 4036.7 ± 400.7 >10000 >10000
HepG2 ﻿11.4 ± 1.9 246.6 ± 9.7 67.4 ± 1.2 2537.3 ± 486.3 >10000 >10000
BEL-7404 ﻿11.0 ± 0.7 725.0 ± 153.5 59.9 ± 8.3 5859.3 ± 384.4 >10000 >10000
BGC-823 ﻿4.7 ± 0.4 231.7 ± 25.3 42.5 ± 1.8 3430.3 ± 577.1 >10000 >10000
HCT116 ﻿8.2 ± 1.2 200.0 ± 19.5 52.4 ± 5.1 3799.7 ± 332.7 >10000 >10000
MCF-7 ﻿18.7 ± 2.2 946.4 ± 206.8 145.8 ± 21.1 839.8 ± 407.8 >10000 >10000
HL-60 ﻿19.8 ± 0.9 713.9 ± 97.6 92.6 ± 1.9 8630.3 ± 515.1 >10000 >10000
A375 ﻿8.3 ± 1.8 212.6 ± 42.8 56.3 ± 6.6 970.2 ± 178.7 >10000 >10000
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186, range = 42-145 nM). Any inverted stereochemistry with respect to the NP; including 7,39-
epi-35-dehydro-33 analog (189), the C7, or C37 epimers render the molecule inactivity with IC50 
> 10,000 nM. Additional biological testing revealed 33 disrupts the mitochondrial membrane 
potential and leads to overproduction of reactive oxygen species (ROS). Proteomic profiling 
identified that 33 altered the expression levels of the Bcl-2 family of proteins including up-
regulation of Bcl-xL, Bcl-2, Mcl-1; in addition to down-regulation of Bax, Bad, and Bid all in a 
dose dependent manner. This family of proteins are known to be involved in regulation of the 
apoptotic cell death pathway.65–67 In conclusion, this work illustrates the importance of 
stereochemical configuration of the NP and gives a rational for a diastereoselective synthesis of 
lagunamide C.  
In 2014, a stereoselective approach towards the polyketide fragment of 33 was published 
by Lui and coworkers.32 Freshly generated S-2-methylbutanal (167) was reacted with methanol in 
the presence of catalytic amounts of p-toluenesulfonic acid (p-TsOH) to form the dimethyl acetal 
compound 190 (Scheme 15). This compound was exposed to the enolate of the N-propyl 
thiazolidinethione (Crimmin’s 
auxiliary) (191) to afford compound 
192 in 62% yield, reported as a single 
diastereomer. Cleavage of the 
auxiliary with DIBAl-H followed by 
allylMgCl addition generated 
compounds 193 and 194 in 99% yield 
in a 2:3 mixture, respectively. 
Compound 194 was then TBS 
Scheme 15: Synthesis of the polyketide of lagunamide 
A by Lui and coworkers. 
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protected (94%) followed by CM using Grubb’s second-generation catalyst to generate the 
polyketide 195 in 59% yield. At this point compound 195 was saponified and coupled to the first 
hydroxy acid; however, the total synthesis was not completed in this work due to limited material 
for cyclization attempts.   
In 2016 Banasik and coworkers published a route that used iterative asymmetric 
vinylogous Mukaiyama aldol reactions (VMAR) to synthesize the polyketide portion of 33, shown 
in Scheme 16.36 The synthesis commenced with the chiral vinylketene silyl N,O-acetal (196) being 
exposed to TiCl4 at -78 oC in the presence of freshly generated S-(2)methyl butanal (167) to afford 
197 in 96% yield with a dr > 98:2 in favor of the C39 (R) hydroxyl. The resulting hydroxyl was 
masked as a propionate (97% yield) 
and then exposed to ozonolysis to 
afford aldehyde 198 in 95% yield. 
The aldehyde was then subjected to 
the second VMAR with 196’ to 
produce 199 in 48% yield with a dr > 
91:9 in favor of the C37 (S) hydroxyl. 
The authors suggest the selectivity of 
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the reaction can be rationalized by the Felkin-Ahn model shown in Figure 25. The authors postulate 
that the (R) stereochemistry of the alpha methyl at C38 leads to steric congestion with the chiral 
auxiliary and slows product formation. However, the reaction allows for selective formation of the 
desired C37 (S) hydroxyl. Protection of the alcohol to the BOM ether group followed by auxiliary 
cleavage with LiOOH provided the carboxylic acid 200 in 98% yield. However, these compounds 
were not carried on to the total synthesis but were coupled to the first hydroxy acid of the peptide 
fragment.  
Developing highly selective methods to access the polyketide fragment have been explored 
extensively, and likely the most selective transformations was seen in the work by Gorges in 
2018.35 Employing a Matteson homologation strategy they were able to achieve the total synthesis 
of 33 through carbon chain elongation, as shown in Scheme 17. First, the methylboronic ester 201 
was exposed to the ethyl Grignard reagent under homologation conditions to give the prolonged 
carbon chain shown in 202 in 99% yield as a single diastereomer. The next homologation took 
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Scheme 17: Matteson homologation strategy to access lagunamide A. 
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elongate the chain further, methyl Grignard reagent produced compound 204 in 99% yield with a 
long reaction time of 14 days. The final C37 stereocenter was added by homologation with p-
methoxybenzylate to give 205 in 66% yield. The homologation strategy to add CH2 groups proved 
to be difficult upon initial attempts; however, in situ generation of bromomethyl lithium from 
dibromomethane and n-BuLi at -60 oC afforded the desired compound (206) in 98% yield. 
Compound 206 was elaborated onto the aldehyde 208 which, after several synthetic steps, was 
used in HWE olefination conditions to afford the polyketide containing compound 209. 
Impressively, this route was used to complete the total synthesis of 33 as a single stereoisomer.  
 
2.10.1 Synthetic Efforts Towards the Polyketide of Lagunamide B  
Efforts towards 34 have been limited to the work published by Pal and coworkers in 2014.68 
Starting with an Evan’s aldol reaction between compound 131 and tiglic aldehyde (210) in the 
presence of TiCl4 provided the C39(R) alcohol (211) in 88% yield with a dr of 97:3 (Scheme 18). 
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Alcohol protection via TBSOTf (93%) followed by auxiliary cleavage with LiBH4 (81%) and 
subsequent oxidation using pyridine-sulfur trioxide complex with Et3N provided the aldehyde 212 
in 93% yield. The enolate of the chiral auxiliary (213) was generated in the presence of Bu2BOTf 
and DIPEA leading to the formation of two diastereomers 214 and 215 in 63% yield with a dr of 
2:1 favoring the C37(S) alcohol (214). The alcohol was protected as a MOM ether (81% yield), 
cleaved from the auxiliary with LiBH4 (85% yield) and oxidized to generate 
aldehyde 216 in 93% yield. With the aldehyde in hand, fragment 217 was 
added in the presence of LiCl and DIPEA to facilitate HWE olefination to 
form the polyketide fragment (218) in 59% yield. However, inability to 
deprotect the MOM ether (219) hindered the completion of the total 
synthesis.  
 
2.10.2 Summary of Lagunamide Polyketide Syntheses  
The key synthetic transformations towards the polyketide 
fragments of the Lagunamide family are shown in Figure 26. In 2012, Dai 
and coworkers completed the first total synthesis of 33, leading to the 
stereochemical revision about C6, C37 and C39. The key stereogenic 
transformations include an Evan’s aldol, a diastereoselective allylation via 
Keck’s protocol, and an HWE-olefination. In 2013, Huang and coworkers 
gained access to the polyketide by employing a Patterson/Evans aldol, a 
diastereoselective allylation, and an olefin cross-metathesis.63 While the 
authors were unable to achieve the late stage macrocyclization from the 
diene, they were able to harness the CM condition to achieve the total 
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O OH O







































Figure 26: Summary of 
synthetic strategy to 
access the polyketide of 
lagunamides. 
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synthesis. In 2016, Banasik and coworkers reported their synthetic efforts using an iterative 
asymmetric VMAR to synthesize a polyketide intermediate towards 33.33 This route included 
consecutive use of 1,4 addition into TBS-enol ethers derived from Evan’s chiral auxiliaries, and 
proved to be a highly efficient. This route is the shortest of the linear sequence but requires thermal 
control for enhanced stereoselectivity. In 2018, Gorges and coworkers employed Matteson 
homologation followed by HWE-olefination to synthesize the polyketide containing fragment of 
33. This route has high selectivity and was able to produce the polyketide as a single stereoisomer, 
but required long reaction times and costly reagents.  
Compounds 33 differs from 34 by the saturation of the exocyclic carbon chain. While no 
total synthesis has been reported, Chakraborty and coworkers published their synthetic efforts in 
2014.68 The key transformations of this strategy include Evans-type aldol reactions followed by 
HWE-olefination; however, low yields upon macrolactonization failed to produce enough material 
to perform full characterization of the natural product.  
In summary the synthetic approaches towards 33 and 34 are highly dependent on the 1,3-
diol to control the stereoselectivity. Again, this renders the approaches unable to access the 1,4-
diol of lagunamide C. Each of these routes were taken into consideration when developing a route 
towards lagunamide C. 
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2.10.3 SAR of Lagunamides 
In 2016, Dang and coworkers employed MTS assay to determine toxicity of 33 and several 
synthetic derivatives, shown in Figure 27.33 
Compound 33 exhibited IC50 values less than 20 
nM in all cell lines tested including; A549, HeLa, 
U2OS, HepG2, BEL-823, HCT116, MCF-7, HL-
60 and A375. However, epimerization of a 
number of stereocenters including C2 (220, IC50 
range = 42.5-145.8 nM), C39 (221, IC50 range = 
191.6-725 nM), C7 (222, IC50 range = 839.8-
8603.3 nM) led to a loss in cytotoxicity. 
Epimerization of the C37 hydroxyl (223, IC50 
range = >10,000 nM), or dehydration (224, IC50 
range = >10,000 nM) rendered the compounds 
inactive to all tested cell lines. Following toxicity 
profiling, the molecular mechanism of 33 was 
investigated using transmission electron microscopy (TEM) and flow cytometry. Exposing A549 
cells to 10 nM of 33 caused pseudopodia retraction, shrinkage, chromatin condensation, and 
karyopyknosis. In addition to the flow cytometric analysis, these data indicate a mitochondrial-
mediated apoptosis pathway were initiated by 33 treatment. In addition, Western blot analysis of 
cells treated with 33 showed an overproduction of reactive oxygen species (ROS) and altered the 
protein expression of the Bcl-2 family. Notably, treatment with 33 led to down-regulation of 
Figure 27: SAR evaluation of lagunamide 
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MCF-7, HL-60, A375
IC50 Range= 4.7- 19.8 nM
Cell viability tested using MTS assay, 48 h treatment.
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antiapoptotic Bcl-2 family of proteins (Bcl-xL, Bcl-2, Mcl-1); but up-regulated the pro-apoptotic 
Bcl-2 family of proteins (Bax, Bad, Bid). 
 
2.10.4 Isolation and Biological Evaluation of Lagunamide D 
Luesch and coworkers published the structure elucidation of 36 in 2019.31 Interestingly, HPLC 
purification of the NP led to two compounds 36 and 225, a 24-membered analog, shown in Figure 
28. Researchers hypothesized this compound was a result of the interconversion under HPLC 
conditions. Both compounds were tested for 
toxicity in A549 cells and identified 225 
exhibited a nearly 10-fold decrease in toxicity 
(IC50 = 68.2 nM). There have been no further 
biological evaluation or synthetic efforts 
towards 36 to date.  
 
2.11 Conclusion of Previous Work on Aurilide Family and Research Outlook 
The synthetic efforts highlighted in this chapter have served as inspiration for the 
development of a route towards the polyketide lagunamide C. The limitations of the mentioned 
routes are due to the additional methylene (C39) which renders all strategies employing the N-
propyl auxiliaries, either Evans or Crimmins, incapable of accessing the polyketide. In addition, 
most of the above routes set the C36 alcohol via predictable 1,3-syn-diol reactivity, as opposed to 
the 1,4-diol contained in lagunamide C. Overall many of the synthetic steps in the outlined work 
have served as the basis of our approach albeit with some alterations. The previous work outline 
in this report will discuss the process of developing a new route to access the polyketide in a 
Figure 28: Lagunamide D and 24-epimer and 
































A549 IC50= 7.1 ± 1.7 nM
*MTT detection method, 48 h treatment
A549 IC50= 68.2 ± 2.6 nM
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diastereoselective approach. In addition, our work towards the polyketide is the first step in 
providing evidence of our hypothesis that would change the understanding of the aurilide class of 
NPs. We believe that synthesis of lagunamide C in addition to the generation of amide analogs in 
place of the ester linkages will result is the inhibition of activity. We hypothesize the cytotoxic 
activity associated with the NP is dependent upon delivery of the polyketide into the cancer cell 
via the peptide fragment that facilitates cell membrane penetration. The peptide fragment is critical 
for cellular penetration and upon cleavage of the ester bonds allows release of the cytotoxic 
polyketide. The SAR investigations highlighted in this chapter present no evidence to counter this 
argument. The data in this chapter suggest that the peptide portion alone has no toxicity (as 
discussed in Table 5), and biological testing also indicates any alteration of the stereochemistry in 
the polyketide can have a significant impact on the activity. For this reason, we set out to develop 




Chapter 3- Total Synthesis of Reniochalistatin E and Synthetic 
Efforts Towards Lagunamide C  
3 Research Motivation and Chapter Outline   
In order to further explore their cytotoxic activities a synthetic route was developed to 
access both reniochalistatin E and lagunamide C. Reniochalistatin E showed modest cytotoxic 
activities in myeloma cell lines, which is the most fatal of all blood-based cancers and has limited 
therapeutic options. To be discussed in this work is the total synthesis route developed to access 
reniochalistatin E and future work involves the development of a new prodrug delivery strategy. 
Lagunamide C was found to be highly toxic in several cancer cell lines including blood-based 
cancers. The work towards accessing lagunamide C involves the development of a novel approach 
to grant diastereoselective access to the polyketide subunit. Upon establishment of a synthetic 
route, SAR investigations will look to provide evidence of a prodrug moiety contained within the 
aurilide class of NPs. Previous work identifies the peptide portion of the NPs is devoid of cytotoxic 
activity, while stereochemical changes to the polyketide significantly attenuates the activity. For 
this reason, we believe the polyketide is the cytotoxic fragment and is released upon cellular uptake 
mediated by the peptide fragment. This chapter will discuss the synthetic efforts made towards 
each of these NPs and will highlight future experiments to validate the hypothesis.  
 
3.1 Total Synthesis of Reniochalistatin E 
 Attention was drawn towards the synthesis of reniochalistatin E (R1) due to ability to 
penetrate cancer cells, specifically myeloma cells, as described in chapter 1. As mentioned, cyclic 
peptides, especially those that are proline-rich, have constrained geometries and leads to enhanced 
biological half-lives and enhanced cellular penetration. Reniochalistatin E was found to be 
59 
comprised of eight amino acids, which are: L-tryptophan, L-leucine, L-isoleucine, L-proline, and L-
valine. There has been no total synthesis of reniochalistatin family to date. Therefore, a route was 
designed to access the structure for the first time with the intentions of using the molecular 
framework as a prodrug to delivery potent chemotherapeutics in future works.  
3.1.1 Retrosynthetic Analysis of Reniochalistatin E 
It was envisioned that reniochalistatin E (23) could be accessed via a macrocyclization from 
the linear percussors 226 or 227 (Scheme 19). Both linear precursors could arise from the coupling 
of the two tetrapeptides 228 and 229, which could be synthesized via standard peptide coupling 
reagents discussed in chapter 2 from commercially available L-amino acids.  
 
3.1.2 Construction of the Tetrapeptides 228 and 229 
The synthesis of 228 commenced with a (PyBOP)-mediated coupling of Boc-protected L-
isoleucine (230) to methyl ester of L-proline (231), to afford the dipeptide (232) in 92% yield, as 


























































































Scheme 19: Retrosynthetic analysis of reniochalistatin E (23). 
60 
tryptophan (234) under the same conditions to access dipeptide 235 in 97% yield. Saponification 
of dipeptide 232 with lithium hydroxide in THF/H2O furnished the free acid 236, and Boc 
deprotection of 235 with HCl in dioxane afforded the amine hydrochloride salt 237, both products 
were obtained in quantitative yields. The coupling of these two dipeptides was accomplished with 
PyBOP under standard conditions to give tetrapeptide 228 in 55% yield. However, when 
employing 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl) with 
HOBt rather than PyBOP the reaction was optimized to 86% yield.  
With tetrapeptide 228 in hand, construction of tetrapeptide 229 was undertaken, shown in 
Scheme 21. Coupling of Boc-L-proline (238) to methyl ester of L-leucine (239) was performed 
with PyBOP to furnish the dipeptide 240 in 97% yield. Treatment of 240 with lithium hydroxide 
in THF/H2O gave access to the saponified free acid dipeptide (241) in quantitative yields. Boc 
Boc-protected L-isoleucine 
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Scheme 21: Construction of tetrapeptide 229 
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deprotection of 232 with HCl in dioxane gave access to the HCl amine salt (242) in quantitative 
yield. Coupling of 241 with 242 under the previously employed PyBOP conditions afforded the 
desired tetrapeptide 229, but unfortunately the product was unable to be separated from the 
undesired urea by-products of the reaction, as described in chapter 2. Employing EDC·HCl and 
HOBt successfully accessed tetrapeptide 229 in 78% yield. The enhanced purity of the compound 
from these conditions was due to the aqueous soluble of the urea by-products of EDC·HCl 
coupling.  
 
3.1.3 Construction of the linear octapeptide 226 and 227 and macrocyclization attempts to 23 
As highlighted in Scheme 19, the linear octapeptide of 23 was envisioned to arise from the 
saponification and Boc deprotections of 228 and 229. Coupling of the free acid of 228 to the free 
base of 229 with EDC·HCl condition furnished octapeptide 226 in 34% yield over three steps 
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243      R1 = H, R2 = H
244      R1 = H, R2 = Me
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Scheme 22: Construction of the linear octapeptides 226 and 227 and 
initial attempts as macrocyclization to afford 23. 
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afford its fully deprotected form 243 in 97% yield. Macrocyclization attempts with this material 
under PyBOP conditions only resulted in the return of starting material (55%) and decomposition. 
We hypothesized the secondary amines of the proline residue, and the BOP-activated ester of the 
tryptophan could provide enough steric congestion to slow the formation of 23. To reduce the 
steric clash of the coupling, aminolysis was attempted for ring closure. To explore this, the Boc 
group on 226 was removed to afford 244, with the methyl ester intact; however, all attempts at 
cyclization failed to provide 23 and resulted in the return of starting material (67%) and 
decomposition. Recognizing the difficulty of cyclizing via the two sterically encumbered proline 
and tryptophan residues of 226, it was thought to couple these two groups first and perform 
macrocyclization elsewhere on the ring. To achieve this, 228 was Boc deprotected and 229 was 
saponified, both in quantitative yields. Introducing these to EDC·HCl coupling conditions gave 
the linear octapeptide 227 in 61% yield over three steps. Compound 227 was altered into its free 
acid and free amine counterpart in 95% yield and subjected to EDC·HCl coupling conditions to 
afford the desired natural product 23 in 9% yield. The 1H and 13C NMR spectra and the MS data 
of the synthesized 23 matched the literature data, shown in chapter 6.  
Cyclization conditions to afford 23 with 
enhanced yields were explored, as shown in Table 6. 
Attempted PyBOP-mediated coupling of 245 (entry 8) 
provided only starting material (78%) and 
decomposition. Employing HOBt, a commonly used 
additive in peptide couplings, with EDC·HCl to cyclize 
243 and 245 (entries 2 and 10) produced 23 albeit in low 
yields of 2% and 6%, respectively. Entry 10 reflects the 
Trial Compound Coupling Agent Additive Result
1 243 EDC·HCl N/A 6%
2 EDC·HCl HOBt 8%
3 DEBPT N/A -
4 DEBPT CsCl -
5 HBTU N/A -
6 HBTU DMAP 4%
7 TBTU DMAP trace







Table 6: Attempts to improve for the 
formation of 23. 
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highest yield of 23 via 245. To expand our reagent scope, macrocyclization was attempted with 3-
(diethoxyphosphoroyloxyl)-1,2,3-benzotriazine-4(3H)-one (DEPBT), a reagent that had been 
successful in the cyclization of similar amino acid based macrocycles.69 Unfortunately, all attempts 
at cyclization with this reagent of 243 and 245 (entries 3 and 11, respectively) as well as using 
cesium chloride as an additive to promote carbonyl coordination (entries 4 and 12) failed to provide 
23 in any increased yield. Uronium-based coupling reagents are well reported for their success in 
macrocyclizations, and as such, N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) and N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
tetrafluoroborate (TBTU) were both attempted with 243 and 245 in the absence and presence of 
4-(dimethylamino)pyridine (DMAP). In all attempted cyclization, these uronium-based reagents 
provided either none or low yields of 23. Employing HBTU with DMAP to cyclize 245 provided 
a 13% yield of 23 (entry 14), but in our hands, EDC·HCl with HOBt gave the best, albeit low, 
15% yield of the natural product. 
 
3.1.4 Biological Evaluation of Reniochalistatin E and Synthetic Intermediates 
Having accessed reniochalistatin E and the synthetic intermediates, including the di-, tetra-
, and octapeptides in both fully protected and deprotected states, SAR investigations were 










HeLa Cervical 17.3 16.9 ± 1.3 >20 18.4 ± 1.7*
U937 Lymphoma - 12.4 ± 2.4 9.5 ± 2.1* >20
RPMI-8226 Myeloma 4.9 4.5 ± 1.8 >20 16.4 ± 3.5*
MM.1R Lymphoblast - 11.2 ± 1.0 >20 >20
MiaPaca Pancreas - >20 19.1 ± 1.3 >20
A549 Lung - >20 >20 >20
MGC-803 Gastric 9.7 - - -
Table 7: Cytotoxicity comparison for natural and synthetic 23, and in vivo toxicity of synthetic 
intermediates.  
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undertaken. All compounds in the route were screened for general cytotoxicity against six human 
cancer cell lines (A549, lung; HeLa, cervical; MiaPaca, pancreatic; U937, lymphoma, RPMI-8226, 
myeloma; and MM.1R, multiple myeloma). However, none of the di- or tetrapeptides in protected 
or partial deprotected states were found to have IC50 values lower than 30 μM against the cell lines 
tested. Our synthetic sample of reniochalistatin E possessed approximately the same IC50 value in 
HeLa and RPMI-8226 cell lines: IC50 of 16.9 μM (±1.9) relative to the reported 17.3 μM in HeLa 
and an IC50 of 4.5 (±2.2) relative to the reported 4.9 μM in RPMI-8226 (Table 7). Reniochalistatin 
E lacked cytotoxicity against all of the remaining tested cell lines showing values >10 μM. Neither 
226 nor 227, the protected octapeptides, showed cytotoxicity; however, the free acid/amine 243 
showed moderate cytotoxicity toward U937 cell line with an IC50 of 9.5 ± 2.1 μM. In contrast to 
the free acid/amine 245 where no cytotoxicity was observed. At this time, no further investigation 
has been performed to draw a conclusion regarding SAR based upon these results. However, one 
can hypothesize the three prolines of 243 could impact the flexability of the structure to allow for 
cellular penetration and cytotoxicty, and would rationalize the low yeilds in cyclization attempts. 
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3.1.5 Reniochalistatin E as a Drug-Delivery Platform  
 With the synthetic route to reniochalistatin E in hand, and the knowledge of modest 
cytotoxicity associated with the natural compound, it was envisioned that this molecule be 
elaborated into a drug delivery vehicle. 
Although reniochalistatin E is not 
highly cytotoxic in comparison to 
known chemotherapeutics, its modest 
toxicity does indicate the compound is 
likely to penetrate various cells 
including multiple myeloma. Multiple 
myeloma is estimated to cause 12,830 
deaths in the United States in 2020, with 
a 5-year survival rate of only 54%.1,3,7 
With the in vitro ability of reniochalistatin E, an analog synthesis was designed to use this 
molecular framework as a way to delivery potent chemotherapeutic agents that would otherwise 
be inaccessible in myeloma treatments. However, first it is important to consider which amino acid 
would serve as the site for drug conjugation. The tryptophan was selected for its heterocyclic 
aromatic character which we could be easily substituted with many of the FDA approved 
anticancer drugs. Moreover, the Rafferty lab was exploring the biological properties of another 
blood cancer treatment option, 6-mercaptopurine (1), shown in Figure 2. This FDA approved drug 
is still being used for the treatment of acute lymphocytic leukemia (ALL), despite severe side-
effects including kidney failure, white blood cell suppression, jaundice, severe vomiting, 
hepatotoxicity, and death.70 With this in mind and the structural commonality between 6TP and 
Scheme 22: Retrosynthetic scheme towards the 






























































the indole moiety of tryptophan, efforts towards designing a linkage point that would allow for 
enhanced delivery of 6TP into myeloma cancer cells was undertaken. A prodrug moiety was 
envisioned which could arise from a disulfide linkage between a cysteine analog of reniochalistatin 
E (247) and the sulfur of 6TP to form compound 246 (shown in Scheme 22). The assembly of this 
reniochalistatin cysteine analog would arise from the same sequence of reactions with the single 
substitution from L-tryptophan for an acetomidly methyl (Acm) protected L-cysteine to afford the 
tetrapeptide 248. However, before this could be completed, we considered the idea of the 
tryptophan importance for the cytotoxicity associated with reniochalistatin E. If the tryptophan is 
critical for the cytotoxic activity, then substitution in that position would render the molecule 
inactive. Therefore, a synthetic analog where L-tryptophan is replaced with L-phenylalanine was 
synthesized to determine the impact on the cytotoxicity. 
To this end an analog with a L-phenylalanine in place of the tryptophan was designed, as 
shown in Scheme 23. This work was done in tandem with Ms. Giovana Baca and resulted in a 
trace amount of 249. The newly syntheisized analog was tested for anticancer activity and showed 























































Scheme 23: Retrosynthetic analysis of L-phenylalanine 
analog of reniochalistatin E (249). 
IC50 (µM)
Cell Line 23 249
RPMI-8226 4.5±1.8 5.1 ±1.3
HeLa 16.9 ±1.9 15.2 ±2.1
U-937 12.4 ±2.4 13.8 ±1.6
MM.1R 11.2 ±1.0 11.0 ±2.3
A549 >20 >20
(384-well plates, 72 h, Alamar Blue Detection)
Table 8: Toxicity profiling of 
phenylalanine analogs (249) 
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was not toxic towards A549 cell line, matching the observed toxicity of the synthesized NP. For 
this reason, we concluded the tyrptophan substitution has a limited impact on cytotoxicity. Future 
work will look to harness  the route developed towards reniochalistatin E to introduce 6TP in place 
of the tyroptophan to be tested for cytotoxicity.  
 
3.2 Synthetic Efforts Towards Lagunamide C 
3.2.1 Retrosynthesis of Lagunamide C 
3.2.1.1 Addressing the Stereochemical Ambiguity of Lagunamide C 
 The motivation to synthesize lagunamide C (35) drew from potent cytotoxicity in an array 
of cell lines and the interesting structural features of the aurilide family. The additional carbon unit 
within the polyketide (C39), renders the previously described synthetic routes incapable of 
accessing 35, as described in chapter 2. In addition, total synthesis of 35 would allow for 
clarification about the absolute stereochemistry, in particular within the polyketide. In light of the 
stereochemical corrections defined by accessing lagunamide A, the C40 and C7 (shown in red in 
Scheme 12) stereocenters are likely to be analogously inverted in the corrected structure of 
lagunamide C. Therefore, a newly propose structure of lagunamide C is shown as compound 252 
in Scheme 24. These stereochemical inversions will mimic the rest of the aurilide family and will 
match the stereochemical configurations as discussed by Dai and coworkers in their synthesis and 
structural elucidation of lagunamide A.  
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Retro-synthetically, accessing lagunamide C (Scheme 24) is envisioned to arise via 
macrolactonization by esterification of the polyketide 253 to the pentapeptide backbone (254) is 
envisioned. This work is focused on the diastereoselective construction of the proposed polyketide 
253. Originally this route was designed to set the C37 alcohol by a facially selective reduction 
using a Corey-Bakshi-Shibata reduction. Compound 253 would arise by performing a Mukaiyama 
Aldol between 255 and methyl-(E)-2-methylbut-2-enoate. In order to generate compound 255, the 
key transformation of the proposed route wherein a facially selective Charette asymmetric 
cyclopropanation of 256 and subsequent ring opening would allow the terminal alkene assigning 
the stereochemistry of the C38 methyl. Assembly of 256 will be accomplished through Wittig 
olefination of aldehyde 257, which can be constructed via an Aldol reaction by the chiral N-acetyl 
thiazolidinethione 258. This reaction will require generation of (S)-2-methylbutanal similar to the 
reports by Huang et al discussed in chapter 2. This work focuses on developing a synthetic route 
to access the polyketide subunit of lagunamide C. Understanding the stereochemistry of C37, C38 
and C40 were in question, a module based approach was designed a to access 253, but could also 





































































Scheme 24: Isolated structure of lagunamide C (35), newly proposed structure (252) 
with stereochemical inversions about C40 and C7 (shown in red), and retrosynthetic 
analysis of lagunamide C. 
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3.2.1.2 Module Based Approach Towards the Polyketide of Lagunamide C 
The first module of the proposed synthesis of the polyketide of lagunamide C begins with 
a Crimmins titanium-mediated aldol reaction between the chiral thiazolidinethione auxiliary (259) 
and freshly generated (S)-2-methyl butanal (167), as shown in Scheme 25. Compound 260 can be 
silyl protected, and the auxiliary cleaved under reducing conditions to produce a primary alcohol 
(not shown) and subsequently oxidized to aldehyde 257. This aldehyde can then undergo Wittig 
olefination and reduction to afford the allylic alcohol 256. The second module involves an 
asymmetric Charrette cyclopropanation71 to access the cyclopropanated compound 261. The 
methyl source of the cyclopropanation (IZnCH2I) can be controlled by boron chelation to set the 
stereochemistry of the C38 methylene. Halogen installation followed by ring-opening of 261 is 
envisioned to afford the stereoselective terminal alkene 255. Oxidative cleavage under Johnson- 
Lemieux oxidation72 will give access to aldehyde 262 which can then be subjected to a vinylogous 
Mukaiyama aldol73 reaction with TMS-enol ether (263) to generate compound 264. In the case 
that no selective addition can be achieved, oxidation to the ketone and chiral reduction would 
enable access to the diastereoselective synthesis of the polyketide portion of lagunamide C, shown 
as 265.  
























































Given the proposed retrosynthesis route developed, the cyclopropanation and subsequent 
ring opening steps to set the C38 methyl were identified as the key step as well as the step with 
great uncertainty. As such, a model system was designed to identify the feasibility of these 
transformation wherein 
commercially available 
butanal (266) was used in 
place of (S)-2-methylbutanal 
(167) in the initial aldol 
reaction. Using compound 266 not only allows for easy access to the allylic alcohol (267) for 
exploration of cyclopropanation conditions, it also can be used to generate a new analog of the 
polyketide of lagunamide C (268) with the C41 methyl group removed (Figure 29).  
3.2.2 Synthesis of the Polyketide Fragment of Lagunamide C   
3.2.2.1 C41 Methyl Truncated Polyketide Model System 
Synthesis of the C41 methyl truncated polyketide began with the construction of the 
acetylated thiazolidinethione (271), which was 
accessed from L-valine (269, Scheme 26). 
Reduction of 269 with LiAlH4 in THF at reflux 
afforded L-valinol in 99% yield. Formation of the 
Crimmins auxiliary was performed under standard conditions74,75 to access 270 in 95% yield over 
two-steps. Acetylation of the auxiliary with acetyl chloride and n-BuLi successfully furnished 271 
in 98% yield with no column chromatography required.  
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Scheme 26: Auxiliary generation for aldol 
reaction.  
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Initial aldol attempts 
between 271 and butanal 
employed the chiral base (-)-
sparteine (0.5 eq) with titanium 
tetrachloride in CH2Cl2, which 
afforded the desired aldol 
product 273 in 27% and 
undesired aldol product 272 in 
<4% yield (Table 9, entry 1). 
The stereoisomers of 273 and 
272 were also accessed by Zhou 
and co-workers76 and were used to confirm product distribution through 1H NMR and optical 
rotation comparisons. Zhou also employed the same Crimmins auxiliary, but under his condition 
of diisopropyl ethylamine (DIPEA) 272 was favored in a 2:1 ratio over 273. Increasing the 
equivalents of the sparteine did provide an increased yield of 273, but only by a marginal 3% with 
0.75 equivalents and 8% with 1.2 equivalents (entries 2 and 3, respectively). Employing various 
amine bases in auxiliary based aldol reactions is well reported in the literature.59,75 Given the poor 
yields with the chiral base (-)-sparteine, efforts were directed towards screening other amine bases. 
Exploring DIPEA (entries 4–6) as the base gave the opposite of the desired selectivity, favoring 
272 over 273, analogous to the reported observations from Zhou.76 Varying the equivalences of 
the base failed to reverse the observed selectivity. The addition of NMP (N-methylpyrrolidone) in 
an equal molar ratio to the base returned the desired selectivity with yields of 30% of 273 and 13% 
of the undesired 272 (entry 7). Considering our previous works with the diamine base sparteine, 






S O R2 R1
Conditions
butanal
272 R1 = H, R2 = OH
273 R1 = OH, R2 = H
Entry SM Coordination Base (eq)
% Yield


















(0.5) - <4 27
(-) sparteine 
(0.75) - <5 30
(-) sparteine 
(1.2) - <2 35
DIPEA (0.5) - 36 13
DIPEA (1.1) - 47 22
DIPEA (2.2) - 47 25
DIPEA (1.05) (1.05) 13 30
DIPEA (2.05) (1.05) 23 38
TMEDA (1.05) - 7 19
TMEDA (2.05) - 8 21
TMEDA (2.05) (1.2) 8 22
LDA (1.2) - 11 53
LDA (1.2) (1.2) 4 79
LDA (1.2) (2.2) <4 65
16 B Bu2BOTf Et3N - 25 16
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we hypothesized bidentate ligand addition onto the titanium would facilitate aldol formation to 
return our desired stereoselectivity. Doubling the base equivalence increased the yield of 273 by 
8%, but also increased 272 by 10% (entry 8). Employ the bidentate base TMEDA alone and with 
NMP failed to provide any yields greater than 22% of 273 (entries 9–11). With weak bases failing 
to provide the desired 273 in both high yields (over 50%) and in selectivity, strong bases were 
screened. Screening the reaction with LDA (entry 12) afforded 273 in 53%, and the undesired 272 
in 11% yield. Utilizing an equal molar ratio of LDA to NMP afforded 273 in 79%, with only 4% 
of the undesired 272 (entry 13). Given the observed trends, increasing the NMP equivalence should 
correlate to increased yields. Unfortunately, this was not observed with LDA and resulted in a 
decreased yield (entry 14). Through these studies, we were able to access 273 in a 70% yield with 
a 20:1 dr.  
With the optimized conditions in hand (Table 1, entry 13), TBS protection of the alcohol 
in 273 was performed with TBSCl, imidazole in THF in 45% yield (Scheme 27). Unfortunately, 
optimization of these conditions failed to result any increase in yield; however, employing 2,6-
lutidine in DMF at room temperature afforded 274 in 65% yield. Increasing the temperature to 32 
°C increased the yield to 86% of 274. Increasing the temperature further led to decomposition of 
the starting material. Treatment of 274 to DIBAl-H in CH2Cl2 gave access to aldehyde 276 in 31% 
yield along with recovered starting material 274 in 29% yield. In this DIBAL-H reduction step 
21% of the auxiliary 270 was obtained and subsequently acetylated to provide 271. All attempts 



































to optimize these conditions to reduced 274 to the aldehyde 276 provide low overall yields. 
Employing 2.2 equivalents of DIBAl-H in CH2Cl2 afforded alcohol 275 in 77% which was then 
oxidized to 276 in 96% yield under Swern oxidation conditions. Subjecting 274 to NaBH4 in 
ethanol furnished 275 in 91% yield, which was also oxidized to 276 in 96% yield. The NaBH4 
reduction also resulted in the recovery of 80% of auxiliary 270, which was successfully recycled 
and elaborated onto 271. Structural integrity of 271, via recycled 270, was confirmed by 1H NMR 
spectral and optical rotation comparison to the originally synthesized 271. Treating 276 with the 
activated ylide methyl-(triphenylphosphoranylidene) acetate in toluene afforded the allylic methyl 
ester 277 in 80% yield.  
With the desired product from the first module in hand, efforts were directed towards 
exploring the cyclopropanation and ring-opening step. Reduction of 277 with NaBH4 in ethanol 
afforded the allylic alcohol 267 in a 19% yield along with high amounts of decomposition. When 
LiAlH4 was employed, it failed to provide a greater yield of 267 yielding 17%. The reaction was 
finally optimized by subjecting 277 to 2.5 equivalents of DIBAl-H in CH2Cl2 at -78 °C affording 
267 in 92% yield (Scheme 28). With compound 267 in hand, efforts were turned towards 
identifying conditions for cyclopropanation and ring opening to prove that our proposed key-steps 
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Scheme 28: Cyclopropanation and ring-opening on model system. 
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failed to generate the desired product, which led us to explore temperature effects. Increasing the 
temperature, nor cooling the reaction to 0 °C then lowering to -20 °C failed to provide any product. 
Finally, stirring the reaction at 0 °C and then allowing it to warm to room temperature, 45 min post 
reagent addition, led to a 3% yield of 278. Excluding TiCl4 resulted in an increase of yield to 48%, 
and running the reaction overnight resulted in a 95% conversion to the desired cyclopropanated 
material 278 as a mixture of diastereomers. Mesylate protection of the alcohol was accomplished 
via methane sulfonyl chloride with Et3N in CH2Cl2 followed by iodine exchange with NaI in 
acetone to afford 279 in 80% yield over the 2 steps. The stability of 279 was found to be fleeting 
(1–2 h) and was immediately carried onto to the lithium-halogen exchange. Subjecting 279 to n-
BuLi and TMEDA in diethyl ether at -78 °C afforded a mixture of the desired ring-open products 
281 and 282 in a combined yield of 71%. The reaction is hypothesized to retain stereochemistry 
set in the cyclopropanation conditions through intermediate 280; however, starting with a racemic 
mixture lead to an inseparable mixture of diastereomers. Using less than 2.0 equivalents of 
tetramethylethylenediamine (TMEDA) resulted in a decrease in yields of 281/282 and led to an 
increase in decomposition of the starting material. Given the success of the model system, efforts 
were directed towards the synthesis of the target polyketide of lagunamide C.  
Scheme 29: Reaction conditions for aldol towards target polyketide. 


































49% best combined yield 21%
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3.2.3 Diastereoselective synthesis of the polyketide of lagunamide C  
3.2.3.1 Aldol Reaction Optimization 
To begin the synthesis towards the target polyketide, the commercially available alcohol 
(S)-2-methylbutanol (166) was oxidized to its corresponding aldehyde via Swern Oxidation 
conditions. Unfortunately, attempts to isolate the aldehyde (167) proved challenging as the product 
is volatile and evaporates under reduced pressure. Therefore, efforts towards generating the 
aldehyde in situ followed by immediate addition to the enolate of the thiazolidine (271) as shown 
in Scheme 29 was attempted. To this end, the crude mixture from the Swern Oxidation was 
subjected to the optimized aldol conditions using LDA wherein the lithium promoted enolate is 
known to proceed through a 6-membered ring transition state to provide the anti-aldol product 
with the C40-(S) configuration, as shown in Scheme 29. Unfortunately, the highest reaction yield 
was 49% of the mixture of diastereomers 283/284 in a 3:2 dr. In addition, the thiazolidine (270) 
was obtained in yields up to 21% and is inseparable from the desired isomer 283. There are limited 
reports of this deacetylation of the auxiliary.77,78 Literature reports identified DIPEA as a more 
selective method of enolate generation. When DIPEA is added in two equivalents, aldol formation 
is known to proceed through an open 6-membered ring transition state and allow preferential 
addition of the aldehyde in an anti-fashion to produce compound 283 as the major isomer, as 
shown in Scheme 30. Addition of one equivalents of DIPEA should generate a closed transition 
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284
283
Scheme 30: Previously reported aldol transition states with one and two equivalents of base.  
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identified that the starting material of the reaction was consumed with the two equivalent of base 
and therefore the major product of the reaction was believed to be the anti-aldol product (283).  
In an attempt to further optimize reaction selectivity, the auxiliary was altered to include 
the more sterically encumbered benzyl thiozolidinones 285 and 286, shown in Scheme 31 
Interestingly, when neat TiCl4 was substituted for a 1 M TiCl4 in CH2Cl2 solution, the reaction 
yielded both diastereomers in 84% and 94%, respectively. However, the reaction continued to 
produce the unwanted deacetylated auxiliary. The deacetylation increased when the high room 
humidity (> 65%), and when the crude reaction mixture was allowed to warm to room temperature 
overnight. To understand why this was occurring an HPLC method was designed to quantify the 
undesired products of the reaction.  
When 286 was subjected to 1 
equivalent of TiCl4 in CH2Cl2 at -78 oC 
followed by dropwise addition of various 
solvents/compounds. Next, the reaction was 
quenched with NH4Cl (sat) and the reaction 
was separated via HPLC and quantified based 
on the polarity. The addition of water lead to 









































Scheme 31: Optimization of aldol reaction using both enantiomers of the 
benzyl thiozolidinones 285 and 286. 































Percent of  
decomposition
(-78 oC -to- 0 oC)
None 5% 17% to 11%
H2O 1% 10% to 8%
EtOH 48% 30% to 76% 
t-BuOH 2% -




- 9% to 55%
Benzyl Alcohol - 33% to 58%
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the control group (5%) where no solvent was added before reaction quench with NH4Cl (sat) 
(shown in Table 10). However, when ethanol was added to 286, 48% of 291 was recovered.  The 
other solvents including tBuOH and isopropanol did. not increase in deacetylation showing 3% 
and 3%, respectively. Since none of the solvents tested are used or produced in the aldol reaction 
conditions, we expanded our test to include the aldol product of the reaction (290).  
One distinct advantage of the Crimmins auxiliaries are the ease of cleavage after aldol 
product formation. Therefore, compound 290 was subjected to one equivalent of TiCl4 and a 
variety of solvents/compounds to determine if this was the cause of the recovery of the 
deacetylated auxiliary (291). In addition, thermodynamic properties of this decomposition were 
explored by quenching half of the reaction at -78 oC and allowing the remainder of the reaction to 
warm to 0 oC before quench. Quantification of the by products via HPLC at -78 oC showed no 
significant increase in decomposition of water addition with 10% in comparison to the control 
group (17%). Increasing the temperature to 0 oC showed only 11% and 8% respectfully. When 
ethanol was added, 30% of 290 was recovered as 291. Moreover, when the temperature was 
increased to 0 oC 76% of 290 had broken down into 291. Interestingly, the addition of (S)-2-
methylbutanol (166) at -78 oC led to a 9% recovery of the auxiliary, but more than half (55%) of 
the starting material had been broken down when warmed to 0 oC. The addition of benzyl alcohol 
also increased with temperature from 33% to 58%, respectively.   
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3.2.3.1.1 Decomposition of N-acetyl Auxiliary 
This data shows evidence that primary alcohols enable decomposition of the N-acetylated 
Crimmins auxiliary (286) and the aldol product of the reaction (290). The instability of the N-
acetylated Crimmins auxiliary is likely due to the lack of inductive effect by the alpha methyl of 
N-propyl auxiliaries, which are widely used and have no reports of decomposition. One can 
conceptualize the titanium coordination allows enough electron deficiency at the carbonyl carbon 
of 286 to allow for a primary alcohol to attack and cleave the auxiliary, as shown in Scheme 32. 
This attack produces a tetrahedral intermediate (292) that may collapse and cleave the 
thiazolidinone (293) containing and an ester (294). Proton transfer produces the thiazolidinone 
(291) which is readily isolated; however, isolation of the ester formed in this reaction has not been 
achieved. The inability to isolate the ester product is attributed to the low molecular weight of the 
compound; which are known to be volatile under reduced pressure. In conclusion, we believe that 
excessing room humidity (>65%) prevents full oxidation of (S)-2-methylbutanol allowing for 
significant decomposition of both the N-acetylated thiazolidinone (286) and the aldol product 
(289/290) of the reaction. To combat this issue, we explored oxidation conditions for (S)-2-





































Scheme 32: Proposed mechanism for N-acylated auxiliary 
decomposition. 
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To optimize the aldol reactivity and decrease undesired decomposition, we looked to 
explore oxidation conditions with minimal side-products and workup. Subjecting (S)-2-
methylbutanol to TEMPO failed to oxidize to the aldehyde; however, PCC conditions allowed for 
full conversion of 166 to 167. In addition, the PCC oxidation requires simple celite filtration before 
use in the aldol reaction. With these new optimized conditions, the aldol reaction proceeded 
smoothly producing 289 
and 290 in a combined 
yield of 83% with a dr of 
4.5:1. Gratifyingly, 
protection of the hydroxyl 
via TBS triflate provided 
compound 295 in 
quantitative yields and afforded crystals for X-ray diffraction analysis. The data indicated the 
absolute configuration of 289 at the C40 as S, shown in Scheme 33.  
 
3.2.3.1.2 Inversion of Aldol Selectivity 
 The crystallographic data generated by this work challenges the proposed transition state 
discussed in the literature. As discussed, two equivalents of DIPEA is proposed to produce the 



































Scheme 33: Optimized aldol reaction and determination of 





































Scheme 34: Proposed boat transition state of N-acetyl Crimmins auxiliaries.  
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which can be attributed to the lack of steric influence associated with the N-acetyl variant of the 
auxiliary. The transition state previously described in Scheme 30 was originally derived from the 
work with the N-propyl auxiliary and contains a methyl in the alpha position of the enolate. This 
methyl induces selectivity by 1,3-diaxial interaction with the approaching aldehyde to enhance the 
selectivity. Contrary to this, the N-acetyl is devoid of this steric clash and can allow for conversion 
of the chair transition state to a boat-like transitions state, as shown in Scheme 34. The proposed 
boat transition state would produce the inverted selectivity, matching the observed selectivity in 
the afore mentioned aldol reactions.  
 
3.2.3.2 Completion of Module 1 towards the Target Polyketide of Lagunamide C  
 With a new understanding of selective aldol formation, the synthesis of polyketide of 
lagunamide C was continued, Scheme 35. Compound 289 was subjected to TBS triflate conditions, 
as previously described, and was subjected to NaBH4 to afford the primary alcohol 296 in 88% 
yield over 2 steps. Oxidation of 296 was performed by PCC and removal of the pyridinium by-
product via celite filtration was subjected to Wittig olefination to afford compound 297 over 2 
steps with an 80% yield. The allylic methyl ester (297) was then reduced to the allylic alcohol 256 
via DIBAl-H reduction in 91% yield. Accessing the allylic alcohol completed the first module with 
high control and enabled the exploration of cyclopropanation conditions to control the chirality of 
























289 296 297 256
Scheme 35: Completion of module one towards target polyketide of lagunamide C. 
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3.2.3.3 Optimization of Cyclopropanation Conditions and Module 2 
 The facially selective cyclopropanation upon the allylic alcohol 256 was performed with 
the addition of the chiral boric acid butylboronic acid N,N,N,N-tetramethyl-L-tartaric acid (298). 
Employing analogous conditions 
used in the C41 methyl truncate 
model system, with the addition 
of 298 furnished 261 in 76% 
yield. Elaboration of 261 to the 
desired iodinated compound 299 
was accomplished in 84% yield 
over 2 steps. Interestingly, 
subjection 299 to the ring-
opening conditions starting at –78 
oC and warming to –30 oC 
afforded both 255 and 301 in 85% yield with a dr of 5:1. When the reaction was maintained at a 
temperature of -78 oC an enhanced selectivity of 10:1 dr and a 99% yield was observed, in favor 
of the desired isomer (255). The loss of selectivity in the ring-opening step is counterintuitive to 
the hypothesized transition state (shown as 300 in Scheme 36) and is unlikely to account for the 
racemization to the undesired diastereomer. Therefore, the selectivity of the reaction indicates the 
cyclopropanation step as a source of the undesired isomer leading to compound 301. However, 
NMR characterization of the cyclopropanated compound 261 is unable to identify the dr of the 
reaction, and future work will look to determine this. Regardless, the route had allowed access to 
compound 255 as the major isomer validating module two of the proposed route.  
TMEDA, n-BuLi
Et2O
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3.2.3.4 Current Efforts on Module 3 
3.2.3.4.1 VMAR Trial 
To construct the polyketide of lagunamide C the final module looked to harness an 
enantioselective vinylogous Mukaiyama aldol reaction (VMAR) similar to the method employed 
by Bergdahl and coworkers.36 Bergdahl and coworkers were able to access the polyketide of 
lagunamide A via a TBS enol based auxiliary approached (Figure 35 A). In their efforts, 199 was 
generated in 48% yield with a dr of 91:1 in favor of the desired C37-S alcohol from the starting 
material aldehyde (198). The authors stated the R-2-methyl center of the aldehyde (198) was 
disfavored in the transition state due to chirality of the auxiliary and was responsible for the low 
yields. Based upon this data, and the fact that compound 262 possesses an R-2-methyl aldehyde, 
the enantiomer of the auxiliary was generated to explore the reaction further. 
Scheme 37: A. Reported transition state of VMAR when using R-2-methyl aldehydes by 




















































































 To investigate whether the L or D auxiliary would provide the desired stereoselectivity of 
the VMAR, a model system was undertaken. Two model aldehydes were chosen along with both 
the D and L valine-based auxiliaries. Oxidation of (S)-2-methylbutanol (166) to the aldehyde 
counterpart (167) was accomplished via PCC. In addition, both chiral oxazolidinones were 
constructed from their corresponding L and D valinol derivatives, respectively, and tiglic acid was 
amidated upon both auxiliaries followed by TBS enol ether formation to access both 196 and 302. 
The TBS enol ethers were treated with both aldehydes, (S)-2-methylbutanal and benzaldehyde at 
-78 °C with LHMDS and TiCl4 and allowed to run overnight (Table 11). Treatment of 196, the L 
valinol derived auxiliary, with (S)-2-methylbutanal (167) afforded a 31% yield of the desired 
VMAR product with a dr of 1:0 (entry 1). Employing the R-auxiliary (302) under the same 
conditions afforded a 32% yield of the expected product with a dr of 2:1 (entry 2). Both entry 1 
and 2 allowed the reaction to warm from -78 oC to RT overnight; however, when the reaction was 
kept at -78 oC for the duration of the 
reaction, a lower yield of 11% was 
obtained but with improved 
diastereoselectivity, a dr of 1:0 (entry 3). 
Interestingly, when benzaldehyde is 
exposed to similar conditions (entry 4) an 
improved yield of 65% is obtained along with the selectivity (1:0 dr). This suggests that the a-
methyl center does slow the MVAR, but the desired diastereoselectivity can be achieved through 
construction of the correct auxiliary. 
Table 11: Exploration of VMAR reactivity on model 
aldehydes (S)-2-methylbutanal and benzaldehyde 
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 Based upon the proven feasibility of the model system, efforts were directed towards 
accessing the required substrate to perform the MVAR to construct the carbon skeleton of the 
polyketide. Subjecting 255 to Lemieux-Johnson conditions, dihydroxylation with OsO4 followed 
by oxidative cleavage with NaIO4, 
furnished 262 in 68% yield (Scheme 
38). Unfortunately, subjecting 262 to 
the same conditions outlined in Table 
11 failed to provide any of the 
expected VMAR product (304). All of the attempted VMAR reactions performed on compound 
262 returned the starting aldehyde and the auxiliary with the TBS group removed. Noting that the 
reactivity in this case is highly dependent on titanium coordination and addition into the aldehyde, 
it is hypothesized that the TBS protecting group at C40, may be the cause for the lack of reactivity. 
As previously discussed, relative reactivities of 1,4-diols are starkly different from 1,3-diols and 
can also be a cause of decreased reactivity. Given the inability to gain access to the polyketide via 





























Scheme 38: Attempted VMAR to access the polyketide 
of lagunamide C.  
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3.2.3.4.2 Allylation and Cross-Metathesis Conditions 
To access the carbon framework of the polyketide, an allylation strategy similar to the work 
by Lin and coworkers was envisioned.63 
To understand the reactivity of the cross 
metathesis (CM) conditions, a model 
system was devised, shown in Scheme 39. 
To start, benzaldehyde (305) was exposed 
to allylmagnesium bromide in diethyl 
ether to afford the alcohol product 306 in 
91% yield as a mixture of enantiomers. 
The enantiomers were subjected to 
Grubb’s second-generation catalyst in the 
presence of methyl methacrylate (307) 
under reflux condition; however, no 
product (308) was isolated. Oxidation of 
compound 306 to the ketone (309) also 
failed to provide the product desired 
product (310) when subjected to the CM 
conditions. The free electrons of the 
oxygen in these cases were identified as a possible cause of the poor reactivity, and therefore 
compound (306) was protected as a PMB ether to afforded compound 311 in 96% yield. Upon 
subjection of 311 to CM conditions the homodimer 312 was isolated in 49% yield. To probe if the 

















































































Scheme 39: Model system using benzaldehyde (305) to 
explore reactivity of cross-metathesis reaction. 
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homodimer (312) to methacrylate (313) to provide the desired di-substituted olefin (314) in 68% 
yield. To explore the effects of TBS protection, compound 311 was protected with TBS triflate to 
afford 315 in 84% yield. Compound 315 was subjected to CM conditions with the aldehyde (316) 
and afforded the disubstituted olefin product 317 in 90% yield. Gratifyingly, subjected 315 to CM 
conditions with methyl methacrylate (307) formed the trisubstituted olefin product 318 in 87% 
yield. The success of the model system encouraged attempts to perform the CM conditions towards 
accessing the polyketide of lagunamide C.  
To access the terminal alkene needed for CM conditions, compound 262 was allylated with 
allylmagnesium bromide to produce 319 in 67% yield as a 1:1 mixture of diastereomers about the 
newly formed alcohol, shown in Scheme 40. Oxidation to the ketone via PCC afforded compound 
320 in 75% yield resolving the mixture of diastereomers via NMR. Unsurprisingly, subjecting 
compound 320 to CM conditions with 307, resulted in 59% recovery of the starting material. 
Compound 319 was protected as a PMB ether (322) in quantitative yields and subjected to CM 
conditions with 307 to afford compound 323 as a mixture of diastereomers in 36% yield. At this 
point a route had been developed to access the carbon framework of the polyketide, but a more 









































Scheme 40: Construction of the carbon framework of lagunamide C using allylation and CM 
conditions. 
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3.2.3.4.3 Diastereoselective Allylation and Access to the Polyketide of Lagunamide C 
 The reported literature of iridium catalyzed diastereoselective allylations prompted an 
investigation into the reactivity in this system.79,80 To this end, a model system was envisioned to 
explore reactivity, shown in Scheme 41. The iridium catalyst (324) was generated based on the 
literature procedure and subjected to allylation conditions with compound 166 to afford the alcohol 
325 in 43% yield with a dr of 2.5:1. Additionally, oxidative cleavage of the TBS protected 
compound 315 with OsO4 followed by reduction with NaBH4 generated compound 326 in 89% 
over 2 steps. Subjecting 326 to the iridium catalyst allylation conditions formed 327 in 27% yield 
with the TBS protected alcohol unaffected; however, the dr of the reaction was not determined. 
With the success of the model systems, compound 255 was subjected to oxidative cleavage 
conditions followed by reduction to generate 328 in 52% yield over 2 steps. Gratifyingly, allylation 
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with the iridium catalyst afforded the desired compound 329 in 63% yield with a dr of 7:3. 
Protection of the alcohol via PMBCl afforded 330 in 78% yield and CM conditions with 307 
afforded the methyl ester product 331 in 18% yield. This completes the third module of the 
proposed polyketide synthesis, and future work is aimed to complete the first total synthesis of 
lagunamide C using this route.  
 
3.2.4 Biological Activity of Lagunamide C Intermediates for SAR 
Several of the synthetic intermediates were tested 
in HeLa cell lines for cytotoxicity to identify SAR 
associated with the polyketide of lagunamide C, shown in 
Figure 30. Interestingly, the most potent compounds were 
enol containing compounds and had low µM toxicities 
including compounds 342, 297, and 344 which presented 
toxicity values of 3.12, 2.97 and 2.10 µM, respectively. 
These toxicity values are significantly different from the 
parent compound (low nM IC50 values), likely due to the 
lack of the peptide fragment which is critical for cellular 
penetration. Compounds without an enol functional group including 341, 343, 256, and 261 
showed low toxicity values of 9.91, >10, >10, 8.01 µM. This data supports the Michael-acceptors 
hypothesis, which is contained within the polyketide of lagunamide C, and is likely responsible 
for the cytotoxic activity. Moreover, further SAR on the complete collection of synthetic 









341 9.91 ± 1.9 µM
342 (R)-isomer 3.12 ± 0.89 µM 
297 (S)-isomer 2.97± 1.2 µM
343 (R)-isomer   > 10 µM
256 (S)-isomer  > 10 µM
261 8.01 ± 0.98 µM
344 2.10 ± 1.0 µM
1500 cells/well, 72 h assay, Alamar blue assay, 
Triplicates performed
Figure 30: Biological evaluation 
of synthetic intermediates for SAR. 
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3.2.5 Chapter Conclusion  
In conclusion, the first total synthesis of reniochalistatin E has been completed in 15 steps 
with an overall 5% yield. With this route established, a drug delivery system has been devised and 
current efforts towards developing a reniochalistatin E analog in which a disulfide bond is 
conjugated to 6TP is in progress. This newly generated analog is envisioned to enhance delivery 
of 6TP for treatment of the deadliest form of blood-based cancer, myeloma. In addition, a 
diastereoselective approach to access the polyketide of lagunamide C has been completed. The 
biological activity of several of the synthetic intermediates have identified the enol moiety as a 
critical for cytotoxic. This data supports our hypothesis regarding cellular penetration by the 
peptide backbone and delivery of the toxic polyketide subunit containing a Michael-acceptor as an 
enol. Future work will look prove the innate prodrug characteristic of lagunamide C and could 





Chapter 4: Conclusion and Future Work 
With the total synthesis route to access reniochalistatin E achieved, future work will access 
analogs of the NP as a new drug delivery platform. As shown in Scheme 42, current efforts are 
towards accessing the cysteine analog of reniochalistatin E to conjugate the FDA approved 
chemotherapeutic 6TP. To identify if the tryptophan amino acid could be exchanged for other 
residues, a phenylalanine analog (249) was generated and showed retention of the cytotoxicity 
from the NP. The tryptophan amino acid was therefore identified as the first sight to attempt to 
install 6TP via disulfide conjugation. Current efforts are underway to synthesize the ACM 
protected cysteine analog which can be deprotected and 6TP can be incorporated via disulfide 
conjugation after macrocyclization. The newly generated disulfide analog (246) is envisioned to 
have enhanced cytotoxicity and future testing will determine the compounds potential as a 
















































Total synthesis achieved 
























Scheme 42: Summary total synthesis of reniochalistatin E (23) structure of 
phenylalanine analog (249) which retained cytotoxicity and proposed drug delivery 
platform (246) through disulfide conjugation to 6TP (shown in red). 
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In addition, a diastereoselective route has been developed to access the polyketide of 
lagunamide C. While the total synthesis of the NP is pending, a module-based approach was 
designed to address the stereochemical ambiguity of the NP and allow for access to any of the 
diastereomers of the NP. The synthesis employs diastereoselective steps including a titanium 
mediated aldol reaction with a chiral auxiliary, an asymmetric cyclopropanation with tandem ring-
opening, and finally an iridium catalyzed allylation. Future work will look to complete the first 
total synthesis of lagunamide C via incorporation of the peptide backbone and macrocyclization. 
Thus far, biological testing on a collection of the synthetic intermediates indicates the enol moiety 
of the polyketide may be responsible for the toxicity; however, the values are substantially lower 
(10-fold decrease) without the peptide fragment. Interestingly, previous works has shown the 
peptide fragment is devoid of toxicity and is likely to allow transport into cells wherein the 
polyketide is released acting as a prodrug. Future work will look to perform further biological 
testing on the intermediates in the route for SAR to prove this. Moreover, this route can also be 
used to access the amide analog (345 in Scheme 43) to identify if lagunamide C acts as a prodrug. 
The amide analog will prevent cleavage of the ester bonds and will render the molecule inactive, 



















































Scheme 43: Hypothesized mechanism of toxicity of lagunamide C (34) is via cellular 
penetration and ester clevage to release the polyketide, and proposed amide analog (345) to be 
generated for identifying the impact of ester bonds.   
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Chapter 6: Procedures and NMRs  
General Methods 
All commercially available reagents were used as received. Optical rotations were 
measured on an Atago Polax-2L polarimeter with a sodium lamp. IR spectra were recorded on a 
Cary 630 FT-IR spectrometer as thin films. Only the strongest and/or structurally important 
absorptions of IR spectra were reported in wavenumbers (cm-1). 1H (400, 600 MHz) and 13C (101, 
151) spectra were obtained on a Varian and Bruker-Ascend spectrometers. The chemical shifts are 
given in parts per million (ppm) relative to residual CHCl3 d 7.26 ppm for proton spectra and 
relative to CDCl3 at d 77.23 ppm for carbon spectra, unless otherwise noted. High-resolution mass 
spectra were obtained using a LCT Premier time of flight mass spectrometer. Flash column 
chromatography was performed with silica gel grade 60 (230-400 mesh). Dichloromethane 
(CH2Cl2), tetrahydrofuran (THF), toluene (PhMe), N,N-dimethylformamide (DMF), acetonitrile 
(CH3CN), triethylamine (Et3N), and methanol (MeOH) were all degassed with argon and passed 




Synthesis of N-Boc-(L)-Ile-(L)-Pro-OMe (232) 
To a stirring solution of N-Boc-L- isoleucine (230; 1.0 g, 4.16 mmol, 1.0 equiv) in CH2Cl2 
(42 mL) were added PyBOP (2.27 g, 4.37 mmol, 1.05 equiv) and iPr2EtN (1.09 mL, 6.24 mmol, 
1.5 equiv). To a separate round-bottom flask (RBF) were added L-proline methyl ester (231; 1.03 
g, 6.24 mmol, 1.5 equiv), iPr2EtN (2.17 mL, 12.48 mmol, 3.0 equiv), and CH2Cl2 (6.3 mL). Both 
reaction mixtures were left to stir for 1 h, at which time they were combined and left to stir 
overnight at room temperature (rt). The reaction was quenched with 1 M HCl (1 vol equiv), and 
the product was extracted with CH2Cl2 (×2), washed with NaHCO3(satd), dried over sodium 
sulfate, and concentrated under reduced pressure. The crude material was purified via flash silica 
gel chromatography (1:2 EtOAc/hexane) to afford 232 (1.30 g, 92% yield). 
1H-NMR (CDCl3, 400 MHz): δ 5.11 (d, J = 9.5 Hz, 1H), 4.52 – 4.44 (m, 1H), 4.24 (dd, J = 9.5, 
7.2 Hz, 1H), 3.80 – 3.73 (m, 1H), 3.66 (s, 3H), 3.65 – 3.58 (m, 1H), 2.22 – 2.12 (m, 1H), 2.01 – 
1.90 (m, 3H), 1.71 (ddq, J = 10.3, 6.5, 3.5 Hz, 1H), 1.53 (td, J = 7.2, 6.6, 3.2 Hz, 1H), 1.37 (s, 
9H), 1.07 (ddd, J = 13.4, 6.7, 2.3 Hz, 1H), 0.96 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H). 
13C-NMR (CDCl3, 101 MHz):  δ 172.64, 171.65, 156.01, 79.70, 59.04, 56.46, 52.35, 47.42, 
38.13, 29.29, 28.56, 25.17, 24.38, 15.47, 11.46. 
IR (film) nmax: 3436, 2973, 1746, 1642, 1436, 1217 cm-1.  
Optical Rotation: 	[α]!"# = +40.3 (c 1.23, CHCl3).  




















Synthesis of N-Boc-(L)-Leu-(L)-Trp-OMe (235) 
To a stirring solution of compound N-Boc-L-leucine (233; 1.0 g, 4.32 mmol, 1.0 equiv) in 
CH2Cl2 (43 mL) were added PyBOP (2.36 g, 4.54 mmol, 1.05 equiv) and iPr2EtN (1.13 mL, 6.48 
mmol, 1.5 equiv). To a separate RBF were added L-tryptophan methyl ester (234; 1.65 g, 6.48 
mmol, 1.5 equiv), iPr2EtN (2.26 mL, 12.96 mmol, 3.0 equiv), and CH2Cl2 (6.5 mL). Both reaction 
mixtures were left to stir for 1 h, at which time they were combined and left to stir overnight at rt. 
The reaction was quenched with 1 M HCl (1 vol equiv), and the product was extracted with CH2Cl2 
(×2), washed with NaHCO3(satd), dried over sodium sulfate, and concentrated under reduced 
pressure. The crude material was purified via flash silica gel chromatography (1:1 EtOAc/hexane) 
to afford 235 (1.81 g, 97% yield) 
1H NMR (400 MHz, DMSO-d6): δ 10.85 (s, 1H), 8.06 (d, J = 7.4 Hz, 1H), 7.45 (d, J = 7.9 Hz, 
1H), 7.31 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 7.07 – 7.02 (m, 1H), 6.96 (td, J = 7.5, 6.9, 
1.1 Hz, 1H), 6.82 (d, J = 8.5 Hz, 1H), 4.51 (q, J = 7.1 Hz, 1H), 3.98 (td, J = 8.7, 6.0 Hz, 1H), 
3.55 (s, 3H), 3.13 – 3.05 (m, 2H), 1.53 (dd, J = 13.6, 6.9 Hz, 2H), 1.35 (s, 9H), 1.26 (s, 1H), 0.84 
(d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d): δ 172.99, 172.44, 155.95, 136.45, 127.76, 123.62, 
122.15, 119.58, 118.63, 111.71, 109.49, 80.22, 53.46, 53.29, 52.54, 41.55, 28.52, 27.81, 24.92, 
23.18, 22.04. 
Optical Rotation: 	[α]!"# = +26.93 (c 0.15, CHCl3).  
IR (film) nmax: 3418, 3018, 2872, 1739, 1513, 1215 cm-1.   






















Synthesis of N-Boc-(L)-Ile-(L)-Pro-OH (236) 
 
To a stirring solution of 232 (556 mg, 1.62mmol, 1.0 equiv) in 1:1 THF/H2O (16 mL) was 
added LiOH (194 mg, 8.12 mmol, 5.0 equiv). The mixture was left to stir at rt for 5 h. The reaction 
was quenched with 1MHCl (1 vol equiv), and the product was extracted with CH2Cl2, washed with 
NaHCO3(satd), dried over sodium sulfate, and concentrated under reduced pressure. The product 
236 was obtained in quantitative yield as an oily residue, which was used without further 
purification. 
IR (film) nmax: 34356, 3304, 2977, 1704, 1314 cm-1.   
1H NMR (400 MHz, Chloroform-d): δ 8.31 (s, 1H), 5.35 (d, J = 9.5 Hz, 1H), 4.57 (t, J = 6.4 
Hz, 1H), 4.32 – 4.25 (m, 1H), 3.82 (dt, J = 9.6, 7.2 Hz, 1H), 3.64 (ddd, J = 9.7, 7.5, 5.4 Hz, 1H), 
2.18 (dd, J = 10.0, 3.9 Hz, 2H), 2.07 – 1.99 (m, 2H), 1.76 (td, J = 7.0, 3.4 Hz, 1H), 1.64 – 1.48 




















Synthesis of N-Boc-(L)-Leu-(L)-Trp-OH (237) 
 
To a RBF was added 1 M HCl in dioxane (4.6 mL), which cooled to 0 °C, at which point 
9 (500 mg, 1.16 mmol) was added. The reaction was allowed to stir for 1.5 h. The solvent was 
removed under reduced pressure to afford a crude white solid (11), which was used without further 
purification 
IR (film) nmax: 3416, 2879, 1651, 1176 cm-1.   
1H NMR (400 MHz, DMSO-d6): δ 9.04 (d, J = 7.2 Hz, 1H), 8.25 (s, 3H), 7.49 (d, J = 7.8 Hz, 
1H), 7.35 (dt, J = 8.1, 1.0 Hz, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.07 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 
7.00 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.63 – 4.54 (m, 1H), 3.81 (t, J = 7.2 Hz, 1H), 3.58 (s, 3H), 

























Synthesis of N-Boc-(L)-Ile-(L)-Pro-(L)-Leu-(L)-Trp-OMe (228) 
 
Compound 236 (1.32 g, 4.02 mmol, 1 equiv), compound 237 (1.08 g, 2.94 mmol, 1 equiv), and 
HOBt (473 mg, 3.09 mmol, 1.05 equiv) were dissolved in dry THF (40 mL) at rt under an argon 
atmosphere. The solution was cooled to 0 °C and stirred for 20 min, after which Et3N (1.43 mL, 
10.29 mmol, 3.5 equiv) was then added and stirred. Lastly, 20 min later EDC·HCl (592 mg, 3.09 
mmol, 1.05 equiv) was added, and the reaction mixture was left to stir overnight. The reaction was 
quenched with H2O (1 vol equiv), and the product was extracted with CH2Cl2, dried over sodium 
sulfate, and concentrated under reduced pressure. The crude material was purified via flash silica 
gel chromatography (3:1 EtOAc/hexane) to give afford 228 (2.22 g, 86% yield) as a clear liquid. 
Optical Rotation: 	[α]!"# = +48.08 (c 1.75, CHCl3).  
IR (film) nmax: 3305, 3017, 2876, 1741, 1631, 1506, 1392, 1215 cm-1.   
1H-NMR (CDCl3, 400 MHz): δ 8.29 (s, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 
7.16 (td, J = 8.2, 7.6, 1.3 Hz, 1H), 7.13 – 7.05 (m, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.97 (d, J = 7.8 
Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 5.20 (d, J = 9.4 Hz, 1H), 4.90 (dt, J = 7.9, 5.5 Hz, 1H), 4.37 (d, 
J = 6.0 Hz, 1H), 4.27 (dd, J = 9.3, 7.0 Hz, 1H), 3.71 (d, J = 8.9 Hz, 1H), 3.66 (s, 3H), 3.60 – 3.51 
(m, 1H), 3.30 (d, J = 5.5 Hz, 2H), 2.12 – 1.87 (m, 3H), 1.73 – 1.56 (m, 5H), 1.43 (s, 9H), 1.13 – 


































13C-NMR (CDCl3, 101 MHz):  δ 172.86, 172.49, 172.08, 171.74, 156.08, 136.32, 127.75, 123.57, 
122.11, 119.61, 118.60, 111.55, 109.58, 79.89, 60.26, 56.61, 52.95, 52.56, 52.15, 47.99, 41.15, 
37.95, 28.60, 25.58, 27.76, 25.31, 24.79, 24.42, 23.10, 23.05, 22.06, 15.65, 11.31. 
HRMS (ESI+): m/z 942.3817 [M+H]+ (calcd for C34H52N5O7 642.3822). 
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Synthesis of N-Boc-(L)-Pro-(L)-Val-OMe (240) 
 
Compounds 238 (3.0 g, 13.94 mmol, 1equiv) and 239 (2.34 g, 13.94 mmol, 1 equiv) were 
added to a stirring solution of HOBt (2.24 g, 14.63 mmol, 1.05 equiv) in dry THF (139 mL) at rt 
under an argon atmosphere. The solution was then cooled to 0°C and stirred for 20 min, after which 
Et3N (6.8 mL, 48.79 mmol, 3.5 equiv) was added. After an additional 20 min of stirring EDC·HCl 
(2.8 g, 14.63 mmol, 1.05 equiv) was added, and the reaction mixture was left to stir overnight. The 
reaction was quenched with H2O (1 vol equiv), and the product was extracted with CH2Cl2, dried 
over sodium sulfate, and concentrated under reduced pressure. The crude material was purified via 
flash silica gel chromatography (1:1 EtOAc/hexane) to give 240 (4.45 g, 97% yield) as a clear 
liquid. 
1H-NMR (CDCl3, 400 MHz): δ 4.50 (dd, J = 8.6, 5.1 Hz, 1H), 4.32 (s, 1H), 3.72 (s, 3H), 3.42 (s, 
2H), 2.29 (s, 1H), 2.15 (pd, J = 6.9, 5.1 Hz, 2H), 1.95 – 1.84 (m, 3H), 1.48 (s, 9H), 0.92 (dd, J = 
8.3, 6.8 Hz, 6H). 
13C-NMR (DMSO, 101 MHz): δ 172.71, 78.98, 59.71, 58.16, 52.30, 47.18, 31.67, 30.41, 28.80, 
28.68, 23.61, 19.77, 18.99, 14.76. 
Optical Rotation: [α]!"# = +80.78 (c 2.05, CHCl3).  
IR (film) nmax: 3680, 3323, 3415, 2973, 2879, 1740, 1681, 1216 cm-1.   
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Synthesis of N-Boc-(L)-Pro-(L)-Val-OH (241) 
 
To a stirring solution of 240 (360 mg,1.1 mmol, 1 equiv) in 1:1 THF/H2O (4.4 mL) was 
added LiOH (131 mg, 5.5 mmol, 5 equiv), and the mixture was left to stir at rt for 3 h. The reaction 
was quenched with 1M HCl (1 vol equiv), and the product was extracted with CH2Cl2, washed 
with NaHCO3(satd), dried over sodium sulfate, and concentrated under reduced pressure. Crude 
241 was obtained in quantitative yield as an oily residue and was used without further purification. 
1H-NMR (CDCl3, 400 MHz): δ 10.37 (s, 1H), 7.51 (s, 1H), 4.50 (s, 1H), 4.40 – 4.19 (m, 1H), 
3.50 – 3.28 (m, 2H), 2.31 – 2.09 (m, 3H), 1.94 – 1.79 (m, 2H), 1.43 (s, 9H), 0.91 (dd, J = 9.9, 6.9 
Hz, 6H). 
IR (film) nmax: 3410 (b), 1676 cm-1.   



















Synthesis of H2N-(L)-Leu-(L)-Trp-OMe (242) 
 
To a RBF containing 232 (857 mg, 2.5mmol) was added 1.0 M HCl in dioxane (10 mL), 
and the mixture was cooled to 0 °C. The reaction mixture was allowed to stir at the same 
temperature for 3 h. The solvent was removed under reduced pressure to afford crude 242 in 
quantitative yield as a white solid, which was used without further purification. 
1H-NMR (CDCl3, 400 MHz): δ 8.34 – 8.27 (m, 3H), 4.61 (dd, J = 8.5, 5.3 Hz, 1H), 4.25 (s, 1H), 
3.97 (s, 1H), 3.68 (s, 3H), 3.52 (d, J = 9.0 Hz, 1H), 2.28 (s, 1H), 2.05 – 1.91 (m, 4H), 1.68 (ddd, J 
= 13.5, 7.5, 3.3 Hz, 1H), 1.35 (ddd, J = 13.3, 10.0, 7.1 Hz, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.94 (t, J 
= 7.3 Hz, 3H). 
IR (film) nmax: 3416, 2879, 1651, 1454 cm-1.   















Synthesis of N-Boc-(L)-Pro-(L)-Val-(L)-Ile-(L)-Pro-OMe (229) 
 
Compounds 242 (1.71 g, 7.06 mmol, 1 equiv) and 241 (2.24 g, 7.13 mmol, 1 equiv) were 
added to a stirring solution of HOBt (1.13 g, 7.41 mmol, 1.05 equiv) and dry THF (71 mL) at rt 
under an argon atmosphere. The solution was cooled to 0 °C and stirred for 20 min, after which 
Et3N (3.46 mL, 24.71 mmol, 3.5 equiv) was added. After an additional 20 min of stirring, 
EDC·HCl (1.42 g, 7.41 mmol, 1.05 equiv) was added, and the mixture was stirred overnight. The 
reaction was quenched with H2O (1 vol equiv), and the product was extracted with CH2Cl2, dried 
over sodium sulfate, and concentrated under reduced pressure. The crude material was purified via 
flash silica gel chromatography (7:1 EtOAc/hexane) to give 229 (1.52 g, 78% yield) as a clear 
liquid. 
1H-NMR (CDCl3, 400 MHz): δ 7.48 (s, 1H), 6.65 (s, 1H), 6.42 (s, 1H), 4.58 (t, J = 8.2 Hz, 1H), 
4.47 (dd, J = 8.6, 4.9 Hz, 1H), 4.31 (s, 1H), 4.26 (dd, J = 8.6, 5.6 Hz, 1H), 3.81 (dt, J = 9.8, 6.3 
Hz, 1H), 3.68 (s, 3H), 3.64 – 3.59 (m, 1H), 3.46 – 3.28 (m, 2H), 2.33 (s, 1H), 2.19 (ddq, J = 12.9, 
6.8, 3.7 Hz, 2H), 2.02 – 1.79 (m, 8H), 1.43 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.89 – 0.80 (m, 9H). 
Optical Rotation:	[α]!"# = +72.3 (c 3.21, CHCl3).  
IR (film) nmax: 3673, 3412, 3306, 2879, 1743, 1632, 1368 cm-1.   

































Synthesis of H2N-(L)-Ile-(L)-Pro-(L)-Leu-(L)-Trp-OMe (Free Amine of Tetrapeptide 228) 
 
To a RBF containing 228 (1.03 g, 1.6 mmol) was added 1.0 M HCl in dioxane (6.4 mL), 
and the solution was cooled to 0 °C. The reaction mixture was allowed to stir at the same 
temperature for 3 h. The solvent was removed under reduced pressure to afford a crude white solid 
(free base of 228), which was used without further purification.  
IR (film) nmax: 3323, 3018, 2879, 1633, 1449, 1216 cm-1.   
1H-NMR (CDCl3, 400 MHz): δ 8.17 (d, J = 44.9 Hz, 2H), 7.51 (d, J = 7.7 Hz, 1H), 7.32 (d, J = 
8.0 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.10 – 7.05 (m, 2H), 6.83 (d, J = 8.3 Hz, 1H), 4.96 (d, J = 
7.8 Hz, 1H), 4.83 – 4.63 (m, 4H), 4.42 (q, J = 7.8 Hz, 2H), 3.91 (d, J = 8.3 Hz, 1H), 3.79 – 3.70 
(m, 2H), 3.65 (s, 5H), 3.30 (d, J = 6.0 Hz, 2H), 2.96 (ddt, J = 22.3, 10.3, 6.4 Hz, 2H), 1.95 – 1.81 































Synthesis of N-Boc-(L)-Pro-(L)-Val-(L)-Ile-(L)-Pro-OH (Free Acid of Tetrapeptide 229) 
 
To a stirring solution of 229 (200 mg, 0.37 mmol, 1 equiv) in 1:1 THF/ H2O (1.5 mL) was 
added LiOH (45 mg, 1.86 mmol, 5 equiv), and the solution was left to stir at rt for 3 h. The reaction 
was quenched with 1M HCl (1 vol equiv), and the product was extracted with CH2Cl2, washed 
with NaHCO3(satd), dried over sodium sulfate, and concentrated under reduced pressure. The 
crude material (free acid of 229), obtained in quantitative yield as an oily residue, was used without 
further purification.  
1H-NMR (CDCl3, 400 MHz): δ 7.50 (s, 0H), 4.63 (t, J = 8.9 Hz, 0H), 4.41 (d, J = 65.5 Hz, 4H), 
3.88 (d, J = 10.7 Hz, 1H), 3.67 (s, 2H), 3.43 (s, 2H), 2.16 (s, 7H), 1.96 – 1.74 (m, 5H), 1.46 (s, 
9H), 1.21 – 0.74 (m, 12H). 































Synthesis of Octapeptide N-Boc-Pro-Val-Ile-Pro-Ile-Pro-Leu-Trp-OMe (226) 
 
Free base of 228 (915 mg, 1.69 mmol, 1 equiv), free acid of 229 (784.5 mg, 1.5 mmol, 1 
equiv), and HOBt (240 mg, 1.56 mmol, 1.05 equiv) were dissolved in dry THF (17 mL) at rt, under 
an argon atmosphere. The solution was then cooled to 0 °C and stirred for 20 min, after which 
Et3N (0.731 mL, 5.25 mmol, 3.5 equiv) was added. After an additional 20 min of stirring, 
EDC·HCl (299 mg, 1.56 mmol, 1.05 equiv) was added, and the mixture was left to stir overnight. 
The reaction was quenched with H2O (1 vol equiv), and the product was extracted with CH2Cl2, 
dried over sodium sulfate, and concentrated under reduced pressure. The crude material was 
purified via flash silica gel chromatography (1:9 EtOAc/MeOH) to afford 226 (605 mg, 27% (34% 
yield over 3 steps)) as an amber liquid. 
1H-NMR (CDCl3, 400 MHz): δ 7.50 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.13 (t, J = 7.2 
Hz, 1H), 7.10 – 7.03 (m, 2H), 6.82 (s, 1H), 4.97 (s, 1H), 4.65 (s, 2H), 4.42 (s, 2H), 4.25 (s, 1H), 
3.88 (d, J = 9.4 Hz, 1H), 3.69 (s, 2H), 3.66 (s, 3H), 3.30 (d, J = 4.9 Hz, 2H), 2.07 (d, J = 145.9 Hz, 
24H), 1.44 (s, 4H), 1.31 – 1.21 (m, 1H), 0.90 – 0.75 (m, 25H).  
13C-NMR (CDCl3, 101 MHz):  δ 17.38, 172.39, 151.82, 142.80, 140.68, 136.40, 127.78, 122.15, 
119.63, 118.69, 111.44, 52.59, 48.15, 28.55, 24.87, 24.87, 23.06, 23.06, 19.62, 19.62, 15.33, 11.24.  
Optical Rotation:	[α]!"# = -25.63 (c 0.21, MeOH). 























































Synthesis of H2N-(L)-Pro-(L)-Val-(L)-Ile-(L)-Pro-OMe (Free Amine of Tetrapeptide 229) 
 
To an RBF containing 229 (151 mg, 0.28 mmol) was added 1.0 M HCl in dioxane (1.1 
mL), and the solution was cooled to 0 °C. The reaction was allowed to stir at the same temperature 
for 3 h. The solvent was removed under reduced pressure, forming a crude white solid (free base 
229), which was used without further purification. 
IR (film) nmax: 3323, 2878, 1742, 1633, 1216 cm-1. 
1H-NMR (CDCl3, 400 MHz): δ 10.92 (s, 1H), 8.76 (s, 1H), 8.16 (s, 1H), 7.83 (d, J = 9.0 Hz, 1H), 
4.92 (s, 1H), 4.76 – 4.68 (m, 1H), 4.52 – 4.35 (m, 2H), 3.87 (s, 2H), 3.69 (d, J = 2.2 Hz, 3H), 3.64 
(dd, J = 8.5, 5.1 Hz, 1H), 3.44 (s, 3H), 2.63 (s, 1H), 2.46 – 2.17 (m, 5H), 2.00 (dd, J = 18.0, 6.0 































Synthesis of N-Boc-(L)-Ile-(L)-Pro-(L)-Leu-(L)-Trp-OH (Free Acid of Tetrapeptide 228) 
 
To a stirring solution of 228 (100 mg, 0.16 mmol, 1 equiv) in 1:1 THF/H2O (640 mL) was 
added LiOH (19 mg, 0.78 mmol, 5 equiv), and the solution was left to stir at rt for 3 h. The reaction 
was quenched with 1M HCl (1 vol equiv), and the product was extracted with CH2Cl2, washed 
with NaHCO3(satd), dried over sodium sulfate, and concentrated under reduced pressure. Crude 
material was obtained in quantitative yield as an oily residue, which was used without further 
purification. 
IR (film) nmax: 3311 (bs), 2965, 1632, 1215 cm-1.  
1H-NMR (CDCl3, 400 MHz): δ 8.42 (s, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.31 (s, 1H), 7.12 (dq, J = 
24.7, 9.6, 7.3 Hz, 3H), 5.22 (s, 1H), 4.83 (d, J = 7.5 Hz, 1H), 4.31 (d, J = 41.9 Hz, 2H), 3.73 (s, 






























Synthesis of Octapeptide N-Boc-Ile-Pro-Leu-Trp-Pro-Val-Ile-Pro-OMe (227) 
 
Free acid of 228 (137 mg, 0.31 mmol, 2.1 equiv) and free base of 229 (92 mg, 0.15 mmol, 
1 equiv) were added to a stirring solution of HOBt (25 mg, 0.16 mmol, 1.05 equiv) in dry THF 
(3.1 mL) at rt under an argon atmosphere. The solution was cooled to 0 °C and stirred for 20 min, 
after which Et3N (0.07 mL, 0.53 mmol, 3.5 equiv) was added and stirred. After an additional 20 
min of stirring, EDC·HCl (31 mg, 0.16 mmol, 1.05 equiv) was added and the reaction mixture was 
left to stir overnight. The reaction was quenched with H2O (1 vol equiv), and the product was 
extracted with CH2Cl2, dried over sodium sulfate, and concentrated under reduced pressure. The 
crude material was purified via flash silica gel chromatography (9:1 EtOAc/MeOH) to afford 227 
(198 mg, 61% yield) as an amber liquid. 
1HNMR (CDCl3, 400 MHz): δ 8.67 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.62 – 7.27 (m, 4H), 7.20 – 
6.85 (m, 6H), 5.21 (d, J = 9.3 Hz, 1H), 5.01 (q, J = 7.2 Hz, 1H), 4.75 – 4.00 (m, 10H), 3.80 (dt, J 
= 35.8, 5.2 Hz, 3H), 3.72 – 3.66 (m, 3H), 3.58 (s, 3H), 3.18 (d, J = 7.3 Hz, 1H), 2.36 – 1.85 (m, 
16H), 1.42 (d, J = 4.6 Hz, 9H), 1.04 – 0.83 (m, 24H). 
13C-NMR (CDCl3, 101 MHz):  δ 172.76, 171.84, 171.74, 171.58, 170.90, 156.03, 136.30, 124.14, 
123.58, 121.96, 119.58, 118.68, 111.55, 109.77, 79.70, 77.52, 77.04, 60.50, 60.27, 59.34, 59.11, 

















































30.91, 30.26, 29.26, 28.58, 28.56, 28.11, 27.78, 25.36, 25.18, 24.80, 24.59, 24.53, 23.32, 23.01, 
21.92, 19.59, 19.04, 18.36, 15.70, 15.60, 15.39, 11.33, 11.27.  
Optical Rotation:	[α]!"# = -29.30 (c 0.78, MeOH).  
IR (film) nmax: 3423, 2925, 1741, 1687, 1612, 1452 cm-1. 
HRMS (ESI+): m/z 1070.6253 [M+H]+ (calcd for C55H85N9O11Na 1070.6267). 
  
118 
Synthesis of Reniochalistatin E (23) via Octapeptide 227 
 
 
To a stirring solution of 227 (470 mg, 0.45 mmol, 1 equiv) in a 1:1 THF/H2O (1.8 mL) 
was added LiOH (54 mg, 2.24 mmol, 5 equiv), and the solution was left to stir at rt for 3 h. The 
reaction was quenched with 1M HCl (1 vol equiv), and the product was extracted with CH2Cl2, 
dried with brine, dried over sodium sulfate, and concentrated under reduced pressure to afford 
the free acid of 227, which was used without further purification. The free acid of 227 (365 mg, 
0.72 mmol) was added to an RBF, and the flask was cooled to 0 °C, to which was added 1.0 M 
HCl in dioxane (2.9 mL). The reaction mixture was stirred for 3 h at rt. The solvent was removed 
under reduced pressure to afford the crude material (245), a white/orange solid that was used 
without further purification. The deprotected compound 245 (115 mg, 0.12 mmol, 1 equiv) was 
added to a stirring solution of HOBt (18 mg, 0.12 mmol, 1 equiv) in dry THF (12 mL) at rt under 
an argon atmosphere. The solution was cooled to 0 °C and stirred for 20 min, after which Et3N 
(0.06 mL, 0.42 mmol, 3.5 equiv) was added. After an additional 20 min of stirring, EDC·HCl (25 
mg, 0.13 mmol, 1.05 equiv) was added and the reaction mixture was left to stir overnight. The 
reaction was quenched with H2O (2 vol equiv), and the product was extracted with CH2Cl2, dried 
over sodium sulfate, and concentrated under reduced pressure. The crude material was purified 
via flash silica gel chromatography (85:15 EtOAc/MeOH) to afford 23 (39 mg, 9% yield). 
1. LiOH
    H2O/THF
2. HCl/dioxane
3. EDC•HCl
    Et3N, THF








































1H-NMR (CDCl3, 400 MHz): δ 10.96 – 10.84 (m, 1H), 8.11 – 7.78 (m, 1H), 7.52 (dd, J = 24.5, 
7.9 Hz, 2H), 7.40 (d, J = 8.2 Hz, 1H), 7.32 (t, J = 8.7 Hz, 1H), 7.02 – 6.92 (m, 2H), 4.38 – 4.33 (m, 
1H), 3.36 (s, 23H), 3.33 – 3.22 (m, 1H), 2.48 (s, 1H), 1.99 – 1.70 (m, 2H), 1.24 (s, 2H), 0.96 – 
0.75 (m, 8H), 0.83 (s, 27H).  
13C-NMR (DMSO, 126 MHz): d 172.37, 171.88, 171.81, 171.48, 171.31, 170.58, 170.22, 169.58, 
136.59, 127.36, 124.18, 121.21, 118.60, 118.38, 111.71, 111.57, 61.20, 60.67, 59.59, 56.74, 55.85, 
54.61, 54.39, 54.22, 47.81, 47.55, 47.41, 38.21, 37.49, 35.09, 33.21, 29.31, 25.22, 25.01, 24.95, 
24.83, 24.10, 23.77, 22.71, 20.87, 19.21, 18.88, 15.69 ,15.10, 11.50, 9.81 
Optical Rotation: [α]!"# = -99.95 (c 0.16, MeOH).  
IR (film) nmax: 3290, 2960, 2927, 1670, 1615, 1501, 1445 cm-1 
HRMS (ESI+): m/z 938.5475 [M+H]+ (calcd for C49H73N9O8Na 938.5473).   
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Comparison of Reniochalistatin E (Natural vs Synthetic) 13C-NMR and trans-Proline 
Confirmation 




  172.3 172.37 
  171.98 171.88 
  171.84 171.81 
  171.4 171.48 
  171.4 171.31 
  170.7 170.58 
  170.3 170.22 
  170 169.58 
  136.5 136.59 
  127.3 127.36 
  124.1 124.18 
  121.2 121.21 
  118.6 118.60 
  118.4 118.38 
  111.7 111.71 
  111.5 111.57 
  61.3 61.20 
  60.8 60.67 
  59.7 59.59 
  56.8 56.74 
  55.9 55.85 
  54.5 54.61 
  54.5 54.39 
  54.3 54.22 
  47.9 47.81 
  47.6 47.55 
  47.4 47.41 
  38.2 38.21 
  37.5 37.49 
  35.23 35.09 
  33.2 33.21 
DdCb-Cg 
Pro   Nat.    Synth. 
1        4.9       4.89 
2        4.2       4.36 
3        4.1       4.06 
b of Pro1 30 30.01 
b of Pro 2 29.3 29.31 
b of Pro 3 29.3 29.28 
g of Pro 3 25.2 25.22 
g of Pro 1 25.1 25.12 
g of Pro 2 25.1 24.95 
  24.8 24.83 
  24.2 24.10 
  23.9 23.92 
  23.7 23.77 
  22.7 22.71 
  20.9 20.87 
  19.3 19.21 
  18.8 18.88 
  15.7 15.69 
  15.1 15.10 
  11.6 11.50 
  9.8 9.81 
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Procedures towards the Lagunamide C C41 methyl truncate Model System:  
Synthesis of (S)-4-isopropylthiazolidine-2-thione (270) via L-Valinol: 
 
To a flame dried round bottom flask, LiAlH4 (1.88 g, 51 mmol, 3 eq) and THF (0.24 M) 
were added, and cooled to 0 °C. L-valine (269) (2.00 g, 17 mmol, 1 eq) was added portion wise 
while stirring, after which the ice bath was removed and the mixture was warmed to room 
temperature. After 30 min, the reaction was refluxed overnight, then cooled to room temperature, 
and a saturated Rochelle salt solution was added and stirred overnight. The aqueous layer was 
extracted with CH2Cl2 (x3), and the resulting organic layers were combined, dried, and 
concentrated to afford an oily, crude product. The crude product was purified via short path 
vacuum distillation resulting in a clear oil (1.74 g, 99% yield) of L-valinol.  
1H-NMR (CDCl3, 400 MHz): d 3.63 (dd, J = 10.4, 4.0 Hz, 1H), 3.27 (dd, J = 10.4, 8.9 Hz, 1H), 
2.54 (ddd, J = 8.9, 6.4, 4.0 Hz, 1H), 1.55 (dq, J = 13.5, 6.7 Hz, 1H), 0.91 (dd, J = 6.8, 6.1 Hz, 6H).  
Next, L-valinol (10.00 g, 96.7 mmol, 1 eq), CS2 (15.2 mL, 251.8 mmol, 2.6 eq), and EtOH (29.3 
mL, 3.3 M) were added to a round bottom flask and purged with argon. An addition funnel was 
added, flushed with argon, and charged with 2.25 M KOH (116.3 mL, 261.6 mmol, 2.25 M). The 
KOH was slowly added to the flask with vigorous stirring. After the KOH was added, the addition 
funnel was replaced with a condensing tube and flushed with argon. The solution was left to reflux 
at 80 °C for 72 h. Over the course of the reflux period, the solution changed from bright orange to 
light yellow. The flask was then cooled to room temperature and volatiles were removed under 
















combined organic layers were then dried and concentrated under reduced pressure, producing a 
crude light yellow solid (14.82 g, 95%) that was used without further purification.  
1H-NMR (CDCl3, 400 MHz): d 8.76 (s, 1H), 4.01 (td, J = 8.2, 6.0 Hz, 1H), 3.42 (dd, J = 11.2, 8.4 
Hz, 1H), 3.20 (dd, J = 11.2, 7.9 Hz, 1H), 1.89 (hept, J = 6.7, 4.7 Hz, 1H), 0.90 (d, J = 6.7 Hz, 3H), 
0.87 (d, J = 6.8 Hz, 3H);  
13C NMR (CDCl3, 101 MHz): d 201.10, 70.08, 35.96, 32.05, 18.85, 18.27; HRMS (ESI): calcd 
for [C6H11NS2 + H+] 162.0406, found 162.0402. 
Optical Rotation: [α]!"# = +183.4 (c 1.9, CHCl3).  
IR (film) nmax: 3185, 2652, 1492, 1380, 1375, 1306, 1270, 1231, 1164, 1144, 1111, 1056, 1033, 
980 cm-1;  
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Synthesis of (S)-1-(4-isopropyl-2-thioxothiazolidin-3-yl)ethan-1-one (271): 
 
Crude 270 (1.00 g, 6.20 mmol, 1 eq) and anhydrous THF (4.13 mL, 1.5 M) were added to 
a flame dried round bottom flask under an argon atmosphere. The solution was cooled to -83 °C 
to which n-BuLi (4.48 mL, 6.82 mmol, 1.6 M in hexanes) was added dropwise, producing a color 
change from light yellow, to orange, to bright yellow. Approximately 25 min later, acetyl chloride 
(0.58 mL, 8.06 mmol, 1.3 eq) was added dropwise and allowed to stir for 20 min after which the 
solution was warmed to room temperature. The reaction was quenched with NH4Cl(sat’d), extracted 
with CH2Cl2 (x3), dried, and concentrated under reduced pressure. The crude material was purified 
via flash silica chromatography (2:1 CH2Cl2: hexane) to afford 271 as a bright yellow oil (1.24 g, 
98% yield). 
Optical Rotation: [α]!"# = +164.2 (c 0.54, CHCl3).  
1H-NMR (CDCl3, 400 MHz): d 5.14 (dt, J = 7.7, 6.1, 1H), 3.50 (dd, J = 11.4, 8.0 Hz, 1H), 3.01 
(dd, J = 11.5, 1.3 Hz, 1H), 2.76 (s, 3H), 2.36 (h, J = 6.8 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.05 (d, 
J = 6.7 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H);  












Synthesis of (R)-3-hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)hexan-1-one 
(272/273): 
 
To a flame dried round bottom flask charged with argon was added (S)-1-(4-isopropyl-2-
thioxothiazolidin-3-yl)ethan-1-one (271, 1.08 g, 5.31 mmol, 1 eq) and anhydrous CH2Cl2 (10.62 
mL, 0.5 M) and cooled to 0 °C. TiCl4 (0.62 mL, 5.58 mmol, 1.05 eq) was added dropwise, changing 
the solution from a bright yellow to a bright orange color. 20 min later, freshly prepared 0.64 M 
LDA (10.27 mL, 6.37 mmol, 1.2 eq) was added to the solution, changing the color from bright 
orange to deep burgundy and left to stir. While at temperature, NMP (0.61 mL, 6.37 mmol, 1.2 eq) 
was added, stirred for 5 min, and then cooled to -78 °C for 10 min, at which time butanal (0.65 
mL, 8.00 mmol, 1.5 eq) in CH2Cl2 (1.5 mL, 5.4 M) was added and left to stir at temperature. The 
solution was warmed to 0 °C 30 min after the addition of butanal, quenched with NH4Cl(sat’d), and 
extracted with CH2Cl2 (x4). The combined organic layers were washed with brine, dried, and 
concentrated under reduced pressure. The crude material was purified via flash silica 
chromatography (2:1 hexane/ EtOAc) and afforded 273 (1.05 g, 72% yield). 
Optical Rotation: [α]!"# = +231 (c 0.390, CHCl3).  
IR (film) nmax: 3452, 2960, 2928, 2870, 1695, 1467 cm-1;  
1H NMR (CDCl3, 400 MHz): d 5.17 (ddd, J = 7.6, 6.4, 1.0, 1H), 4.03 (m, 1H), 3.55 – 3.40 (m, 
2H), 3.31 (d, J = 17.2, 2.7 Hz, 1H), 3.18 (s, 1H), 3.03 (dd, J = 11.5 Hz, 1H), 2.35 (m, 1H), 1.60 – 
1.34 (m, 4H), 1.06 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.54 Hz, 3H), 0.93 (t, J = 7.0 Hz, 3H);  
13C NMR (CDCl3, 101 MHz): d 174.03, 71.57, 68.43, 45.37, 38.97, 30.99, 30.80, 19.31, 18.90, 



















To a flame dried round bottom flask charged with argon was added (R)-3-hydroxy-1-((S)-
4-isopropyl-2-thioxothiazolidin-3-yl)hexan-1-one, (273, 900 mg, 3.27 mmol), DMF (13.6 mL, 
0.24 M), TBSCl (1.97 g, 13.08 mmol, 4 eq), and 2,6-lutidine (1.90 mL, 16.35 mmol, 5 eq). The 
solution was stirred at 32 °C under argon. After 24 h the reaction was cooled to room temperature, 
diluted with water and extracted with EtOAc (x3). The organic layers were combined, washed with 
brine, dried and concentrated under reduced pressure. The crude yellow compound was purified 
via flash silica chromatography (20:1 hexane/EtOAc) to produce 274 as a bright yellow viscous 
oil (1.10 g, 86% yield).  
Optical Rotation: [α]!"# = +207.3 (c 0.74, CHCl3).  
IR (film) nmax: 2950, 1692, 1460 cm-1;  
1H NMR (CDCl3, 400 MHz): d 5.13 (ddd, J = 7.7, 5.9, 1.2 Hz, 1H), 4.26 (p, J = 5.8 Hz, 1H), 3.54 
– 3.44 (m, 2H), 3.38 (dd, J = 16.8, 6.3 Hz, 1H), 3.01 (dd, J = 11.5, 1.2 Hz, 1H), 2.36 (dt, J = 13.5, 
6.7 Hz, 1H), 1.47 – 1.32 (m, 4H), 1.05 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.90 (s, 3H), 
0.87 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H);  
13C NMR (CDCl3, 101 MHz): d 174.03, 71.85, 68.99, 46.20, 40.11, 31.08, 30.38, 26.06, 25.92, 















Synthesis of (R)-3-((tert-butyldimethylsilyl)oxy)hexanal (276): 
 
To a flame dried round bottom flask charged with argon was added 274 (225 mg, 0.58 
mmol, 1.0 eq) and cooled to -78 °C, at which time, DIBAl-H (1 M in toluene, 0.59 mmol, 1.02 eq) 
was added. The reaction was allowed to stir until a second product spot was visible via TLC 
analysis, at which time Rochelle’s Salt(sat’d) was added and allowed to stir overnight. The mixture 
was extracted with CH2Cl2 (x3); the organic layers were combined, washed with brine, dried, and 
concentrated under reduced pressure. The crude material was purified via distillation to afford 276 
(41 mg, 31% yield), alcohol 275 (39 mg, 29% yield), and recovered auxiliary 270.  
IR (film) nmax: 2958, 2931, 2858, 2720, 1722, 1255, 836, 776 cm-1;  
1H NMR (CDCl3, 400 MHz): d 9.81 (t, J = 2.5 Hz, 1H), 4.18 (p, J = 5.9 Hz, 1H), 2.51 (dd, J = 












Synthesis of (R)-3-((tert-butyldimethylsilyl)oxy)hexanol (275): 
 
To a flame dried round bottom flask charged with argon was added 274 (1.76 g, 4.50 
mmol), EtOH (26.47 mL, 0.17 M), followed by NaBH4 (681 mg, 18 mmol, 4 eq). The solution was 
allowed to stir for approximately 4 h, over which time the bright yellow color of the starting 
material disappeared. The reaction was quenched with the slow addition of NH4Cl(sat’d) and 
extracted with CH2Cl2 (x3). The organic layers were combined, washed with brine, dried, and 
concentrated under reduced pressure. The crude, clear oil was purified via flash silica 
chromatography (20% EtOAc/hexane) to afford 275 as a clear oil (951 mg, 91% yield) along with 
recovered auxiliary 270. 
Optical Rotation: [α]!"# = -11.26 (c 4.51, CHCl3).  
IR (film) nmax: 3358, 2952, 2930, 2858, 1744, 1461, 1250, 1109, 1072, 833, 774, 695 cm-1;  
1H NMR (CDCl3, 400 MHz): d 3.92 – 3.84 (m, 1H), 3.81 – 3.73 (m, 1H), 3.70 – 3.62 (m, 1H), 
2.73 (s, 1H), 1.83 – 1.67 (m, 1H), 1.66 – 1.55 (m, 1H), 1.52 – 1.41 (m, 2H), 1.36 – 1.21 (m, 3H), 
1.00 – 0.68 (m, 11H), 0.04 (d, J = 6.2 Hz, 6H);  
13C NMR (CDCl3, 101 MHz): d 71.99, 60.51, 39.29, 37.88, 26.05, 18.82, 18.19, 14.46, -4.22, -
4.49;  
HRMS (ESI): calcd for [C19H34O2Si + Na+] 345.2226, found 345.2213. 
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Synthesis of (R)-3-((tert-butyldimethylsilyl)oxy)hexanal (276 from 275): 
 
To a flame dried round bottom flask charged with argon was added oxalyl chloride (0.25 
mL, 2.83 mmol, 1 eq) and CH2Cl2 (5.66 mL, 0.5 M). The solution was cooled to -78 °C and stirred 
for 10 min; then, DMSO (0.40 mL, 5.59 mmol, 2.2 eq) was slowly added to the solution. 
Approximately 15 min later, 275 (597.5 mg, 2.57 mmol, 1.0 eq) in CH2Cl2 (2.28 mL, 1.13 M) was 
added and left to stir at temperature. Approximately 1 h later triethylamine (1.78 mL, 12.85 mmol, 
5 eq) was added. The reaction was stirred at -78 °C for 10 min, and then warmed to room 
temperature and stirred for 1 h, at which point, water was added, and the solution was extracted 
with CH2Cl2 (x3). The organic layers were combined, washed once with 2% HCl solution and once 
with 5% Na2CO3 solution, washed with brine, dried, and concentrated under reduced pressure to 







Synthesis of Methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-enoate (277): 
 
To a flame dried round bottom flask charged with argon was added the activated Witting 
reagent (1.28 g, 3.84 mmol, 1.5 eq) as well as anhydrous toluene (7.68 mL, 0.5 M) and stirred 
vigorously. Meanwhile, in a separate flame dried round bottom flask 276 (591 mg, 2.56 mmol, 1 
eq) in anhydrous toluene (3.2 mL, 0.8 M) was added and allowed to stir. Approximately 20 min 
later, the second-round bottom flask containing the activated Wittig reagent was added to the 
original flask and allowed to stir under argon overnight at room temperature. The reaction was 
diluted with water and extracted with EtOAc (x3). The organic layers were combined, washed with 
brine, dried, and concentrated under reduced pressure. The crude oil was purified via flash silica 
chromatography (1:5, EtOAc/hexane) to afford 277 has a clear colorless oil (8.26 g, 80% yield). 
Optical Rotation: [α]!"# = +16.7 (c 0.63, CHCl3).  
IR (film) nmax: 2957, 2929, 1725, 1645, 1251, 1173, 1038, 830, 773 cm-1;  
1H NMR (CDCl3, 400 MHz): d 7.02 – 6.93 (m, 1H), 5.84 (dd, 1H), 3.80 – 3.75 (m, 1H), 3.73 (s, 
3H), 2.37 – 2.29 (m, 2H), 1.47 – 1.35 (m, 4H), 0.90 (d, J = 7.2 Hz, 3H), 0.89 – 0.87 (m, 9H), 0.04 
(s, 6H);  
13C NMR (CDCl3, 101 MHz): d 191.67, 180.00, 146.60, 123.00, 71.28, 51.61, 40.46, 39.69, 
26.05, 18.78, 14.39;  















Synthesis of (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-en-1-ol (267): 
 
 To a flame dried round bottom flask charged with argon was added 277 (375 mg, 1.31 
mmol, 1 eq) and anhydrous CH2Cl2 (6.55 mL, 0.2 M) and was cooled to -78°C. After stirring for 
15 min, DIBAL-H (1 M in toluene) (3.28 mL, 3.28 mmol, 2.5 eq) was added dropwise and was 
allowed to stir until TLC analysis showed no remaining starting material (approximately 10-15 
minutes). Rochelle Salt(sat’d) was then added and left to stir overnight. The solution was extracted 
with CH2Cl2 (x3). The combined organic layers were washed with brine, dried, and concentrated 
under reduced pressure. The crude oil was purified via flash silica chromatography (1:5 
EtOAc/hexane) to afford 276 as a clear pure oil (311 mg, 92% yield).  
Optical Rotation: [α]!"# = +17.5 (c 0.99, CHCl3).  
1H NMR (CDCl3, 400 MHz): d 5.76 – 5.61 (m, 2H), 4.10 (d, J = 4.8 Hz, 2H), 3.71 – 3.67 (m, 
1H), 2.24 – 2.14 (m, 2H), 1.43 – 1.27 (m, 7H), 0.90 – 0.86 (m, 12H), 0.04 (s, 6H);  
13C NMR (CDCl3, 101 MHz): d 131.33, 129.87, 72.04, 64.02, 40.47, 39.39, 26.10, 18.85, 18.37, 
14.46, -4.16, -4.31;  













Synthesis of (2-((R)-2-((tert-butyldimethylsilyl)oxy)pentyl)cyclopropyl)methanol (278): 
 
To a flame dried round bottom flask charged with argon was added 267 (257 mg, 0.99 
mmol, 1 eq) and anhydrous CH2Cl2 (3.0 mL, 0.33 M); the mixture was cooled to 0 °C. In a separate 
flame dried round bottom flask charged with argon was added diiodomethane (0.24 mL, 3.95 
mmol, 2.5 eq) and anhydrous CH2Cl2 (23 mL, 0.17 M); the mixture was cooled to 0°C. To each 
flask was added diethyl zinc (1 M in hexanes, 1.58 mL, 1.58 mmol, 1.5 eq) and stirred at 
temperature. The flasks were combined 45 min later, slowly allowed to warm and left to stir 
overnight. The reaction was quenched with the addition of NH4Cl(sat’d) and was then extracted with 
CH2Cl2 (x3). The organic layers were combined, washed with brine, dried, and concentrated under 
reduced pressure. The crude material was purified via flash silica gel chromatography (4:1, 
hexane/EtOAc) to afford 278 as a clear oil (256 mg, 95% yield).  
1H NMR (CDCl3, 400 MHz): d 3.82 – 3.65 (m, 1H), 3.54 – 3.37 (m, 2H), 1.58 – 1.42 (m, 4H), 
1.41 – 1.23 (m, 4H), 0.92 – 0.85 (m, 13H), 0.73 (s, 1H), 0.74 – 0.61 (m, 1H), 0.42 – 0.28 (m, 2H), 
0.08 (s, 6H);  
13C NMR (CDCl3, 101 MHz d): d 72.73, 72.43, 67.43, 41.28, 41.05, 39.56, 39.35, 26.14, 21.55, 
18.83, 14.54, 13.74, 13.49, 10.23, 10.00, -4.18;  
Optical Rotation: [α]!"# = +53.7 (c 1.1, CHCl3).  
HRMS (ESI): calcd for [C15H32O2Si + Na+] 295.4932, found 295.4934. 
Reaction Note: Flask should ALWAYS be added to flask A. Drawing out the activated 












Synthesis of Tert-butyl(((2R)-1-(2-(iodomethyl)cyclopropyl)pentan-2-yl)oxy)dimethylsilane 
(279) 
 
To a dry round bottom flask was added 278 (260 mg, 2.27 mmol, 1 eq), CH2Cl2 (15 mL, 
0.15 M) , triethylamine (0.94 mL, 6.81 mmol, 3 eq), and methylsulfonyl chloride (0.30 mL, 3.86 
mmol, 1.7 eq) which was cooled to 0°C. The solution was stirred for 10 min before warming to 
room temperature and stirring for an additional 25 min. The solvent was then removed under 
reduced pressure, resulting in a yellow solid. To the solid was added dry acetone (15 mL, 0.15 M) 
and NaI (3.06 g, 20.43 mmol, 9 eq). The solution was stirred for 1 h at room temperature under 
argon. The reaction was quenched with sodium bicarbonate(sat’d) and sodium thiosulfate(sat’d) and 
washed with ether (x3). The combined organic layers were washed with brine, dried, and 
concentrated under reduced pressure. The crude product was purified via flash silica 
chromatography (4:1 hexane/EtOAc) to afford 279 as a clear oil, composed of two diastereomers, 
(694 mg, 80% yield).  
1H NMR (CDCl3, 400 MHz): d 3.71 (p, J = 5.8 Hz, 1H), 3.30 – 3.02 (m, 2H), 1.52 – 1.25 (m, 
6H), 1.11 – 1.01 (m, 1H), 0.92 – 0.86 (m, 12H), 0.79 – 0.72 (m, 1H), 0.67 – 0.57 (m, 1H), 0.50 – 
0.42 (m, 1H), 0.04 (d, J = 3.3 Hz, 6H);  
13C NMR (CDCl3, 101 MHz): d 72.73, 67.43, 41.28, 41.05, 39.56, 39.35, 26.14, 21.55, 18.83, 












Synthesis of Tert-butyldimethyl(((4R)-6-methyloct-7-en-4-yl)oxy)silane (281/282): 
 
To a flamed dry round bottom flask charged with argon was added 279 (830 mg, 2.17 
mmol, 1.0 eq), cooled to -78 °C, then TMEDA (0.66 mL, 4.34 mmol, 2.0 eq.) followed by n-BuLi 
(1.6 M in hexanes, 2.72 mL, 4.34 mmol, 2.0 eq.) was added. The reaction was warmed to -30 °C 
for 45 mins. The reaction was warmed to 0 °C 3 h later, at which the reaction was quenched with 
water and extracted with diethyl ether (x3). The organic layers were combined, washed with 10% 
HCl, 5% NaHCO3 and brine, then dried and concentrated under reduced pressure. The crude 
material was purified via flash silica gel chromatography (4:1 hexane/EtOAc) to afford 281 and 
282 in (395 mg) 43% and 28% yields, respectively.  
1H NMR (CDCl3, 400 MHz): d 5.89 – 5.62 (m, 1H), 5.06 – 4.84 (m, 2H), 3.78 – 3.57 (m, 1H), 
2.31 – 1.93 (m, 2H), 1.52 – 1.25 (m, 7H), 1.00 – 0.90 (m, 4H), 0.90 – 0.87 (m, 9H), 0.04 (s, 6H);  
13C NMR (CDCl3, 101 MHz): d139.23, 114.50, 112.46, 72.20, 70.23, 44.47, 39.61, 36.77, 34.47, 
26.15, 24.80, 20.52, 18.47, 14.55, -4.06;  

















Procedures Towards the Target Polyketide of Lagunamide C: 
Synthesis of (S)-2-methylbutanal (167) via Swern Oxidation. 
 
To a flame dried round bottom flask charged with argon was added oxalyl chloride (1.05 
mL, 11.8 mmol, 1.2 eq) and CH2Cl2 (23.6 mL, 0.5 M). The solution was cooled to -78 °C and 
stirred for 10 min; then, DMSO (1.54 mL, 21.64 mmol, 2.2 eq) was slowly added to the solution. 
Approximately 15 min later, 166 (1.07 mL, 9.84 mmol, 1.0 eq) was added dropwise and left to stir 
at temperature. Approximately 1 h later triethylamine (6.86 mL, 49.18 mmol, 5 eq) was added. 
The reaction was stirred at -78 °C for 10 min, and then warmed to room temperature and stirred 
for 1 h, at which point, NH4Clwas added, and the solution was extracted with CH2Cl2 (x3). The 
organic layers were combined, washed once with 1 M HCl solution and once with brine, dried, 
and concentrated under reduced pressure at room temperature to afford crude 167 (619 mg, 95% 
yield). The crude aldehyde was used immediately. 
Reaction Reference: AF2-310 
NMR FILE: AF2-370-400 
  





Synthesis of (S)-2-methylbutanal (167) via PCC Oxidation: 
 
To a FDRBF, PCC and celite were added in a 1:1 mass ratio (1,610 mg, 7.47 mmol, 1.5 eq. of 
PCC and 1,610 mg of celite) and charged with anhydrous CH2Cl2 (0.5 M, 10 mL). Next, (S)-2-
methylbutanol (166) (0.54 mL, 4.98 mmol, 1 eq.) was added dropwise and allowed to stir for 1 h. 
After that time diethyl ether was added to the reaction mixture and allowed to stir for another 5 
mins. The reaction mixture was then filtered through celite and directly added to the next 
reaction.  






Synthesis of (R)-4-benzylthiazolidine-2-thione: 
 
Freshly prepared 3M KOH (66.2 mL, 198.6 mmol, 6.0 eq.) was added to a RBF and 
allowed to cool to room temperature (rt). L-Phenylalinol (5 g, 33.1 mmol, 1 eq.) was then added 
in one portion, followed by CS2 (10 mL, 165.5 mmol, 5 eq.). The mixture was then warmed to 110 
ºC and reflux overnight. The reaction was then cooled to rt and was diluted with DCM. Then the 
reaction mixture was quenched with saturated NH4Cl and allowed to stir. After a few mins the 
reaction was quenched with 1 M HCl slowly to avoid boiling over. The resulting mixture was then 
extracted with DCM (3x), dried with Na2SO4, and concentrated under reduced pressure to produce 
crude product without further purification to produce the product in quant. yields and used without 
further purification. The same reaction was fun with D-phenylalaninol to provide 285 in quant 
yields.  
(S) isomer: 
1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.3 (m, 5H), 7.3 – 7.2 (m, 1H), 4.5 – 4.4 (m, 1H), 3.6 
(dd, J = 11.2, 7.7 Hz, 1H), 3.4 (dd, J = 11.2, 6.9 Hz, 1H), 3.0 (dd, J = 7.3, 3.0 Hz, 2H). 
Reaction Reference and File Name: AF4-426-400 
(R) Isomer: 
1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.3 (m, 5H), 7.3 – 7.2 (m, 1H), 4.5 – 4.4 (m, 1H), 3.7 
(dd, J = 11.2, 7.6 Hz, 1H), 3.4 (dd, J = 11.2, 7.0 Hz, 1H), 3.0 (d, J = 7.3 Hz, 2H). 
























General Procedure for Acetylation of (S/R)-4-benzylthiazolidine-2-thione to form 285 and 
286: 
 
 To a FDRBF was charged with (S/R)-4-benzylthiazolidine-2-thione (1 eq.) and Dry DCM 
(1M). The mixture was cooled to 0 ºC and then pyridine (1.2 eq.) was added and stirred for 15 
mins. Then acetyl chloride (1.5 eq.) was added and allowed to stir for 1h. The reaction was warmed 
to rt and then quenched with water and saturated NH4Cl. The compound was then extracted with 
DCM (3x) and dried with Na2SO4 and concentrated under reduced pressure. The compound was 
then purified using flash chromatography (1:1 EtOAc/hexane) mixture to produce yellow 
crystalline compound (82% of 285 and 79% of 286). 
 
NMR File Names: 285 =AF3-121-A-400, 286 = AF5-187-600  
285: 1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.35 (m, 2H), 7.31 (dd, J = 7.4, 1.3 Hz, 3H), 
5.44 – 5.37 (m, 1H), 3.41 (ddd, J = 11.6, 7.3, 1.2 Hz, 1H), 3.25 (dd, J = 13.1, 3.8 Hz, 1H), 3.06 
(dd, J = 13.2, 10.6 Hz, 1H), 2.91 (dd, J = 11.5, 0.7 Hz, 1H), 2.82 (s, 3H). 
A8: 1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.35 (m, 2H), 7.31 (dd, J = 7.4, 1.3 Hz, 3H), 
5.44 – 5.37 (m, 1H), 3.41 (ddd, J = 11.6, 7.3, 1.2 Hz, 1H), 3.25 (dd, J = 13.1, 3.8 Hz, 1H), 3.06 
(dd, J = 13.2, 10.6 Hz, 1H), 2.91 (dd, J = 11.5, 0.7 Hz, 1H), 2.82 (s, 3H). 




























General Procedure for Aldol reaction to form (4S/R)-1-((S/R)-4-benzyl-2-thioxothiazolidin-
3-yl)-3-hydroxy-4-methylhexan-1-one (287, 288, 289, and 290). 
 
To a FDRBF was charged with DCM (0.17 M) and (S/R)-1-(4-benzyl-2-thioxothiazolidin-3-
yl)ethan-1-one (285/286) (1 eq.) and molecular sieves were cooled to 0 ºC. A solution of 1 M TiCl4 
in DCM (1 eq.) was added dropwise to the mixture and allowed to stir for 5 mins. DIPEA (2 eq.) 
was added dropwise and allowed to stir for 20 mins. The reaction was cooled to -78 ºC and (S)-2-
methylbutanal (crude transfer calculated for 3 eq.) in the DCM/ether mixture after celite 
purification was added dropwise and allowed to stir for 2 h. The resulting mixture was immediately 
quenched with saturated NH4Cl and then warmed to rt. The product was extracted with DCM (3x), 
dried with Na2SO4, and concentrated under reduced pressure. The resulting mixture of 
diastereomers was a yellow oil was then purified using column chromatography (1:3 
EtOAc/hexane). Each diastereomer was then collected as a yellow oil (290= 15% and 289= 68%) 
yields, and a mixed yield of 11%. Total yield for this reaction, by weight, produces an 94% yield. 
The same reaction procedure with changes to amounts added was done to produce 287 (19%) and 
288 (27%) with a mixture of isomers (38%). 
Notebook entry: AF4-361, AF4-090 











































287: 1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.3 (m, 5H), 5.4 (ddd, J = 10.8, 7.1, 4.0 Hz, 1H), 
4.1 – 4.0 (m, 1H), 3.6 (dd, J = 17.9, 2.0 Hz, 1H), 3.4 (ddd, J = 11.6, 7.2, 1.0 Hz, 1H), 3.3 (dd, J = 
13.2, 4.0 Hz, 1H), 3.2 (dd, J = 17.8, 10.2 Hz, 1H), 3.1 (dd, J = 13.2, 10.5 Hz, 1H), 2.9 (d, J = 11.6 
Hz, 1H), 1.7 – 1.6 (m, 3H), 1.3 – 1.2 (m, 2H), 1.0 (dd, J = 8.2, 6.9 Hz, 3H). 
 
288:
 1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.3 (m, 5H), 5.4 (ddd, J = 10.7, 7.1, 4.0 Hz, 1H), 
4.0 (dtd, J = 10.3, 4.2, 2.2 Hz, 1H), 3.6 (dd, J = 17.3, 10.1 Hz, 1H), 3.4 (dd, J = 11.6, 7.2, 1.1 Hz, 
1H), 3.3 – 3.2 (m, 2H), 3.1 (dd, J = 13.2, 10.3 Hz, 1H), 3.0 (d, J = 4.2 Hz, 1H), 2.9 (d, J = 11.5 
Hz, 1H), 1.3 – 1.2 (m, 2H), 1.0 – 0.9 (m, 6H). 
289: 1H NMR (600 MHz, Chloroform-d) δ 7.40 – 7.35 (m, 2H), 7.34 – 7.29 (m, 3H), 5.43 (ddd, 
J = 10.8, 7.1, 4.0 Hz, 1H), 4.16 – 4.09 (m, 1H), 3.59 (dd, J = 17.7, 2.0 Hz, 1H), 3.43 (ddd, J = 
11.5, 7.2, 1.1 Hz, 1H), 3.28 – 3.20 (m, 2H), 3.08 (dd, J = 13.2, 10.5 Hz, 1H), 2.93 (d, J = 11.5 Hz, 
1H), 2.53 (d, J = 3.9 Hz, 1H), 1.56 – 1.50 (m, 2H), 1.31 – 1.19 (m, 1H), 0.96 (t, J = 6.9 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 201.49, 173.75, 136.45, 129.48, 128.97, 127.32, 77.25, 77.04, 
76.83, 70.67, 68.43, 43.51, 39.76, 36.85, 32.07, 25.56, 14.15, 11.83. 
290: 1H NMR (600 MHz, Chloroform-d) δ 7.37 – 7.33 (m, 2H), 7.31 – 7.27 (m, 3H), 5.42 (ddd, 
J = 10.8, 7.2, 3.9 Hz, 1H), 3.94 (dt, J = 8.0, 4.0 Hz, 1H), 3.49 (dd, J = 17.4, 10.2 Hz, 1H), 3.41 
(dd, J = 11.5, 7.2 Hz, 1H), 3.30 (dd, J = 17.4, 2.0 Hz, 1H), 3.23 (dd, J = 13.3, 4.0 Hz, 1H), 3.14 
(d, J = 4.2 Hz, 1H), 3.05 (dd, J = 13.2, 10.4 Hz, 1H), 2.91 (d, J = 11.5 Hz, 1H), 1.59 (d, J = 6.3 
Hz, 1H), 1.55 – 1.50 (m, 1H), 1.23 – 1.15 (m, 1H), 0.95 – 0.90 (m, 6H). 
13C NMR (151 MHz, CDCl3) δ 201.78, 174.59, 136.52, 129.59, 129.10, 127.44, 72.20, 68.49, 
42.21, 40.13, 36.90, 32.12, 29.85, 25.19, 14.71, 11.76. 
  
141 
General Procedure for TBS protection of Aldol Product: (3S,4S)-1-((R)-4-benzyl-2-
thioxothiazolidin-3-yl)-3-hydroxy-4-methylhexan-1-one (295). 
 
A FDRBF was charged with A8 (341 mg, 1.01 mmol, 1 eq.) and dry DCM (0.1 M, 10.1 mL) and 
was cooled to 0 ºC. Et3N (0.56 mL, 4.04 mmol, 4 eq.) was added in one portion and allowed to 
react for 10 mins. Then tert-Butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) (0.46 mL, 
2.02 mmol, 2 eq.) was added and allowed to stir overnight warming to rt. The resulting mixture 
was then quenched with saturated NH4Cl, extracted with DCM (3x), dried with Na2SO4, and 
concentrated under reduced pressure. The resulting yellow oil was then separated via column 
chromatography (1:12 EtOAc/hexane) to produce a yellow oil in 495 mg quantitive yield. 
 
1H NMR (600 MHz, Chloroform-d) δ 7.38 (t, J = 7.5 Hz, 2H), 7.35 – 7.29 (m, 3H), 5.29 (ddd, J 
= 10.7, 7.0, 3.7 Hz, 1H), 4.34 (dt, J = 8.7, 3.1 Hz, 1H), 3.58 (dd, J = 17.0, 8.7 Hz, 1H), 3.36 (ddd, 
J = 11.5, 7.1, 1.1 Hz, 1H), 3.28 (dd, J = 13.2, 3.7 Hz, 1H), 3.11 – 3.00 (m, 2H), 2.91 (d, J = 11.4 
Hz, 1H), 1.64 (ddd, J = 13.2, 7.5, 4.4 Hz, 1H), 1.50 (td, J = 6.3, 3.4 Hz, 1H), 1.10 – 1.03 (m, 1H), 
0.97 – 0.91 (m, 6H), 0.91 – 0.89 (m, 4H), 0.89 
(s, 3H), 0.87 (s, 9H), 0.04 (d, J = 8.3 Hz, 6H). 
NMR File: AF5-183-600 














General Procedure for Auxiliary cleavage to form (3R/S,4S)-3-((tert-butyldimethylsilyl)oxy)-
4-methylhexan-1-ol. 
 
An RBF was charged with (3S/3R,4S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-((tert-
butyldimethylsilyl)oxy)-4-methylhexan-1-one (1 eq.) and dissolved in EtOH (0.17 M) and cooled 
to 0 ºC. In one addition, NaBH4 (4 eq.) was added and allowed to stir overnight warming to rt. The 
resulting mixture was then cooled to 0 ºC and quenched with (½ saturated) NH4Cl, extracted with 
DCM (3x), dried with Na2SO4, and concentrated under reduced pressure. The crude material was 
then separated with flash silica gel chromatography (1:6 EtOAc/hexane) to produce (78%) a 
clear/yellowish oil. 
 
1H NMR (600 MHz, Chloroform-d) δ 3.81 – 3.69 (m, 3H), 2.09 (t, J = 5.1 Hz, 1H), 1.70 (td, J = 
7.2, 5.6 Hz, 2H), 1.65 – 1.60 (m, 1H), 1.52 (td, J = 6.7, 3.5 Hz, 1H), 1.09 – 1.01 (m, 1H), 0.92 (s, 
12H), 0.87 (d, J = 6.8 Hz, 3H), 0.10 (d, J = 14.5 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 75.38, 60.97, 40.34, 34.28, 25.89, 23.87, 18.06, 15.07, 12.20, -
4.32, -4.55. 
NMR File Name: AF5-185-B-600 
296’: AF5-189-600 
1H NMR (600 MHz, Chloroform-d) δ 3.82 (ddd, J = 8.4, 4.9, 3.4 Hz, 1H), 3.79 – 3.75 (m, 2H), 
2.24 – 2.20 (m, 1H), 1.73 – 1.65 (m, 1H), 1.64 – 1.54 (m, 2H), 1.38 (ddd, J = 13.0, 7.5, 5.2 Hz, 














General Procedure for Wittig Olefination: Methyl (5S/R,6S,E)-5-((tert-
butyldimethylsilyl)oxy)-6-methyloct-2-enoate. 
 
A FDRBF was charged with PCC and Celite (2.5 eq.) and dry DCM (0.08 M) and then 
(3R/S,4S)-3-((tert-butyldimethylsilyl)oxy)-4-methylhexan-1-ol (1eq.) was dissolved in minimal 
volume of DCM and added dropwise and allowed to stir for 1 h at rt. The resulting mixture was 
then quenched with ether and allowed to stir. After 10 mins, the mixture is filtered through celite 
and, then the yilide was added and left to stir o/n. The reaction was quenched with water and 
NH4Cl, extracted with DCM (3x), dried with Na2SO4, and concentrated under reduced pressure. 
The resulting extract was then purified via flash column chromatography (1:12 EtOAc/hexane) to 
produce a colorless oil (80%).  
297: 
NMR File Name: AF5-016-400 
1H NMR (400 MHz, Chloroform-d) δ 6.94 (dt, J = 15.4, 7.5 Hz, 1H), 5.84 (dt, J = 15.7, 1.5 Hz, 
1H), 3.73 (s, 3H), 3.69 – 3.64 (m, 1H), 2.37 – 2.27 (m, 2H), 1.53 – 1.45 (m, 1H), 1.42 – 1.36 (m, 
1H), 1.08 (s, 1H), 0.88 (s, 12H), 0.84 (d, J = 6.7 Hz, 3H), 0.03 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 166.95, 147.06, 122.51, 74.69, 51.45, 40.05, 37.16, 25.86, 25.23, 
18.12, 13.80, 12.11, -4.30, -4.56. 
297’:  












1H NMR (600 MHz, Chloroform-d) δ 7.01 (dt, J = 15.4, 7.5 Hz, 1H), 5.86 (dt, J = 15.6, 1.4 Hz, 
1H), 3.75 (s, 3H), 3.67 (s, 1H), 2.34 – 2.27 (m, 2H), 1.50 (s, 1H), 1.44 – 1.40 (m, 1H), 1.16 – 1.04 
(m, 1H), 0.90 (s, 12H), 0.89 – 0.83 (m, 3H), 0.05 (d, J = 3.2 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 166.94, 147.51, 122.50, 74.87, 51.42, 40.51, 35.86, 29.73, 25.85, 
25.20, 18.10, 14.05, 11.99, -4.43, -4.56. 
  
146 
General Procedure for reduction to allylic alcohol: (5S/R,6S,E)-5-((tert-
butyldimethylsilyl)oxy)-6-methyloct-2-en-1-ol. 
 
A FDRBF was charged with Methyl (5S/R,6S,E)-5-((tert-butyldimethylsilyl)oxy)-6-
methyloct-2-enoate (1 eq.) and dry THF (0.2 M) and cooled to -78 ºC. Freshly diluted DIBAl-H 
in THF in a 1M solution (2.5 eq.), was then added and allowed to stir o/n warming to rt. The 
reaction was then cooled to 0 ºC and quenched slowly with Rochelle’s salts, and allowed to stir 
o/n. The resulting solution was then quenched again with 1 M HCl, extracted with EtOAc (3x), 
dried with Na2SO4, and concentrated under reduced pressure. The resulting material was then 
purified via flash chorography (1:6 EtOAc/hexane) to produce a colorless oil (98.8 mg, 91%).  
NMR File Name: AF5-191-A-400 
1H NMR (400 MHz, Chloroform-d) δ 5.76 – 5.59 (m, 2H), 4.22 – 3.97 (m, 2H), 3.60 (td, J = 
6.2, 3.5 Hz, 1H), 2.30 – 2.07 (m, 2H), 1.55 – 1.35 (m, 2H), 1.29 – 1.21 (m, 1H), 1.17 – 1.02 (m, 
1H), 0.90 (s, 12H), 0.86 (t, J = 6.7 Hz, 3H), 0.05 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 130.78, 130.33, 75.33, 63.88, 39.50, 37.13, 25.91, 25.47, 18.17, 










General Procedure for facially selective cycloropanation: ((1S,2R)-2-((2S,3S/R)-2-((tert-
butyldimethylsilyl)oxy)-3-methylpentyl)cyclopropyl)methanol. 
 
A FDRBF (A) was charged with dry DCM (0.1 M), with MS, and cooled to 0 ºC. A 1M solution 
in Et2Zn in THF, (10 eq.)  was added and stirred for 15 mins, followed by the addition of CH2I2 
(20 eq.) in a dropwise manner. To a second FDRBF (B) (5S/R,6S,E)-5-((tert-
butyldimethylsilyl)oxy)-6-methyloct-2-en-1-ol (1 eq.) was added with dry DCM (0.1M) and MS. 
A dropwise addition of 298 (4R,5R)-2-butyl-N4,N4,N5,N5-tetramethyl-1,3,2-dioxaborolane-4,5-
dicarboxamide (1.2 eq.) was added and both RBF were allowed to stir for 15 mins. The contents 
of flask B were then added to flask A via cannula and allowed to stir o/n. The resulting mixture 
was quenched with saturated NH4Cl (until the emulsion broke), extracted with DCM (3x), dried 
with Na2SO4, and concentrated under reduced pressure. The resulting extract was then purified via 
flash column chromatography (1:6 EtOAc/hexane) to produce a colorless oil (76%). 
NMR File Name: AF5-206-B-400 
1H NMR (400 MHz, Chloroform-d) δ 3.68 – 3.62 (m, 1H), 3.55 (dd, J = 11.1, 6.8 Hz, 1H), 3.39 
(dd, J = 11.1, 7.3 Hz, 1H), 1.59 – 1.50 (m, 2H), 1.45 – 1.40 (m, 1H), 1.40 – 1.32 (m, 1H), 1.32 – 
1.26 (m, 2H), 1.15 – 1.03 (m, 1H), 0.91 (d, J = 2.2 Hz, 12H), 0.83 (d, J = 6.7 Hz, 3H), 0.68 – 0.59 
(m, 1H), 0.42 (dt, J = 8.7, 4.7 Hz, 1H), 0.36 (dt, J = 8.2, 5.0 Hz, 1H), 0.05 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 75.92, 67.19, 39.44, 37.61, 25.93, 25.40, 21.34, 13.99, 13.84, 



















General Procedure for Iodination: tert-butyl(((2S,3S/R)-1-((1R,2S)-2-
(iodomethyl)cyclopropyl)-3-methylpentan-2-yl)oxy)dimethylsilane. 
 
A FDRBF was charged with ((1S,2R)-2-((2S,3S/R)-2-((tert-butyldimethylsilyl)oxy)-3-
methylpentyl)cyclopropyl)methanol (1 eq.) with dry DCM (0.15 M) and 4 A MS. Upon cooling 
the solution to 0 ºC Et3N (3 eq.) was added followed by MsCl (1.5 eq.). The resulting solution was 
stirred for 15 mins, then warmed to rt. The solution was then concentrated under reduced pressure. 
The yellowish solid was then dissolved in acetone (0.15M) with 4A MS followed by the addition 
of NaI (9 eq.) in one portion. The solution was stirred for 1 h and then quenched with a 50:50 
mixture of saturated NaCO3H and saturated Na2S2O3. The compound was then extracted with Et2O 
(3x), dried with Na2SO4, and concentrated under reduced pressure. The resulting extract was then 
purified via flash column chromatography (1:30 EtOAc/hexane) to produce a colorless oil (84%). 
299:  
NMR File Name: AF5-330-600 
1H NMR (600 MHz, Chloroform-d) δ 3.70 – 3.58 (m, 1H), 3.27 (dd, 1H), 3.08 (dd, J = 9.8, 8.3 
Hz, 1H), 1.56 – 1.48 (m, 1H), 1.40 – 1.31 (m, 1H), 1.16 – 1.04 (m, 2H), 0.90 (d, J = 3.4 Hz, 14H), 
0.82 (d, J = 8.4, 6.7 Hz, 3H), 0.76 – 0.74 (m, 1H), 0.65 (dt, J = 8.3, 5.2 Hz, 1H), 0.48 (dt, J = 9.0, 
4.7 Hz, 1H), 0.06 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 75.70, 75.21, 39.60, 37.88, 25.94, 25.24, 23.38, 22.67, 18.13, 
17.81, 13.93, 13.80, 12.33, -4.09, -4.44. 
299’: 










1H NMR (600 MHz, Chloroform-d) δ 3.65 (td, J = 6.2, 2.9 Hz, 1H), 3.27 (dd, J = 9.7, 7.2 Hz, 
1H), 3.09 (dd, J = 9.7, 8.4 Hz, 1H), 1.55 – 1.48 (m, 2H), 1.36 – 1.31 (m, 2H), 1.11 – 1.04 (m, 2H), 
0.92 – 0.88 (m, 13H), 0.83 (d, J = 6.8 Hz, 3H), 0.75 (dq, J = 12.1, 6.1 Hz, 1H), 0.65 (dt, J = 8.3, 
5.2 Hz, 1H), 0.48 (dt, J = 9.1, 4.7 Hz, 1H), 0.06 (d, J = 0.7 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 77.25, 77.04, 76.83, 75.70, 39.60, 37.88, 29.73, 25.94, 25.24, 
23.38, 22.67, 18.13, 17.82, 13.93, 13.80, 12.33, -4.09, -4.43. 
  
150 
General Procedure for Ring-openeing Reaction: tert-butyl(((3S,4S,6R)-3,6-dimethyloct-7-
en-4-yl)oxy)dimethylsilane (Q3/Q4): 
 
A FDRBF was charged with (299) and cooled to -78 oC with MS. Dropwise addition of 
TMEDA (2 eq.) followed by dropwise addition to n-BuLi (1.2 eq of 1.6 M solution). The reaction 
was maintained at -78 oC for 1 h and quenched with H2O. Upon warming to rt, the compound was 
diluted with NH4Cl (sat.), extracted with ether (3x), dried over Na2SO4 and the solvents were 
evaporated under ambient temperature. The resulting extract was then purified via flash column 
chromatography (1:3 heptane/hexane) to produce a colorless oil (99%). 
255: 
NMR File Name: AF5-257-400 
1H NMR (400 MHz, Chloroform-d) δ 5.77 – 5.62 (m, 1H), 5.02 – 4.90 (m, 2H), 3.68 – 3.61 (m, 
1H), 2.31 – 2.16 (m, 1H), 1.59 – 1.54 (m, 1H), 1.47 – 1.37 (m, 1H), 1.37 – 1.26 (m, 2H), 1.16 – 
1.03 (m, 1H), 1.00 (dd, J = 6.7, 5.2 Hz, 3H), 0.92 – 0.88 (m, 12H), 0.82 (dd, J = 6.8, 3.8 Hz, 3H), 
0.06 (d, J = 1.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 112.69, 77.34, 77.02, 76.71, 73.75, 40.28, 39.98, 34.31, 25.99, 
25.94, 24.42, 21.19, 18.18, 14.12, 12.40, -4.21. 
255’: 















A FDRBF was charged with (R)-4-isopropyloxazolidin-2-one (543.8 mg, 4.21 mmol, 1.0 
eq.) and dry THF (8.4 mL, 0.5 M) and cooled to -78 ºC. A 1.37 M solution of nBuLi (3.69 mL, 
5.05 mmol, 1.2 eq.) was added dropwise and allowed to stir for 20 mins. Freshly distilled tiglic 
acid (498.6 mg, 4.21 mmol, 1 eq.) was dissolved in dry THF (4.21 mL, 1 M) was cooled to -78 ºC 
and then was added to the mixture in a dropwise fashion. The solution was allowed to stir for 30 
mins then warmed to 0 ºC. The reaction was then quenched with saturated NH4Cl, extracted with 
DCM (3x), washed with sat NaaCO3H, dried with Na2SO4, and concentrated under reduced 
pressure. The resulting extract was then purified via flash column chromatography (1:3 
EtOAc/hexane) to produce the final compound (533.1 mg, 60%). 
1H NMR (400 MHz, Chloroform-d) δ 6.21 (t, J = 7.0, 1.5 Hz, 1H), 4.55 – 4.48 (m, 1H), 4.31 (t, 
J = 8.9 Hz, 1H), 4.17 (dd, J = 9.0, 5.5 Hz, 1H), 2.41 – 2.31 (m, 1H), 1.93 – 1.88 (m, 3H), 1.80 (dq, 
J = 6.9, 1.2 Hz, 3H), 0.91 (t, J = 6.8 Hz, 6H). 
1H NMR (400 MHz, Chloroform-d) δ 6.25 – 6.15 (m, 1H), 4.55 – 4.48 (m, 1H), 4.30 (t, J = 8.9 
Hz, 1H), 4.16 (dd, J = 9.0, 5.5 Hz, 1H), 1.90 – 1.87 (m, 3H), 1.79 (dq, J = 7.0, 1.1 Hz, 3H), 0.90 








-78 oC to 0 oC
60%
152 
General Procedure for TBS-enol ether formation: (R,Z)-3-(1-((tert-butyldimethylsilyl)oxy)-
2-methylbuta-1,3-dien-1-yl)-4-isopropyloxazolidin-2-one. 
 
To a FDRBF was added the starting material (1 eq), with dry THF (0.1 M) and the 
solution was cooled to -78 oC. Following this KHMDS (1.5 eq.) was added dropwise and stirred 
for 10 mins. After this time, TBSOTf (1.5 eq.) was added and left to stir for 20 mins. At this 
point the reaction was quenched with NH4Cl (sat.), extracted with DCM (3x), dried over Na2SO4, 
and and concentrated under reduced pressure. The crude material was used in the next reaction 
without further purification.  
302: AF3-391-400 
1H NMR (400 MHz, Chloroform-d) δ 6.59 – 6.48 (m, 1H), 5.14 (d, J = 17.3 Hz, 1H), 5.03 (dd, 
J = 10.8, 1.4 Hz, 1H), 4.32 (t, J = 8.8 Hz, 1H), 4.11 (t, J = 7.8 Hz, 1H), 4.01 (s, 1H), 1.96 – 1.90 
(m, 1H), 1.60 (s, 1H), 1.27 – 1.24 (m, 3H), 0.98 (s, 9H), 0.94 – 0.89 (m, 5H), 0.20 (s, 6H). 
196: AF3-373-400 
1H NMR (400 MHz, Chloroform-d) δ 6.60 – 6.51 (m, 1H), 5.14 (dd, J = 16.8 Hz, 1H), 5.03 (dd, 
J = 10.8, 1.3 Hz, 1H), 4.32 (t, J = 8.7 Hz, 1H), 4.11 (t, J = 8.5 Hz, 1H), 4.06 – 3.98 (m, 1H), 1.98 










-78 oC to rt
quant 302
153 
Synthesis of (2R,4S,5S)-4-((tert-butyldimethylsilyl)oxy)-2,5-dimethylheptanal (262): 
 
To a RBF was added 255 in a 3:1 mixture of Dioxane:H2O (0.13 M total).To this was added 2,6-
lutidine (1.3 eq.) then OsO4 (2.5g/100 mL in tBuOH, 0.15 eq.) and stirred for 30 mins. At this 
time, NaIO4 (2.3 eq.) and stirred o/n. The reaction is quenched with Na2S2O3 and allowed to stir. 
The mixture was then extracted with ether, dried over Na2SO4 and the solvents were evaporated 
under ambient temperature. The resulting extract was then purified via flash column 
chromatography (1:30 EtOAc/hexane) to produce a colorless oil (68%). 
262: 
NMR File Name: AF5-043-B-400 
1H NMR (400 MHz, Chloroform-d) δ 9.66 – 9.58 (m, 1H), 3.70 – 3.63 (m, 1H), 2.53 – 2.44 (m, 
1H), 1.91 – 1.82 (m, 1H), 1.46 (dddd, J = 14.1, 8.6, 7.4, 3.0 Hz, 2H), 1.15 – 1.02 (m, 4H), 0.93 (d, 
J = 1.9 Hz, 1H), 0.91 – 0.89 (m, 12H), 0.88 – 0.82 (m, 3H), 0.08 – 0.04 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 204.93, 77.34, 77.03, 76.71, 73.63, 42.99, 39.94, 34.09, 25.92, 
















Synthesis of (2R,4S,5S)-4-((tert-butyldimethylsilyl)oxy)-2,5-dimethylheptan-1-ol (328): 
 
 To an RBF was added 255 (1 eq., 91.8 mg, 0.34 mmol) with a 3:1 mixture of dioxane in 
water (1.5 mL diox: 0.5 mL H2O, overall 0.13 M soln.) was added 2,6-lutidine (1.3 eq., 0.05 mL, 
0.15 mmol) and OsO4 (as a 2.5 g/100 mL solution) (0.15 eq., 0.51 mL, 0.05 mmol) and the reaction 
was stirred for 30 mins. At that point NaIO4 (2.3 eq., 166.8 mg, 0.78 mmol) was added and the 
reaction was left to stir overnight. The reaction is quenched with Na2S2O3 and allowed to stir. The 
mixture was then extracted with ether, dried over Na2SO4 and the solvents were evaporated under 
ambient temperature. The crude material was then cooled to 0 oC and dissolved into EtOH (0.17 
M, 2 mL) to which NaBH4 (2.5 eq., 31.8 mg, 0.85 mmol) was added and allowed to stir overnight 
warming to rt. The reaction was cooled to 0 oC quenched with NH4Cl (sat.) extracted with CH2Cl2 
(3x), dried over Na2SO4 and the solvents were evaporated under ambient temperature. The 
resulting extract was then purified via flash column chromatography (1:30 EtOAc/hexane) to 
produce a colorless oil (52% yield over 2 steps, 48.2 mg ). 
NMR File Name: AF5-244-B-2 
1H NMR (400 MHz, Chloroform-d) δ 3.7 – 3.6 (m, 1H), 3.5 – 3.4 (m, 2H), 1.9 – 1.7 (m, 1H), 1.7 
– 1.5 (m, 1H), 1.5 – 1.4 (m, 3H), 1.3 – 1.2 (m, 2H), 1.1 (ddt, J = 22.1, 9.0, 7.1 Hz, 1H), 1.0 – 0.9 
(m, 12H), 0.9 – 0.8 (m, 4H), 0.1 – 0.0 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 77.35, 77.03, 76.71, 74.41, 68.54, 38.85, 38.62, 32.11, 25.96, 

















The starting material (262, 1 eq.) was added to a FDRBF with ether and cooled to 0 oC. AllylMgBr 
(2 eq.) was added and the reaction was stirred for 30 mins warming to rt. Upon consumption of 
the SM, the reaction was quenched with NH4Cl (sat), extracted with DCM (3x), dried over Na2SO4, 
and the solvents were evaporated. The resulting extract was then purified via flash column 
chromatography (1:7 EtOAc/hexane) to produce a colorless oil (67%) as a mixture of 
diastereomers.  
262:  
NMR File Name: AF5-160-600 
1H NMR (600 MHz, Chloroform-d) δ 5.94 – 5.81 (m, 1H), 5.20 – 5.10 (m, 2H), 3.74 – 3.62 (m, 
1H), 3.58 – 3.43 (m, 1H), 2.24 – 2.10 (m, 1H), 1.72 – 1.60 (m, 2H), 1.52 – 1.39 (m, 2H), 1.35 – 
1.23 (m, 2H), 1.20 – 1.10 (m, 1H), 0.94 (dd, J = 6.8, 2.2 Hz, 3H), 0.92 – 0.89 (m, 13H), 0.86 – 











Synthesis of 1-phenylbut-3-en-1-ol (306) 
 
 To a FDRBF was added diethyl ether (2 mL, 1 M), magnesium metal (48.6 mg, 2 eq., 2 
mmol), then allyl bromide (0.13 mL, 1.5 eq., 1.5 mmol) in diethyl ether (1.5 mL, 1 M) and allowed 
to stir at rt. After 30 mins benzaldehyde (305) (0.10 mL, 1 eq., 1 mmol) was added and the reaction 
was allowed to stir overnight. The reaction was cooled to 0 oC and quenched with NH4Cl (sat), and 
allowed to warm to rt for 2 h. The product was extracted with diethyl ether (3x), dried over Na2SO4, 
and the solvents were evaporated. The resulting extract was then purified via flash column 
chromatography (1:9 EtOAc/hexane) to produce a colorless oil (127.6 mg, 91%) as a mixture of 
enantiomers.  
1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.29 (m, 5H), 5.91 – 5.77 (m, 1H), 5.24 – 5.14 (m, 
2H), 4.82 – 4.73 (m, 1H), 2.60 – 2.48 (m, 2H), 2.08 (d, J = 3.3 Hz, 1H). 







Synthesis of methyl (E)-5-((tert-butyldimethylsilyl)oxy)-2-methyl-5-phenylpent-2-enoate 
(318) 
 
 To a FDRBF was added 315 (100 mg, 0.38 mmol, 1 eq.) and dry CH2Cl2 (0.04 M, 9.5 mL) 
with molecular sieves. Methyl methacrylate (307) (0.41 mL, 3.8 mmol, 10 eq.) then Grubbs II was 
added (4 mg, 0.0004 mmol, 0.01 eq.). The reaction was warmed to 43 oC in an oil bath and left to 
stir overnight. The reaction was then allowed to cool to rt and the solvents were evaporated under 
reduced pressure. The resulting crude material was purified via flash chromatography (1:9 
EtOAc/hexane) to produce a colorless oil (109.7 mg, 86%) as a mixture of enantiomers.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.3 (d, J = 3.9 Hz, 4H), 7.3 – 7.2 (m, 1H), 6.9 (tq, J = 
7.6, 1.5 Hz, 1H), 4.8 (dd, J = 7.6, 4.9 Hz, 1H), 3.7 (s, 3H), 2.6 – 2.5 (m, 2H), 1.8 (d, J = 1.3 Hz, 
3H), 0.9 (s, 9H), 0.0 (s, 3H), -0.1 (s, 3H). 
















Synthesis of 1-phenylbut-3-en-1-one (309) 
 
 To a vial containing 306 (201.4 mg, 1.36 mmol, 1 eq.) was added dry CH2Cl2 (2.7 mL, 0.5 
M) then PCC (586.3 mg, 2.72 mmol, 2 eq.) and allowed to stir for 2 h. At that time the reaction 
was diluted with diethyl ether and allowed to stir. The crude reaction was filtered through celite 
and the solvents were reduced. The resulting mixture was then purified via flash chromatography 
(1:9 EtOAc/hexane) to produce a colorless oil (125.9 mg, 63%) as a single enantiomers. 
 









Synthesis of tert-butyldimethyl((1-phenylbut-3-en-1-yl)oxy)silane (315) 
 
 To a FDRF was added 311 (411.6 mg, 2.8 mmol, 1 eq.) in CH2Cl2 (0.1 M, 28 mL) and the 
reaction was cooled to 0 oC. At that time, Et3N (1.56 mL, 11.2 mmol, 4 eq.) was added, followed 
by TBSoTf (1.29 mL, 5.6 mmol, 2 eq.) and allowed to stir overnight. The reaction was quenched 
with NH4Cl (sat), extracted with CH2Cl2 (3x), dried over Na2SO4, and the solvents were 
evaporated. The resulting extract was then purified via flash column chromatography (1:9 
EtOAc/hexane) to produce a colorless oil (620.4 mg, 84%) as a mixture of enantiomer.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.28 (m, 5H), 7.27 – 7.22 (m, 1H), 5.87 – 5.74 (m, 
1H), 5.07 – 5.00 (m, 2H), 4.70 (dd, J = 7.3, 5.2 Hz, 1H), 2.52 – 2.34 (m, 2H), 1.14 – 1.03 (m, 
1H), 0.90 (d, J = 5.4 Hz, 13H). 











Synthesis of 1-methoxy-4-(((1-phenylbut-3-en-1-yl)oxy)methyl)benzene (311) 
 
 
 To a FDRBF was added 306 (127.6 mg, 0.86 mmol, 1 eq.) with dry THF (4.3 mL, 0.2 M) 
and cooled to 0 oC. To the solution was added TBAI (15.9 mg, 0.043 mmol, 0.05 eq.) then KHMDS 
(0.5 M soln. in toluene, 3.44 mL, 1.72 mmol, 2.0 eq.) and allowed to stir for 30 mins. Next PMBCl 
(0.19 mL, 1.38 mmol, 1.6 eq.) and allowed to stir overnight warming to rt. The reaction was 
quenched with NH4Cl (sat), extracted with EtOAc (3x), dried over Na2SO4, and the solvents were 
evaporated. The resulting extract was then purified via flash column chromatography (1:9 
EtOAc/hexane) to produce a colorless oil (127.6 mg, 91%) as a mixture of enantiomers.  
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.32 (m, 5H), 7.28 – 7.22 (m, 2H), 6.93 – 6.87 (m, 
2H), 5.86 – 5.74 (m, 1H), 5.09 – 5.00 (m, 2H), 4.43 (d, J = 11.5 Hz, 1H), 4.37 (dd, J = 7.7, 5.9 
Hz, 1H), 4.23 (d, J = 11.5 Hz, 1H), 3.84 (d, J = 3.3 Hz, 3H), 2.68 – 2.60 (m, 1H), 2.49 – 2.40 (m, 
1H). 
 











Synthesis of (E)-1,6-bis((4-methoxybenzyl)oxy)-1,6-diphenylhex-3-ene (312) 
 
 To a FDRBF was added 311 (221.3 mg, 0.82 mmol, 1 eq.) with dry CH2Cl2 (20.5 mL, 0.04 
M) followed by Grubbs II (6.8 mg, 0.0082 mmol, 0.01 eq.) then methyl methacrylate (307) (0.9 
mL, 8.25 mmol, 10 eq.) and the reaction was heated to 45 oC in an oil bath and left to stir overnight. 
The reaction was then cooled to rt and the solvents were removed under reduced pressure. The 
resulting mixture was purified via flash column chromatography (1:9 EtOAc/hexane) to produce 
a colorless oil (125.9 mg, 45%). 
1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.2 (m, 10H), 6.9 – 6.8 (m, 2H), 5.4 – 5.3 (m, 1H), 
4.5 – 4.3 (m, 2H), 4.3 – 4.1 (m, 2H), 2.6 – 2.5 (m, 1H), 2.4 – 2.3 (m, 1H). 
Reaction Reference/NMR: AF5-013 













Synthesis of methyl (E)-5-((4-methoxybenzyl)oxy)-5-phenylpent-2-enoate (314) 
 
 Cross-metathesis conditons as previous described produced 314 as a colorless oil in 55.1 
mg 68% yield.  
1H NMR (400 MHz, Chloroform-d) δ 7.4 – 7.3 (m, 6H), 7.3 – 7.2 (m, 2H), 7.0 (dt, J = 15.7, 7.2 
Hz, 1H), 6.9 – 6.9 (m, 2H), 5.8 (dt, J = 15.7, 1.5 Hz, 1H), 4.5 – 4.4 (m, 2H), 4.3 – 4.2 (m, 1H), 
3.8 (s, 3H), 3.7 (d, J = 2.5 Hz, 3H), 2.8 – 2.7 (m, 1H), 2.6 (dddd, J = 14.6, 7.0, 5.3, 1.5 Hz, 1H). 















Synthesis of (E)-5-((tert-butyldimethylsilyl)oxy)-2-methyl-5-phenylpent-2-enal (317) 
 
 Analogous CM conditions were used to produce 317 as a colorless oil in 90% yield 122.9 
mg. 
1H NMR (400 MHz, Chloroform-d) δ 9.4 (s, 1H), 7.4 – 7.3 (m, 4H), 7.3 – 7.3 (m, 1H), 6.6 (tq, 
J = 7.4, 1.4 Hz, 1H), 4.9 (dd, J = 7.1, 4.9 Hz, 1H), 2.8 – 2.7 (m, 2H), 1.7 (q, J = 1.0 Hz, 3H), 1.3 
(s, 1H), 0.9 (s, 9H), 0.1 (s, 3H), -0.1 (s, 3H). 















Standard PCC oxidation conditions as described above resulted in a colorless oil which was 
resulted in crude material in 75% yield.  
1H NMR (600 MHz, Chloroform-d) δ 5.99 – 5.90 (m, 1H), 5.23 – 5.11 (m, 2H), 3.61 – 3.53 (m, 
1H), 3.31 – 3.18 (m, 2H), 2.74 – 2.59 (m, 1H), 1.91 – 1.71 (m, 1H), 1.58 – 1.52 (m, 1H), 1.46 – 
1.38 (m, 1H), 1.32 – 1.25 (m, 1H), 1.10 (d, 3H), 0.93 – 0.88 (m, 13H), 0.86 (dd, J = 11.9, 5.1 Hz, 
3H), 0.10 – 0.01 (m, 6H).  















To a FDRB was added 319 (1 eq.) and charged with dry THF (0.2 M). TBAI (0.05 eq.) was 
added followed by dropwise addition of KHMDS (2.0 eq.), and PMBCl (1.6 eq.) and left to stir 
o/n. After this time, the reaction was quenched with n-Butyamine, extracted with ether (3x), 
dried over Na2SO4, and the solvents were evaporated. The resulting extract was then purified via 
flash column chromatography (1:9 EtOAc/hexane) to produce a colorless oil (in quantitative 
yields) as a mixture of diastereomers.  
 
NMR File Name/NMR: AF5-162-B-600 
1H NMR (600 MHz, Chloroform-d) δ 7.17 – 7.05 (m, 1H), 6.92 – 6.81 (m, 3H), 5.99 – 5.76 (m, 
1H), 5.18 – 5.01 (m, 2H), 4.55 – 4.40 (m, 2H), 3.86 – 3.80 (m, 3H), 3.40 – 3.18 (m, 1H), 2.40 – 
2.22 (m, 2H), 1.76 – 1.62 (m, 1H), 1.48 – 1.41 (m, 1H), 1.38 – 1.34 (m, 1H), 1.28 (s, 3H), 1.20 – 













Synthesis of Methyl (6R,8S,9S,E)-8-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)-
2,6,9-trimethylundec-2-enoate (323): 
 
The starting material (322, 1 eq.) was added to a FDRBF with dry DCM (0.04 M). Compound 307 
(10 eq.) was added then the Grubbs second generation catalyst (0.1 eq.). The mixture was heated 
to 43 oC and allowed to reflux o/n. After this time, the reaction solvents were reduced under low 
pressure and he resulting extract was then purified via flash column chromatography (1:10 
EtOAc/hexane) to produce a colorless oil (36%) as a mixture of diastereomers.  
 
NMR File Name/NMR: AF5-120-B-2-400 
1H NMR (600 MHz, Chloroform-d) δ 7.17 – 7.05 (m, 1H), 6.92 – 6.81 (m, 3H), 5.99 – 5.76 (m, 
1H), 5.18 – 5.01 (m, 2H), 4.55 – 4.40 (m, 2H), 3.86 – 3.80 (m, 3H), 3.40 – 3.18 (m, 1H), 2.40 – 
2.22 (m, 2H), 1.76 – 1.62 (m, 1H), 1.48 – 1.41 (m, 1H), 1.38 – 1.34 (m, 1H), 1.28 (s, 3H), 1.20 – 















General Procedure for diastereoselective allylation: methyl (5S,6R,8S,9S,E)-8-((tert-
butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)-2,6,9-trimethylundec-2-enoate (329): 
 
To a flame dried pressure tube was added the SM (1 eq.) in dry THF (0.4 M), 3,4-(NO2)2-BzOH 
(0.1 eq.), CsCO3 (1 eq.), allyl acetate (2 eq.), and water (10 eq.). The reaction tube was sealed and 
heated to 100 oC and left to stir o/n. The solvents of the crude reaction were then reduced and then 
purified via flash column chromatography (1:9 EtOAc/hexane) to produce a colorless oil (63%). 
 
NMR File Name/NMR: AF5-285-2-400 
1H NMR (400 MHz, Chloroform-d) δ 5.97 – 5.79 (m, 1H), 5.25 – 5.10 (m, 2H), 3.71 (td, 1H), 
3.47 (q, 1H), 2.40 – 2.23 (m, 1H), 2.19 – 2.07 (m, 2H), 1.73 – 1.61 (m, 2H), 1.51 – 1.44 (m, 1H), 
1.36 – 1.21 (m, 3H), 1.15 (ddd, J = 11.9, 7.3, 3.6 Hz, 1H), 0.96 – 0.87 (m, 15H), 0.87 – 0.78 (m, 
3H), 0.07 (d, J = 6.3 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 135.0, 118.0, 74.71, 73.63, 38.56, 36.90, 35.13, 25.94, 16.31, 









(S)-Ir-b-NO2 cat (5 mol %)
3,4-(NO2)2-BzOH
(10 mol %)
CsCO3 (100 mol %)
THF-H2O (14:1, 0.4 M)








Standard PMB protection conditions were used to afford a colorless oil in 78% yield. 
NMR File Name/NMR: AF5-288-A-400 
1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.98 – 5.78 
(m, 1H), 5.16 – 5.01 (m, 2H), 4.56 – 4.41 (m, 2H), 3.83 (s, 3H), 3.71 (ddd, J = 8.0, 5.4, 2.2 Hz, 
1H), 3.25 (dt, J = 6.6, 5.1 Hz, 1H), 2.28 (ddd, J = 8.1, 6.1, 2.0 Hz, 2H), 1.78 – 1.71 (m, 1H), 1.69 
– 1.62 (m, 1H), 1.49 – 1.42 (m, 1H), 1.35 (dd, J = 10.0, 4.4 Hz, 1H), 1.23 – 1.13 (m, 2H), 0.94 – 
0.86 (m, 15H), 0.81 (t, J = 6.8, 5.0 Hz, 3H), 0.05 (d, 6H). 
NMR File Name/NMR: AF5-288-A-MeOD-600 
1H NMR (600 MHz, Methanol-d4) δ 7.33 – 7.21 (m, 2H), 6.90 (d, J = 8.6 Hz, 2H), 5.93 – 5.82 
(m, 1H), 5.15 – 5.00 (m, 2H), 4.57 – 4.39 (m, 2H), 3.80 (s, 3H), 3.78 – 3.68 (m, 1H), 3.28 (dt, J = 
6.6, 4.9 Hz, 1H), 2.35 – 2.24 (m, 2H), 1.75 – 1.66 (m, 2H), 1.52 – 1.43 (m, 1H), 1.37 (q, J = 7.2 
Hz, 1H), 1.22 – 1.14 (m, 2H), 0.94 – 0.89 (m, 15H), 0.82 (d, 3H), 0.07 (d, 6H). 
13C NMR (151 MHz, MeOD) δ 159.35, 135.45, 130.71, 129.29, 129.18, 115.63, 113.23, 82.99, 
















Synthesis of Methyl (5S,6R,8S,9S,E)-8-((tert-butyldimethylsilyl)oxy)-5-((4-
methoxybenzyl)oxy)-2,6,9-trimethylundec-2-enoate (331): 
 
The previously described CM conditions were used to provide colorless oil in 18% yield.  
NMR File Name/NMR: AF5-294-600 
1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.98 – 5.78 
(m, 1H), 5.16 – 5.01 (m, 2H), 4.56 – 4.41 (m, 2H), 3.83 (s, 3H), 3.71 (ddd, J = 8.0, 5.4, 2.2 Hz, 
1H), 3.25 (dt, J = 6.6, 5.1 Hz, 1H), 2.28 (ddd, J = 8.1, 6.1, 2.0 Hz, 2H), 1.78 – 1.71 (m, 1H), 1.69 
– 1.62 (m, 1H), 1.49 – 1.42 (m, 1H), 1.35 (dd, J = 10.0, 4.4 Hz, 1H), 1.23 – 1.13 (m, 2H), 0.94 – 
0.86 (m, 15H), 0.81 (t, J = 6.8, 5.0 Hz, 3H), 0.05 (d, 6H). 

















EXTRA REACTIONS NOT SHOWN IN TEXT: 
 
 
NMR File Name/NMR: AF5-155-crude-600 
1H NMR (600 MHz, Chloroform-d) δ 7.3 – 7.2 (m, 2H), 7.0 – 7.0 (m, 1H), 6.9 – 6.9 (m, 2H), 
4.5 – 4.4 (m, 2H), 3.8 (d, J = 3.9 Hz, 3H), 3.8 – 3.7 (m, 1H), 3.4 – 3.3 (m, 1H), 2.4 – 2.3 (m, 2H), 
1.9 – 1.8 (m, 3H), 1.8 – 1.7 (m, 2H), 1.5 – 1.4 (m, 2H), 1.4 – 1.3 (m, 1H), 1.2 – 1.2 (m, 2H), 1.0 
– 0.9 (m, 3H), 0.9 – 0.9 (m, 12H), 0.8 – 0.8 (m, 3H), 0.1 (d, J = 2.4 Hz, 6H). 
 
 
1H NMR (600 MHz, Chloroform-d) δ 7.3 – 7.1 (m, 9H), 7.1 – 6.9 (m, 1H), 6.9 – 6.8 (m, 2H), 
6.5 (d, J = 8.7 Hz, 1H), 5.6 (t, J = 7.6 Hz, 1H), 5.3 – 5.2 (m, 1H), 4.9 (d, J = 12.0 Hz, 1H), 4.8 (p, 
J = 6.9, 5.8 Hz, 1H), 4.7 (dd, J = 8.8, 4.6 Hz, 1H), 4.6 (d, J = 11.9 Hz, 1H), 4.5 (pd, J = 10.9, 6.5 
Hz, 2H), 4.3 (dd, J = 15.3, 3.6 Hz, 1H), 3.8 (d, J = 4.4 Hz, 3H), 3.7 (dt, J = 10.7, 4.0 Hz, 2H), 3.4 
– 3.4 (m, 1H), 3.3 – 3.2 (m, 1H), 3.1 (s, 3H), 2.9 – 2.9 (m, 3H), 2.4 (q, J = 9.7, 8.6 Hz, 1H), 2.1 – 
2.1 (m, 2H), 2.0 (ddq, J = 9.6, 4.9, 2.5 Hz, 2H), 1.9 (d, J = 6.3 Hz, 3H), 1.8 – 1.7 (m, 2H), 1.7 – 
1.6 (m, 3H), 1.5 (dq, J = 16.5, 7.2, 6.0 Hz, 2H), 1.4 – 1.3 (m, 3H), 1.3 (s, 6H), 1.2 – 1.2 (m, 2H), 
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 Understanding neurological diseases such as Parkinson’s disease, Alzheimer’s disease and 
chronic traumatic encephalopathy continue to challenge clinicians and researchers due to the 
complexity of disease development and limited access to the brain. To begin developing 
treatments for such diseases it is critical to determine what factors effect disease 
pathophysiology. This report will look to explore new pathways of investigating disease 
development, specifically regarding neuroinflammation. Through the construction of small 
molecular probes, this proposal will look to find new targets within microglia cells of the brain 
for targeted drug therapy.  
 
Specific Aim 1: Development of a synthetic route based on the flavonoid natural products to 
create a library of small molecule probes. Incorporation of both a diazirine photo-crosslinker and 
an alkyne tag will provide a covalent adduct and a protein purification handle.  
 
Specific Aim 2: Incubation of photoaffinity probes in microglia cells to determine the pathway of 
anti-inflammation within the brain. Treatment of cells with an inflammation inducer, such as 
lipopolysaciride, will allow for in-vitro quantification of neuroinflammation. Upon treatment of 
microglia cells with flavonoid and UV irradiation the active proteins will be determined via 
standard proteomic measures. 
  
 4 
Section 1.1: Introduction and Specific Aims 
 
 Neuroinflammation can be produced through a variety of ways including; cytokines, 
chemokines, reactive oxygen species, or secondary messengers,1 however, is generally defined 
as any type of inflammatory response within the brain or spinal cord.2 Microglia cells are the 
resident immune cells within the brain and are known to regulate neuroinflammation. 
Intercellular conditions cause microglia cells to become activated into various states by sensing 
their environment. There are many diseases that are caused by, or enhanced by, prolonged 
neuroinflammation including, but not limited to: Parkinson’s disease, Alzheimer’s disease, 
chronic traumatic encephalopathy (CTE), multiple sclerosis (MS), and amyotrophic lateral 
sclerosis (ALS).3 To combat such diseases, researchers have been interested in developing 
neuroprotective and anti-inflammatory drugs to help reduce the onset, or impact, of 
inflammation. One such class of molecules includes the naturally occurring polyphenols, 
flavonoids. Regular dosage of certain flavonoids have been investigated for treatment and 
prevention of neurological diseases, but mode-of-action studies for flavonoids suggests these 
molecules interact with several biological pathways.4–6 
The specific aims of this proposal are to enhance our understanding of 
neuroinflammation through determining new pathways of drug interaction, and to possibly 
identify novel therapeutic targets for treatment. To begin, a library of photoaffinity probes (PAPs) 
based on the class of polyphenol natural products, flavonoids, will be synthesized. To understand 
how these small molecules are interacting with the immune system of the brain, these PAPs will 
be incubated in microglial cells in-vitro, and UV irradiated to covalently bind the probe to the 
interacting proteins. Standard proteomic strategies will be used to identify the active enzymes 
involved in anti-inflammation. Upon completion, this work will look to both heighten our 
understanding of neuroinflammation and potentially provide new targets for treating 
neurodegenerative diseases. 
 
Section 1.2: Background and Significance  
There is recent evidence suggesting that malfunction of the cerebral immune system may 
have a significant impact on many diseases involving cognitive decline.7–9 Resident immune cells, 
 5 
called microglia, function as maintenance for cellular debris and waste within the brain.10–13 
Various exogenous factors lead to chronic inflammation, while simultaneously leading to the 
release of toxic molecules and biomarkers into the intercellular space. This chronic up-regulation 
of the microglial activity leads to severe toxicity and neurodegradation.  
 Flavonoids are a class of natural products which are known to reduce neuroinflammation 
through various different pathways. These compounds are known as pleotropic natural products, 
meaning they elicit therapeutic action through multiple distinct pathways allowing for enhanced 
phenotypic change. These naturally occurring compounds derived from plants, including flowers, 
fruits and vegetables, are known to 
possess antioxidant and anti-
inflammatory activity.14–16 An example of 
these low molecular weight phenolic 
compounds is shown in Figure 1A. The 
molecular scaffold of flavonoids contains 
a tricyclic structure and is considered a 
down-stream biosynthetic intermediate of the bicyclic chalcones.  
 The biological activity of these molecules is known to have an array of interactions 
throughout the body, and these scaffolds are known to penetrate the blood-brain barrier (B-BB) 
and allow for interaction within the central nervous system (CNS).17–22 Figure 1B displays a 
collection of CNS active flavonoids. Quercetin (1) is known to inhibit acetylcholinesterase, a 
known therapeutic pathway for the treatment of AD.23 Luteolin (2) has neuroprotective 
properties via different mechanisms to have antioxidative and cytoprotective properties through 
interaction within the NRF2 pathway.24,25 Apigenin (3) was discovered to affect the production of 
multiple enzymes, such as cyclooxygenase-2 (COX-2) within cultured microglial cells.27 COX-2 
enzymes are known to produce prostaglandin E2, which is a proinflammatory signaling molecule 
in the brain.28 Studies show that BV2 cells, cultured with lipopolysaccharide (LPS) have a reduced 
nitric oxide (NO) production when treated with apigenin. Based on these findings, a dose 
dependent decrease of COX-2 enzyme production was observed using an immunochemistry 
assay. In addition, evidence supports that mitogen-activated protein kinase, an up-stream 
Figure 1: A) Core structure of both Flavonoid core and biosynthetic 








































signaling enzyme, is also affected. Lastly, fisetin (4) acts on multiple pathways to reduce the 
impact of aging involved in neurotropic signaling.26 From these data it is clear that the pleotropic 
reactivity of structurally similar molecules have a variety of interactions in the brain. These mode-
of-action investigations highlight the downstream effects of these molecules, but the specific 
molecular interaction has not been identified. Since these molecules may be interacting weakly 
with various proteins, it is important to determine all the proteins responsible for the reduced 
inflammatory response.  This proposal will seek to confirm previous flavonoid mode-of-action 
studies and determine new weak binding proteins that may be involved in reducing 
neuroinflammation.  
Identifying drug-protein interaction is one of many important aspects for early 
development of pharmaceuticals to determine specific mode of action and identify possible side 
effects. Early detection of undesired side effects can prevent the high cost of drug development 
and clinical failures.29 Current techniques for identifying drug-protein interactions include 
genome-wide genetic assays,29 chemical proteomics,30 expression profiling, and bioinformatics.30 
In addition, cellular thermal shift,32 drug affinity responsive targets (DARTS),33 and 
chromatography assays can also be used to identify drug targets.33 However, recently the use of 
PAPs has become more popular for determining novel drug targets and to identify off targets side 
effects.  
The use of PAPs has become a powerful tool for chemical biologists interested in 
understanding molecular interactions of drugs. This technique has been developed for identifying 
specific protein-drug interactions,35 mapping binding 
sites,36 identifying ligand targets,37 investigating 
protein-protein interactions,38 and imaging live cells.39 
An illustration of the two functional groups required 
for protein identification are shown in Figure 2. Figure 
2-A shows a diazirine which is a photo-crosslinker that 
generates a reactive intermediate when excited with 
UV light. Diazirines and other groups, such as azides and benzophenones become covalently 
bound to the protein through direct insertion into the active-site of the nearby protein.35 
Figure 2: Illustration of the two major components 
of PAP synthesis. A) Photo-cross linker for covalent 


















Additionally, incorporation of terminal alkyne moiety allows for a copper mediated [2+3] 
cycloaddition, known as click-chemistry, to a florescent tag or a biotin moiety (Figure 2-B). This 
reaction allows for the addition of either a fluorophore or a biotin to the covalently bound drug-
protein complex; allowing visualization, or purification of cell lysate to identify the bound protein. 
This proposal will focus on the synthesis of diazirine containing probes to generate a carbene 
within the active-site of a protein to produce a drug-protein complex, and will be discussed later. 
Click-chemistry to the terminal alkyne moiety with a biotin containing azide will allow for 
purification of the cell lysate with streptavidin affinity beads. After the select proteins have been 
extracted from the lysate, gel electrophoresis purification methods are used to separate the 
protein targets. Following the purification, standard proteomic strategies will be used to identify 
the unknown bound proteins. With the use of bioinformatics the protein of interest can be 
identified and then verified by other molecular biology tools. This proposal will look to identify 
multiple individual proteins to highlight the pleotropic effect produced by the flavonoid 
molecules.  
 
Section 1.3: Innovation  
The incorporation of PAPs has been the focus of many research publications and is known 
to work well on many different substrates.37,40,41 In this proposal, diazirines will be incorporated 
into flavonoid molecules to determine active proteins within microglia cells. Contrary to the azide 
and benzophenone functional groups which produce either a nitrene or a diradiacal; diazirine 
containing probes produce a carbene, a species with extremely short lifetimes and high reactivity 
(Figure 3).37 The reactive carbene 
can insert into nearby C–H or O–H 
bonds, or with various residues 
within the active site. In addition 
to the fast kinetics of the carbene 
generation, other benefits of 
using diazirine probes include the 
non-hazardous irradiation at 340- Figure 3: Most common types of PAP moieties with respective advantages and 
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380 nm to allow for live cell imaging, and the small size to avoid the effects of steric bulk within 
the enzyme active-site.41 To increase the stability of the diazirine compound, it was determined 
that the addition of trifluoromethyl group in the alpha position increases stability and reduces 
the formation of undesired side reactions.36 Without this electron withdrawing character of the 
trifluoromethyl, a prolonged reactive diazoisomer can be produced. This prolonged decay will 
eventually regress to a carbene resulting in off-target conjugation. With addition of these groups, 
the trifluoromethyl phenyl diazirine (TPD) have been found to be stable in both biological settings 
and through many synthetic manipulations.39 In brief, TPDs have been found to tolerate a range 
of reaction conditions including reduction,42,43 oxidation,44–46 acid,42,47 base,48,49 hydrolysis,50,51 
nucleophiles,52 electrophiles,37 thermal heat,53 metal catalysis,42 and ambient light.39 
The incorporation of diazirines has been categorized into 3 different subclasses; 
appended, replaced, and nested,39 as shown in Figure 4 (adapted from reference 39). These 
classes can be ranked corresponding to 
the degreed of alteration of the 
photoprobe from the parent 
compounds. Of the three, nested is 
considered to have the lowest amount 
of structural perturbation, meaning 
there is less alteration in the structures 
physiochemical properties (PCPs), and shortest proximity to the pharmacophore.54 Minimal PCP 
alteration is important for retention of cellular mode-of-action and penetration of parent 
compounds to allow for similar interaction with active proteins. Moreover, appended and 
replaced diazirines onto the compounds leads to an increased likelihood of limiting interactions 
within cells, leading to false negatives, and low labeling efficiency.54 However, due to challenging 
synthesis, the nested strategy has had limited application with current reports indicating only 
20% of diazirine in literature are nested. The other two strategies have had more attention with 
52% appended, and 28% replaced.54 This proposal will detail a synthetic strategy towards nested 
TPDs to limit the amount of perturbation from the parent pharmacophore in hopes to identify 
the weak interactions within microglia that are key for determining pleotropic effects.  
Figure 4: Types of diazirine replacement strategies onto unlabeled 




























The main focuses of this route are to harness known chemistry to selectively install 
trifluoroacetyl groups without using ketone protecting groups, and to install the diazirine late in 
the synthesis to prevent any functional group intolerance or minor light mediated 
decomposition. Starting from a bromo-aryl compound, the reported literature use standard 
lithium halogen exchange, or Grignard formation to add trifluoroacetyl. However, due to both a 
ketone and enone system within the target molecules and intermediates, a new strategy is 
needed to eliminate ketone protecting groups. To overcome this obstacle, this proposal will 
harness the Weinreb amide chemistry to install trifluoroacetyl group for the use of PAPs.  
The synthetic route to install the TPD is shown in Scheme 1. Using a reaction developed 
by Buchwald and co-workers a Pd-catalyzed aminocarbonylation at atmospheric pressure can be 
performed to afford the Weinreb 
amide (6) from the aryl bromide (5).55 
In addition, this reaction has shown to 
be selective to the installation at the 
bromine carbon and has no effect on 
adjacent ketones on  the starting 
material.56 The Weinreb amide can 
then be converted into the compound 7 by the use of a Ruppert–Prakash reagent (TMS–CF3) 
under mild conditions.57 With the installation of the trifluoroacetyl there is many literature 
precedence that describe the installation of the diazirine through various conditions.58–60 It is 
envisioned that the electron deficiency of the trifluoroacetyl will be more reactive than the 
adjacent ketone functionality in the formation of the diaziridine (10). Various conditions can be 
used to form the diazirine compound (11).  
  







































Section 1.4: Approach and Methods 
The construction of a diverse library of PAPs will allow for the identification of multiple 
enzymes involved in the flavonoids mediated reduction of neuroinflammation. As a proof of 
concept several molecules deriving from the fisetin (4) will be reported here. To ensure that none 
of the weakly bound proteins are missed in the 
target validation; a range of molecules are 
envisioned from the same starting material. 
Figure 5 highlights some of the target molecules 
and shows the potential effects that positioning 
of the PAP functional groups may have on cellular 
interaction. For example, 12 and 13 differ by the 
positioning of the diazirine moiety which may be 
important for interactions in the protein. 
Molecules 14 and 15 differ in the saturation of their core ring structure which also may affect the 
molecules ability to bind into the active sites. 
In order to develop a more complex library, this proposal will use inspiration from the 
biosynthetic pathway to first access the chalcone in route to the flavonoid compound. This will 
allow for testing of both types of compounds and allow for a more diverse library to be created.61 
Fortuitously, the chalcone intermediates within the synthesis can also be synthesized into PAPs 
and tested for activity. In addition a route that allows for late stage manipulations will create a 
complex library of flavonoid analogs quickly. As shown in the proposed retrosynthetic analysis in 
Figure 6, to reduce undesired side reactions it will be important to install the diazirine and the 
terminal alkyne 
functional groups 
in the final steps of 
the synthesis 
shown as structure 
16. Orthogonal phenolic protecting groups will be used for selective deprotection and 
manipulations of core structure (19 and 20). One major step in the synthesis will be the 
Figure JJ: Library of PAP based on fisetin natural product to be 
synthesized. 
Figure 6: Proposed 
retrosynthesis of one 
flavonoid analog 
envisioned. 
i  5 Examples of diazirine containing fiestin analogs 












































































installation of the trifluoroacetyl group onto the protected benzophenone compound 21 to 22. 
The use of Weinreb amide over Grinard formation or lithium-halogen exchange will reduce the 
need to protect the starting material ketone. This route in Figure 6 can also be applied to various 
different mono and di-phenolic compounds which will allow for the synthesis of structural 
analogs.  
Diversification of the flavonoid library can be 
expanded by the use of synthetic manipulations to 
create various different core ring structures. The 
chalcone based substrates can be cyclized under 
various conditions to produce different ring sizes, 
oxidation states, and degree of unsaturation around 
the central C ring, as shown in Scheme 2. While these 
cyclization reactions are well precedented in the 
literature, the functional group compatibility with 
advanced material will need to be investigated.  
Upon construction of the library, initial efforts will be to determine which of the analogs 
gives the strongest phenotypic change for anti-inflammation. There are several assays that allow 
for the detection and quantification of inflammation for BV-2 cells in vitro.62 Detection of selected 
biomarkers can indicate neuroinflammation including: NO production via Griess reaction,63 ELISA 
based cytokines production including IL-6 and TNF-a,64 total protein level via Lowry Assay,65 and 
cell viability via MTT assay.66 Compounds that show the best overall anti-inflammatory activity 
will be selected as lead compounds to move onto the protein identification process. Ideally, lead 
compounds will have high degree of activity in multiple enzymatic pathways, as this will allow for 
identification of many protein-drug interactions within the microglial cells.  
Parent natural products can be purchased from commercially available sources to allow 
for testing of the original phenotypic response. Achievement of probe synthesis will also allow 
for competitive binding assays between parent compound and PAP analogs and will provide a 
range of ligand binding values to the various enzymatic partners. This data will serve as a 
Scheme 2: Cyclization conditions from chalcone 
























structure activity relationship (SAR) and help determine the important components of each 
structure for specific enzyme interaction.  
Quantification of unknown binding partners can be done through the combination of 
biochemical and analytical techniques, such as gel purification and LC-MS/MS analysis.67 To allow 
for identification of active proteins, a terminal alkyne incorporation onto the drug will allow for 
copper catalyzed click-chemistry, with an azide containing biotin, to allow for the pull-down of 
conjugated enzymes.68 The cell lysate can then be purified with either gel electrophoresis,69 or 
streptavidin pull-down assays,70 respectively. This allows for the isolation of enzymes based on 
florescent and affinity properties of the conjugate. Upon isolation of the protein, LC-MS/MS is 
performed to fragment the peptide and determine the sequence. To confirm these findings, 
several additional methods for validation can be performed, in addition to individual gene 
knockout therapies to selectively eliminate potential targets.  
The protein bands of interest can be extracted and digested into peptide fragments 
before LC-MS/MS analysis is used to determine common sequences. From the data the overall 
protein size and the sequences of the fragmented peptide can be used in tandem with 
bioinformatics to identify possible partners.71 Such computer software as MaxQuant, Peaks, and 
OpenMS are used to predict possible proteins based on these common sequences and overall 
protein size. However, due to a high degree of homologs, the computer software’s may produce 
many possible matches. Validation of target protein can be time consuming, but the additional 
methods, mentioned above, can be done to repeat findings of initial bioinformatic results. 
 
Section 1.5  Synthetic Route and Application  
Creation of polyphenol natural products 
requires orthogonal protecting groups for 
selective synthesis of core ring structure. To 
achieve this, a linear sequence of deprotection 
will need to be considered, in addition to the 
stability of the alkyne tag. Shown in Figure 7, is 
the linear sequence of the selective deprotections 
Figure 7: Types of O-protections and deprotection conditions 
that can be used in phenolic positions. Specific Pt catalyst is 
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effect other groups
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Acid conditions are 
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Specific Pt catalyst can 








that will allow for synthesis of PAP containing TPDs. The mildest of these protecting groups is the 
triflouropyridine (TFP) group which is easily cleaved under mild conditions with KF and methyl 
thioglycolate.72 These conditions will allow for selective deprotected without effecting the other 
groups. Following this the use of standard silyl protecting groups can be deprotected using 
fluoride ions. The strategy will require for the silyl deprotection to occur before the third 
deprotection which is the methoxymethyl acetals (MOM) group which requires acidic conditions. 
Literature precedence shows that late stage deprotection under both TFA and aqueous HCl are 
possible without diazirine decomposition.73,74 Finally, allyl protection of the phenolic position can 
allow for deprotection and is stable under all of the above conditions. While the standard 
deprotection conditions of H2 and Pt are not ideal considering the target molecule contains a 
terminal alkyne tag, there have been reported literature that involves a bulky Pt catalyst that 
allow for allyl deprotection without reduction of the alkyne.75 This sequence of deprotection 
conditions will allow for selectivity of the synthetic route. 
Synthetic manipulations to prepare the diphenolic acetophenone compound 23 for aldol 
conditions is shown in scheme 3. Employing 1 equivalent of THP will afford compound 24 
followed by MOM 
installation of the other 
phenolic group to afford 
compound 25, allowing for 
orthogonal protecting 
groups. As shown 
compound 25 will allow for a mixture of otho- and para- bromonations to occur (26 and 27), 
however both compounds can be utilized in the library construction. It is suggested that the 
compound 26 will be favored in this addition due to electronics of the acetyl group acting as an 
EWG. From here, 26 and 27 can be carried on to aldol conditions, or the trifluoroacetyl group can 
be installed via reactions previously mentioned using the Weinreb amide protocol to afford 28 
or 29.  












































Concurrently, the aldehyde unit (30) will also be prepared for aldol condensation 
conditions, as shown in Scheme 4. The propargyl cross-linker can be installed first with propargyl 
bromide and 
potassium carbonate 
to afford compound 31 
or 32. Again, a mixture 
of compounds will be 
produced, but this 
allows for 
diversification of library synthesis. Following this installation, the remaining phenolic OH can be 
protected with TBSCl and pyridine to give compounds 33 and 34. The terminal alkyne contains 
acidic protons that will be liable in the strongly basic aldol conditions, so selective silylation in the 
terminal position can install a trimethylsilane using ZnBr2 to afford compounds 35 and 36.76 
Fortuitously, both protecting groups on this molecule will be liable under TBAF conditions which 
should be considered as one of the final steps in the synthesis. If this terminal silyl protecting 
group fails to void decomposition in the following steps, then dual TBS protections will be 
considered as an alternative route (37), and will require late stage propargyl installation.  
With 28 and 35 in hand, aldol 
condensation conditions with KOH in 
EtOH will afford the chalcone 
intermediate (38), as shown in Scheme 5. 
From here, phenolic deprotection of 
compound 38 and addition of PAP 
functional groups will allow for testing of 
the chalcone intermediate. Parallel to 
this, selective deprotection of the THP 
group using mild KF conditions, will afford 
compound 39 to be prepared for 
cyclization conditions. The conditions discussed earlier will be used to synthesize the various core 










































Note: Final deptrotection with 
TBAF will remove both. Silyl 







































































flavonoid ring structures (40-42). Again, these steps will need to be examined for stability of 
functional groups to ensure phenolic oxygens remain protected. If the ketone functionality of the 
flavonoid core becomes problematic later in the synthesis, then during cyclization the enolate 
intermediate can be trapped as a TMS ether for protection and can be released in final steps. The 
iodine cyclization step towards compound 40, will also deprotect the phenolic MOM groups, 
which could strategically shorten the synthetic route. Although early installation of the diazirine 
would be ideal for diversification it may be necessary to optimize protecting groups through 
experimental testing. 
Upon cyclization of the various intermediates, the final steps will be to install the PAP 
functional groups, and to deprotect the phenolic protecting groups. As shown in Scheme 6, 
following the installation of the 
trifluoroacetyl group to compound 41, 
the addition of hydroxyamine will 
install the N-oxide (43). Tosylation of 
43 and treatment with liquid ammonia 
will afford the diazirine containing 
compound (44). Final deprotection of 
the TBS groups upon treatment with 
TBAF will afford compound 45 with 
either the free phenolic OH on the B-
ring, or will complete they 
deprotection of the terminal alkyne in 
tandem to afford the final product (46). 
If dual TBS installation was required for synthetic stability, then following the deprotection, a 
non-selective alkylation will be performed to create compounds 46, 47 or 48. This late stage 
installation will afford several analogs that can be tested for various binding values within 
proteins.  
In summary, while this synthesis may require extensive use of selective phenolic 
protecting groups throughout, this pathway will afford several compounds for testing from each 
































































of the products formed. In addition the generality of the synthesis will allow for reapplication of 
the route to the different starting materials and will allow for a large collection of compounds to 
be gathered quickly. As mentioned before, it is pivotal to synthesize a variety of analogs that will 
have various structural difference to be able to detect the weak binding partners that may have 
a significant impact within microglial proteomes.  
 There are many steps in the protein purification and separation that will need to be 
optimized during this work. The process of identification will be done with the help of 
collaborations with researchers in the proteomic field. Potential works with known researchers 
in this field include Deepak Nijhawan and Jef De Brabander at UTSW, and John Pezacki at the 
UOttowa have both communicated interest in collaboration/training. Each respective group have 
produced several publications in the synthesis and use of PAPs. 
 
Section 1.6: Conclusion and Broader Impacts 
 Recently the use of diazirine based PAPs has begun to attract more attention for their 
innate characteristics to bind near the active site without effecting the original drugs properties. 
This proposal seeks to synthesize a library of flavonoid analogs with diazirines to monitor the 
weak interactions that dictate the pleotropic effect of these molecules. It is envisioned that these 
molecules will be able to interact with the immune system of the brain to reduce the amount of 
neuroinflammation in various disease states. Upon collection of this molecular probe library, 
detection of microglial proteomic activity on a basal level vs. inflammatory conditions will provide 
an SAR investigation for important pharmacophore properties. By doing this it may be possible 
to determine the underlying mechanisms of inflammatory diseases and could illuminate 
undiscovered avenues of treatment.  
 If this proposal were to fall short on providing a drugable target within microglial cells, 
the library of PAPs could have lasting implications for more discoveries in chemical biology. The 
aim of this proposal was based on modulation of microglia activity in the brain; however, 
flavonoids are also known to interact within other biological systems of the body. Using these 
PAPs on various cancer cell lines in-vitro could also indicate new paths of treatment in cancer 
cells. Another possible application would be identification of the mechanism responsible for B-
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BB penetration. A B-BB model system can be made of a CaCo-2 monolayer of cells, and the PAPs 
can be used to find new mechanisms of small molecule penetration to the brain.  
If these PAPs lack all reactivity in cells, the route proposed here can be applied to more 
complex natural products including flavon-chalcone hybrids that could have altered activity 
within cells. Moreover, another avenue of reapplication could be to move the active cross-linker 
further way from the active portion of the molecule. A carbon chain tether will covalently bind 
adjacent proteins acting as secondary proteins. Overtime a library of complex molecules can be 
collected and tested on a variety of biological systems, and with more advanced biological and 
genetic tools being developed, our understanding of challenging diseases will continue to 
improve. 
 
Section 1.7: Timeline  
 The synthesis of the PAP library could be accessed over an extended period with 
increasing diversity. However compounds can be accessed quickly and be tested immediately. 
This will allow for testing of individual polyphenols to be examined within the first year of 
research onset. Any of these probes could provide several hits for the identification of interacting 
proteins. With advancements in automation and proteomic assays, identification of a target 
could be done within 3 years. Finding this new target could lead to several synthetic efforts in 
medicinal chemistry for drug design and synthesis.  
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a b s t r a c t
Lagunamide C is a depsipeptide natural product with low nM cytotoxicity towards numerous cancer cell
lines. Synthetically, it is disconnected to a pentapeptide backbone and polyketide unit that possesses four
stereogenic centers, of which two of centers are in question (C38 & 40). Our model system highlights a
high-selective aldol addition via a Crimmin’s auxiliary setting the C40 ester linkage, and a non-facially
selective cyclopropanation with subsequent ring opening for the installation of the C38 methyl center.
! 2018 Elsevier Ltd. All rights reserved.
Introduction
The Lyngbya genus of marine cyanobacteria continues to be a
plentiful source for the discovery of new natural products.1,2 The
secondary metabolites isolated from this genus have been found
to possess diverse biological activity across multiple health related
diseases. Specifically, they show antimicrobial, antimalarial, as
well as cytotoxic and neurotoxic properties.3–8 In addition to their
shared biological activities, the natural products from this genus
also share common structural characteristics (amino acid based
backbone and polyketide unit). In the quest to discover new bioac-
tive secondary metabolites, Tan and co-workers successfully iden-
tified a persistent strain of filamentous marine cyanobacterium,
Lyngbya majuscula.9 Investigations into this strain led to the dis-
covery of the lagunamide family of cyclodepsipeptide natural
products in 2010 shown in Fig. 1; lagunamide A (1) and B (2)10 fol-
lowed by C (3) in 2011.11
The family has low nM cytotoxicity against lymphoma (P388),
and 3 possesses additional cytotoxicity towards lung cancer
(A549), prostate cancer (PC), ileocecal colorectal adenocarcinoma
(HCT8), and ovarian cancer (SK-OV) with IC50 values of 2.4, 2.6,
2.1, and 4.5 nM, respectively. All three molecules also possess anti-
malarial activity towards Plasmodium falciparumwith IC50’s of 0.19,
0.91, and 0.29 lM, respectively.10,11 Anti-swarming activity against
the gram-negative bacterial strain Pseudomonas aeruginosa (PA01)
has also been reported for 1 (62%), 2 (56%), and 3 (49%) relative to
controls. The potent cytotoxicity exhibited by the lagunamide fam-
ily has drawn the interest by multiple groups12 and resulted in two
total syntheses of 1.13,14 In addition to the common potent cytotox-
icity, the lagunamide family shares a highly conserved amino acid
based backbone and a polyketide unit, wherein the presence and
stereochemistry of a C37-hydroxyl (R-configuration) and C38-
methyl (R-configuration) are conserved. The key structural differ-
ence between 1&2 and 3 is the presence of an additional methy-
lene carbon within 3 upon C39. The same C39 position within 1
and 2 is the ester linkage position connecting the amino acid based
backbone. It was the common biological activity exhibited by this
family, along with the presence of an extra methylene within 3
drew our attention. While the stereochemistry about these two
carbon centers are conserved, the extra methylene unit does
impact the confirmation of 3 relative to 1 & 2. This structural dif-
ference, methyl insertion, could translate into variable binding
upon the cellular target(s) for cytotoxicity. Recalling the similari-
ties in cytotoxicity’s between the family members, it could be
assumed that the compound-target interactions should be the
same. As such, we propose that the amino acid based backbone
directs penetration, and possibly general selectivity. Upon cellular
uptake, the backbone is cleaved off, in full or in-part, exposing the
cytotoxic arm of this family that could allow and justify the
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common cytotoxicity profiles. Given the interesting methylene
addition within the polyketide, potent cytotoxicity, ambiguity of
the C38 stereocenter (vida infra), and our proposed mechanism of
action, our laboratory has undertaken synthetic efforts towards
lagunamide C.
Lagunamide A was first synthesized by Dai et al. in 2012,13 and
a second total synthesis was accomplished by Huang et al. in
2013.14 In the route established by Dai et al., assembly of the
polyketide commenced with the enolization of the Evans (R)-oxa-
zolidinone (4) with dibutylboron ditriflate followed by (S)-2-
methylbutanal (5) to give access to the aldol product (Scheme 1).
The corresponding alcohol was converted into the anisylidine
acetal (6), which was further elaborated onto the PMB protected
alcohol homoallylic alcohol 7. Through three synthetic steps (dihy-
droxylation, oxidative cleavage, and Horner-Wadsworth-Emmons
reaction), 7 was successfully elaborated onto the desired polyke-
tide (8) present within lagunamide A. Construction of the pen-
tapeptide backbone was accomplished with successive coupling
of commercially available amino acids. Esterification about the
C39 carbon to the backbone followed by macrolactamization gave
access to the reported structure of lagunamide A. Comparison of
the natural and synthetic material access revealed that the pro-
posed stereochemistry about the C7 and C39 were incorrect
(Fig. 1). The route was adjusted to allow for the two epimers about
these carbons to be installed and cyclized in the same fashion. This
furnished the macrocycle, which allowed for the elucidation of the
final, and correct, structure of lagunamide A (Fig. 1). The route
developed by Huang et al. accessed 1 in an analogous fashion to
Dai et al., via polyketide unit (8). Huang’s approach towards 8
was based upon a crotylation strategy upon (S)-2-methylbutanol
(9) that furnished olefin 10 over multiple steps. The polyketide 8
was accessed by the cross-metathesis of 2-methyl-acrolein (11)
and 10. Their total synthesis also confirmed the structural assign-
ment of lagunamide A. To date, no total synthesis of lagunamide
B has been reported, but an analog, C28 epimer, has been con-
structed by Pal and Chakraborty15 employing the route developed
by Dai and co-workers. In an analogous route to that employed by
Huang et al., they constructed the polyketide via a HWE-olefina-
tion reaction from the aldehyde surrogate of 7.
Unfortunately, employing the methods developed by Dai and
Huang will not give access to polyketide 12 for the construction
of lagunamide C. These routes fail to provide synthetic means for
the installation of the extra methylene carbon at C39 within 12
(highlighted by the dash box insert within Scheme 1). Further-
more, there is ambiguity about the stereochemical assignment of
the C38 methyl (proposed R-configuration) within lagunamide
C.11 Therefore, any route designed and employed to gain access
to polyketide 12 must allow for synthetic versatility about the
C38 center for structural elucidation studies, and be robust for
structural-activity relationship studies for biological evaluation
and mode of action of studies.
Our envisioned route to access lagunamide C (Scheme 2) relies
upon esterification and macrolactonization of the polyketide 12 to
the pentapeptide backbone similar to previous routes.13–15 Our
proposed route differs in the construction of the functionalized
polyketide unit 13. Installation of the C37 alcohol within 12, will
be accomplished through a Corey-Bakshi-Shibata reduction upon
ketone 13.16 Performing a Mukaiyama Aldol between 14 and
methyl-(E)-2-methylbut-2-enoate will give access to ketone 13.
The key step in our proposed route invokes a facially selective
Charette cyclopropanation upon 15 with subsequent ring opening,
accessing 14. This critical step will allow access to both the R and S
versions of the polyketide unit about the C38 carbon for final struc-
tural elucidation. Assembly of 15 will be accomplished through a
Wittig olefination upon the aldehyde of 16, and the construction
Fig. 1. Lagunamide family of natural products. Including their proposed and revised
structures for A&B and published and proposed for C.
Scheme 1. Construction of polyketides within lagunamide A & B. Scheme 2. Retrosynthetic analysis of lagunamide C.
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of 16 from an Aldol reaction of an acetylate thiazolidinethione, 17,
and (S)-2-methylbutanal in an analogous fashion to Huang et al.14
Rather than employing the Evans auxiliary, we chose to utilize the
Crimmins auxiliary for potential enhanced facial selectivity
through the use a bidentate amine to favor coordination of the tita-
nium to the amines rather than the thiocarbonyl sulfur, thus, favor-
ing the desired cis aldol product. The key step in our proposed
synthesis route of polyketide (13) lies within the cyclopropanation
and subsequent ring opening steps. Said steps are known for their
substrate sensitivity, and difficulty in optimization. Noting the
need to investigate if cyclopropane ring opening is achievable in
our system, gaining access to the C40 methyl center, cyclopropana-
tion was performed under non-facially selective conditions in this
explorative work. To expedite accessing these key, and critical
steps, we chose to employ butanal, lacking the desired C41 methyl
group, as our starting aldehyde.
Results and discussion
Assembly of the C41 methyl truncated version of 12 com-
menced with the construction of the acetylated thiazolidinethione,
accessed from L-valine (18) outlined in Scheme 3. The reduction of
18 was accomplished with LiAlH4 in THF at reflux to afford L-vali-
nol in 99% yield. Formation of the Crimmins auxiliary was per-
formed under standard conditions17–20 to access 19 in 96% yield
over two-steps. Acetylation of the auxiliary with acetyl chloride
and n-BuLi successfully furnished 17 in 98% yield with no column
chromatography required.
The chiral base (!)-sparteine (0.5 eq) was used for the aldol
reaction between 17 and butanal with titanium tetrachloride in
CH2Cl2, which afforded the desired aldol product 20a in 27% and
undesired aldol product in <4% yield (Table 1, entry 1). The stere-
ochemistry of the 20a/b was confirmed through 1H NMR and opti-
cal rotation comparisons to the same compound accessed by Zhou
and co-workers21 in a different synthetic fashion (data shown in
the Supplemental). Zhou also employed the same Crimmins auxil-
iary, but under his condition of diisopropyl ethylamine 20b was
favored in a 2:1 ratio over 20a. Increasing the equivalents of the
sparteine did provide an increase in 20a, but only by a marginal
3% with 0.75 equivalents and 8% with 1.2 equivalents (entries 2
and 3, respectively). Employing various amine bases in auxiliary
based aldol reactions is well reported in the literature.19,22 Given
the poor yields with the chiral base (!)-sparteine, efforts were
directed towards screening other amine bases. Exploring diiso-
propyl ethylamine (entries 4–6) as the base rather than sparteine,
a diamine base, gave the opposite of the desired selectivity, favor-
ing 20b over 20a, analogous to the reported observations from
Zhou.21 Varying the equivalences of the base failed to reverse the
observed selectivity. The addition of NMP (N-methylpyrrolidone)
in an equal molar ratio to the base returned the desired selectivity
with yields of 30% of 20a and 13% of the undesired 20b (entry 7).
Recalling the selectivity observed with sparteine, a diamine base,
the return to the desired selectivity is assumed to be through a
similar bidentate ligand addition onto the titanium. Doubling the
base equivalence increased the yield of 20a by 8%, but also
increased 20b by 10% (entry 8). Employ the bidentate base TMEDA
alone and with NMP failed to provide any yields greater than 22%
of 20a (entries 9–11). With weak bases failing to provide the
desired 20a in both high yields (over 50%) and in high selectivity,
strong bases were screened. Screening the reaction with LDA
(entry 12) afforded 20a in 53%, and the undesired 20b in 11% yield.
Optimization of this condition was undertaken, but failed to pro-
vide any increase in yield or selectivity. Utilizing an equal molar
ratio of LDA to NMP afforded 20a in 79%, with only 4% of the unde-
sired 20b (entry 13). Given the observed trends, increasing the
NMP equivalence should correlate to increased yields. Unfortu-
nately, this was not observed with LDA and resulted in a decreased
yield (entry 14). Through these studies, accessing 20a in a 70%
yield with a 20:1 dr was obtained, a stark difference from the 1:2
dr observed by Zhou.21
With the optimized conditions in hand (Table 1, entry 13), pro-
tection of the alcohol within 20a was performed. Treating 20a
under standard TBSCl protection conditions, imidazole in THF,
afforded the TBS protected alcohol 21 in 45% (Scheme 4). Optimiza-
tion of these conditions failed to afford any increase in yield.
Employing 2,6-lutidine in DMF at RT afforded 21 in 65% yield.
Increasing the temperature to 32 "C increased the yield to 86% of
21. Any further increasing in temperature failed to result in yield
increase, but rather lead to decomposition of the material. Treat-
Scheme 3. Formation of the acetylated Crimmin’s auxiliary.
Table 1
Optimization of Aldol Reaction Conditions.
Entry Reaction conditionsa Yield (%)
20a 20b
1 TiCl4, sparteine (0.5 eq) 27 <4
2 TiCl4, sparteine (0.75 eq) 30 <4
3 TiCl4, sparteine (1.2 eq) 35 <2
4 TiCl4, DIPEA (0.5 eq) 13 36
5 TiCl4, DIPEA (1.1 eq) 22 47
6 TiCl4, DIPEA (2.2 eq) 25 47
7 TiCl4, DIPEA (1.05 eq), NMP (1.05 eq) 30 13
8 TiCl4, DIPEA (2.05 eq), NMP (1.05 eq) 38 23
9 TiCl4, TMEDA (1.05 eq) 19 7
10 TiCl4, TMEDA (2.05 eq) 21 8
11 TiCl4, TMEDA (2.05 eq), NMP (1.2 eq) 22 8
12 TiCl4, LDA (1.2 eq) 53 11
13 TiCl4, LDA (1.2 eq), NMP (1.2 eq) 79 4
14 TiCl4, LDA (1.2 eq), NMP (2.2 eq) 65 <4
a Reactions run with 1.05 eq. of TiCl4 in CH2Cl2 at [0.5 M] relative to 17.
Scheme 4. Chain elongation and olefin installation-via Wittig olefination.
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ment of 21 to DIBAl-H in CH2Cl2 gave access to aldehyde 22 in
addition to alcohol 23 in 31% and 29% yields, respectively. In this
DIBAL-H reduction step 21% of the auxiliary 19 was obtained and
acetylated, thus providing 17. All attempts at the optimization of
the DIBAl-H reduction of 21 to give 22 failed to provide any
increase in yields. Alcohol 23, obtained in the DIBAL-H reduction,
was oxidized to 22 in 96% yield under Swern oxidation conditions.
Employing 2.2 equivalents of DIBAl-H gave access to alcohol 23 in
77% yield, but subjecting 21 to NaBH4 in ethanol furnished 23 in
91% yield, which was subsequently oxidized to 22 in 96% yield.
The NaBH4 reduction also resulted in the recovery of 80% of auxil-
iary 19, which was successfully recycled and elaborated onto 17.
Structural integrity of 19, via recycled 17, was confirmed by 1H
NMR spectral and optical rotation comparison to the originally
synthesized 19. Treating 22with the activated ylide methyl-(triph-
enylphosphoranylidene)acetate in toluene afforded the allylic
methyl ester 24 in 80% yield.
With 24 in hand, the reduction of the ester to its corresponding
allylic alcohol 25 was then undertaken. The reduction of 24 with
NaBH4 in ethanol afforded allylic alcohol 25 in a 19% yield along
with high levels of decomposition. Employing LiAlH4 failed to pro-
vide a greater yield of 25 (17% yield). All optimization conditions
with these reductants failed to afford 25 in yields greater than
19%. Subjecting 24 to 2.5 equivalents of DIBAl-H in CH2Cl2 at
!78 "C afforded 25 in 92% yield (Scheme 5). With 25 in hand,
efforts towards cyclopropanation and ring opening could be per-
formed. Non-facially selective cyclopropanation conditions were
attempted first in the efforts to prove that our proposed key-steps
for the synthesis of lagunamide C was feasible. The initial attempts
of cyclopropanation with Et2Zn, CH2I2, and TiCl4 at 0 "C failed to
provide any of the desired material, which led us to explore tem-
perature optimization. Starting the reaction at 0 "C and then lower-
ing to !20 "C failed to provide any product, as did the increase of
temperatures. To our surprise, setting up the reaction at 0 "C and
then warming to room temperature, 45 min post reagent addition,
led to a 3% yield of 26. Exclusion of TiCl4 under the same conditions
resulted in an increase in yield to 48%, and upon running the reac-
tion overnight resulted in a 95% conversion to the desired cyclo-
propanated material 26 as a mixture of diastereomers. Mesylate
protection of the alcohol was accomplished with methanesulfonyl
chloride, NEt3 in CH2Cl2. The material was subsequently converted
to the iodine counterpart (27) with NaI in acetone with an 80%
yield over the 2-steps. The stability of 27 was found to be fleeting
(1–2 h) and was therefore pushed onto the lithium-halogen
exchange step immediately. Subjecting 27 to nBuLi and TMEDA
in diethyl ether at !78 "C afforded a mixture of the desired
terminal alkenes 29 and 30 in 71% combined yield, via intermedi-
ate 28. Using less than 2.0 equivalents of TMEDA resulted in a rapid
decrease in yields of 29/30 and led to an increase in decomposition
of material.
Conclusion
We have developed a route that will allow for the assembly of
the polyketide required to access lagunamide C, as well as possible
analogs for the elucidation of the stereochemical assignment about
C38. This strategy highlights the employed valinol based Crimmins
auxiliary, used in the setting of the C40 stereocenter, via an opti-
mized LDA/NMP aldol reaction with a 20:1 selectivity. This highly
selective aldol, in comparison to the literature on like systems, pre-
sents a new method on accessing these type of b-hydroxyl-car-
bonyl. Elaboration of this material onto the allylic alcohol
successively allowed for the proof-of-concept in our route; cyclo-
propanation with subsequent ring opening. Through this devel-
oped route, the proposed polyketide is currently being assembled
and will be used for the first total synthesis of lagunamide C.
Through these efforts, key mode of action studies will be explored
to elucidate the means at which this family elicits their cytotoxic
properties.
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ABSTRACT: Reniochalistatin E (1) is one of the !ve related
cyclic peptides isolated from the marine sponge Reniochalina
stalagmitis. The discovery of these compounds resulted from a
screening program directed toward the identi!cation of proline-
rich bioactive compounds. Reniochalistatin E is the only
member of the family to possess a tryptophan amino acid
residue. Given the cytotoxicity observed for 1, e"orts were
directed toward developing a synthetic route to 1. The !rst total
synthesis of 1 has been accomplished in a 15-step route in an
overall 5.0% yield. The synthetic sample of reniochalistatin E
was shown to have similar activity toward HeLa and RPMI-
8226 cell lines compared to the natural sample, with IC50 values
of 16.9 vs 17.3 !M and 4.5 vs 4.9 !M, respectively.
Interestingly, both of the fully deprotected octapeptides
constructed toward the synthesis of reniochalistatin E were shown to have cytotoxicity. The route provides a means to probe
the structure!activity relationship of 1 and further biological investigations.
The reniochalistatin family of cyclic peptides was isolatedfrom the marine sponge Reniochalina stalagmitis near
Yongxing Island in the South China Sea in 2014 by Lin and co-
workers.1 The family was discovered as part of a screening
program designed to !nd new bioactive cyclic peptides from
marine sponges in the South China Sea.2!5 Cyclic peptides that
are proline-rich have been shown to have a variety and wide
scope of biological activity, such as antiviral, antitumor,
antimicrobial, and general cytotoxic properties.6!8 The members
of the reniochalstatin family were found to be proline-rich and
composed of apolar and aromatic amino acid residues. Leucine
and isoleucine are present in all !ve members, along with
multiple proline units (two within reniochalistatins A, B, and C
and three within D and E). The aromatic amino acid residue
varies among the members of the family; B, C, and D contain
phenylalanine, whereas E is the only one with a tryptophan
residue.8 Reniochalistatins A through D are cyclic heptaptides,
whereas E is the only cyclic octapeptide that was isolated. Only
reniochalistatin E showed biological activity, with cytotoxicity
toward myeloma (RPMI-8226, IC50 of 4.9 !M) and gastric
(MGC-803, IC50 of 9.7 !M) cancer cell lines. It was the activity
toward myeloma that drew the attention of our laboratory and
resulted in a total synthesis campaign to be undertaken.
We envisioned that 1 could be synthesized via successive
amino acid couplings in tandem with selective deprotection
steps. The cyclic compound could be obtained from the coupling
and macrocyclization of the two desired tetrapeptides (2 and 3).
Each of these tetrapeptides could be constructed from their
corresponding commercially available L-amino acids, with
selective protection about either the free carboxylic acid or
amine (Scheme 1).
According to the retrosynthetic plan outlined in Scheme 1,
e"orts were directed toward the construction of tetrapeptide 2
(Scheme 2). Starting from the Boc-protected L-isoleucine (4) an
amidation was performed though a benzotriazole-L-yl-oxy-tris-
pyrrolidino-phosphonium hexa#uorophosphate (PyBOP)-medi-
ated coupling with the methyl ester of L-proline (5), a"ording the
dipeptide 6 in 92% yield. Analogously, Boc-L-leucine (7) was
coupled to the methyl ester of L-tryptophan (8) under the same
conditions to access dipeptide 9 in 97% yield. Saponi!cation of
dipeptide 6 furnished the free acid 10, and Boc deprotection of 9
accessed the amine hydrochloride salt 11. Both reactions
provided quantitative yields. The coupling of these two
dipeptides was accomplished with PyBOP under standard
conditions to give tetrapeptide 2 in 55% yield. Employing 1-
ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride
(EDC·HCl) with HOBt as the coupling conditions, yields were
optimized at 86%.
With tetrapeptide 2 in hand, e"orts were directed toward the
construction of tetrapeptide 3 (Scheme 3), which will allow for
access to 1. The coupling of Boc-L-proline (12) to the methyl
ester of L-leucine (13) was performed with PyBOP to furnish the
dipeptide 14 in 97% yield. Saponi!cation of 14 gave access to the
free acid dipeptide 15 in quantitative yields. The second half of
the tetrapeptide was accessed from the Boc deprotection of
dipeptide 6 in quantitative yield. The coupling of 15 to 16 under
the previously employed PyBOP conditions a"orded the desired
tetrapeptide 3, but unfortunately as an impure mixture based
upon the 1H NMR spectrum obtained. All attempts at
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puri!cation (workup procedures, chromatographic eluents, and
silica) of this material continued to provide the same
contaminant peaks within the acquired 1H NMR spectrum.
When this material was carried forward, either through
saponi!cation or Boc deprotection, none of the desired material
was collected. Pure tetrapeptide 3 was successfully accessed
through the use of EDC·HCl and HOBt in 78% yield.
Scheme 1. Retrosynthetic Approach to Reniochalistatin E
Scheme 2. Assembly of Tetrapeptide 2 with Successive PyBOP Coupling and Deprotection Steps
Scheme 3. Construction of Tetrapeptide 3 through Successive Amide Forming Coupling Reactions along with Deprotection Steps
Scheme 4. Tetrapeptide Couplings and Cyclization Strategies Accessing Reniochalistatin E (1)
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Having accessed both of the desired tetrapeptides 2 and 3, the
coupling and macrocyclization were performed. The initial
approach to the linear octapeptide of 1 was through the
saponi!cation of 2 and the Boc deprotection of 3. Coupling of
the free acid of 2 to the free base of 3 with EDC·HCl furnished
octapeptide 17 in 34% yield over three steps (Scheme 4).
Compound 17 was subjected to saponi!cation followed by Boc
deprotection to a"ord its fully deprotected form 17a in 97%
yield. The attempted macrocyclization of this material under
PyBOP conditions failed to provide any of the desired product,
but rather resulted in the return of starting material (55%) and
decomposition. It is hypothesized that the bulk of both the
secondary amine within the proline residue and the BOP-
activated ester of the tryptophan residue could provide su$cient
steric congestion, thereby preventing cyclization from occurring.
To reduce the steric hindrance about these centers, aminolysis
was then attempted for ring closure. For this, the Boc group on
17 was removed to a"ord 17b, with the methyl ester intact.
Unfortunately, all attempts at cyclization in this fashion failed to
provide 1 and resulted in the return of starting material (67%)
and decomposition. Recognizing the di$culty in macrocycliza-
tion of these two sterically encumbered proline and tryptophan
residues of 17a, it was envisioned that coupling of these two
centers to access the linear octapeptide would be more attainable
followed then by macrocyclization. As such, 2 was saponi!ed to
its free acid and Boc deprotection of 3 a"orded the free amine,
both accomplished in quantitative yields. The EDC·HCl
coupling of these two units furnished the linear octapeptide 18
in 61% yield over three steps. Compound 18 was transformed
into its free acid and free amine counterpart in 95% yield and
then subjected to EDC·HCl coupling conditions to a"ord the
desired natural product 1 in 9% yield. The 1H and 13C NMR
spectra as well as theMS data of the synthesized 1match with the
literature data (see the Supporting Information). Con!rmation
of the trans prolines within 1 was con!rmed based on the
comparison of the reported !"C#!C$ values of proline residues
(4.9, 4.2, and 4.1 ppm for Pro,1 Pro,2 and Pro,3 respectively). The
successful macrocyclization of the free acid/amine of 18 with
EDC·HCl on the !rst attempt led us to attempt the same
conditions for cyclization upon the unsuccessful closure of the
free acid/amine of 17. To our surprise, treating 17a with EDC·
HCl a"orded reniochalistatin E in 6% yield. All spectroscopic
(NMR and IR) and MS data matched both the literature and the
previously synthesized material.
Screening various coupling reagents and conditions was then
performed to increase the yield of 1 (Table 1). Entries 1 and 9
highlight the coupling a"ording 1 outlined in Scheme 4 from 17a
and 18a, respectively. The attempted PyBOP-mediated coupling
of 18a (entry 8) provided only recovered starting material (78%)
and decomposition. Employing HOBt, a commonly used
additive in peptide couplings, with EDC·HCl to cyclize 17a
and 18a (entries 2 and 10) resulted in low yields of 1 of 2% and
6%, respectively. Entry 10 re#ects the highest yield of 1 in our
synthetic approach via 18a. Next, macrocyclization was
attempted employing 3-(diethoxyphosphoroyloxyl)-1,2,3-ben-
zotriazine-4(3H)-one (DEPBT), a reagent that has been
successful in the cyclization of similar amino acid based
macrocycles.9 Unfortunately, all attempts at cyclization with
this reagent of 17a and 18a (entries 3 and 11) as well as using
cesium chloride as an additive to promote carbonyl coordination
(entries 4 and 12) failed to provide 1 in any increased yield.
Uronium-based coupling reagents are well reported for their
success in macrocyclizations, and as such, N,N,N!,N!-tetrameth-
yl-O-(1H-benzotriazol-1-yl)uronium hexa#uorophosphate
(HBTU)10!13 and N,N,N!,N!-tetramethyl-O-(1H-benzotriazol-
1-yl)uronium tetra#uoroborate (TBTU)13!16 were both at-
tempted with 17a and 18a in the absence and presence of 4-
(dimethylamino)pyridine (DMAP).17,18 In all attempted cycliza-
tions, these uronium-based reagents provided either none or low
yields of 1. Employing HBTU with DMAP to cyclize 18a
provided a 13% yield of 1 (entry 14), but in our hands, EDC·HCl
with HOBt gave the best, albeit low, 15% yield of the natural
product.
With reniochalistatin E and numerous di-, tetra-, and
octapeptides in both fully protected and deprotected states in
hand, all compounds were screened for general cytotoxicity
against six human cancer cell lines (A549, lung; HeLa, cervical;
MiaPaca, pancreatic; U937, lymphoma, RPMI-8226, myeloma;
andMM.1R, multiple myeloma). None of the di- or tetrapeptides
in protected and partial deprotected states were found to have
IC50 values lower than 30 !M against these cell lines. Our
synthetic sample of reniochalistatin E possessed approximately
the same IC50 value toward the HeLa and RPMI-8226 cell lines:
IC50 of 16.9 !M (±1.9) relative to the reported 17.3 !M in HeLa
and an IC50 of 4.5 (±2.2) relative to the reported 4.9 !M in
RPMI-8226 (Table 1). Reniochalistatin E lacked cytotoxicity
against all of the tested cell lines (cytotoxicity = IC50 < 10 !M).
Both 17 and 18, diprotected octapeptides, were shown to have
no cytotoxicity. Interestingly, the free acid/amine 17awas shown
to have borderline cytotoxicity toward the U937 cell line with an
IC50 of 9.5 ± 2.1 !M. In comparison to the free acid/amine 18a,
no cytotoxicity was observed. No further investigational studies
at this time have been performed that could draw conclusions
regarding structure!activity relationships based upon the results
obtained.
In conclusion, we have accomplished the !rst total synthesis of
reniochalistatin E in 15 steps with an overall 5.0% yield from
commercially available materials. Cytotoxicity studies with
reniochalistatin E and all intermediates accessed within the
route revealed a general lack of cytotoxicity. However, the
synthetic and isolated reniochalistatin E are shown to possess
nearly the same activity toward the HeLa cervical cancer cell line,
further supporting the total synthesis outlined herein. In
addition, an interesting and unexpected cytotoxicity was
observed for the free acid/amine of 17a (linear octapeptide
precursors to the natural product) toward the U937 cell line.
With a route established to this cyclic octapeptide, e"orts are
Table 1. Screening of Coupling Conditions of Fully
Deprotected 17a and 18a
entry cmpd coupling agent additive result
1 17a EDC·HCl N/A 6%




6 HBTU DMAP 4%
7 TBTU DMAP trace
8 18a PyBOP N/A trace
9 EDC·HCl N/A 9%
10 EDC·HCl HOBt 15%
11 DEBPT N/A
12 DEBPT CsCl 5%
13 HBTU N/A
14 HBTU DMAP 13%
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currently being pursued toward probing the e"ects of single
amino acid variations as well as the transposition of phenyl-
alanine for tryptophan. The resulting analogues of 1 will be
evaluated for cytotoxicity.
! EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured on an Atago Polax-2L polarimeter with a sodium lamp. IR
spectra were recorded on a Cary 630 FT-IR spectrometer as thin !lms.
Only the strongest and/or structurally important absorptions of IR
spectra were reported in wavenumbers (cm!1). 1H (400, 500 MHz) and
13C (100, 151 MHz) spectra were obtained on Varian and Bruker-
Ascend spectrometers. The chemical shifts are given in parts per million
(ppm) relative to residual CHCl3 at " 7.26 ppm for proton spectra and
relative to CDCl3 at " 77.23 ppm for carbon spectra, unless otherwise
noted. High-resolution mass spectra were obtained using an LCT
Premier time-of-#ight mass spectrometer. Flash column chromatog-
raphy was performed with silica gel grade 60 (230!400 mesh).
Dichloromethane (CH2Cl2), tetrahydrofuran (THF), toluene (PhMe),
N,N-dimethylformamide (DMF), CH3CN, triethylamine (Et3N), and
MeOH were all degassed with argon and passed through a solvent
puri!cation system containing alumina or molecular sieves. All
commercially available reagents were used as received.
N-Boc-L-Ile-L-Pro-OMe (6). To a stirring solution of N-Boc-L-
isoleucine (4; 1.0 g, 4.16 mmol, 1.0 equiv) in CH2Cl2 (42 mL) were
added PyBOP (2.27 g, 4.37 mmol, 1.05 equiv) and iPr2EtN (1.09 mL,
6.24 mmol, 1.5 equiv). To a separate round-bottom #ask (RBF) were
added L-proline methyl ester (5; 1.03 g, 6.24 mmol, 1.5 equiv), iPr2EtN
(2.17 mL, 12.48 mmol, 3.0 equiv), and CH2Cl2 (6.3 mL). Both reaction
mixtures were left to stir for 1 h, at which time they were combined and
left to stir overnight at room temperature (rt). The reaction was
quenched with 1 M HCl (1 vol equiv), and the product was extracted
with CH2Cl2 (!2), washed with NaHCO3(satd), dried over sodium
sulfate, and concentrated under reduced pressure. The crude material
was puri!ed via #ash silica gel chromatography (1:2 EtOAc/hexane) to
a"ord 6 (1.30 g, 92% yield): [%]D
25 +40.3 (c 1.23, CHCl3); IR (!lm) &max
3436, 2973, 1746, 1642, 1436, 1217 cm!1; 1HNMR (CDCl3, 400 MHz)
" 5.11 (d, J = 9.5 Hz, 1H), 4.52!4.44 (m, 1H), 4.24 (dd, J = 9.5, 7.2 Hz,
1H), 3.80!3.73 (m, 1H), 3.66 (s, 3H), 3.65!3.58 (m, 1H), 2.22!2.12
(m, 1H), 2.01!1.90 (m, 3H), 1.71 (ddq, J = 10.3, 6.5, 3.5 Hz, 1H), 1.53
(td, J = 7.2, 6.6, 3.2 Hz, 1H), 1.37 (s, 9H), 1.07 (ddd, J = 13.4, 6.7, 2.3 Hz,
1H), 0.96 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR
(CDCl3, 101 MHz) " 172.64, 171.65, 156.01, 79.70, 59.04, 56.46, 52.35,
47.42, 38.13, 29.29, 28.56, 25.17, 24.38, 15.47, 11.46; HRESIMS m/z
343.2193 [M + H]+ (calcd for C17H30N2O5, 343.2188).
N-Boc-L-Leu-L-Trp-OMe (9).To a stirring solution of compoundN-
Boc-L-leucine (7; 1.0 g, 4.32 mmol, 1.0 equiv) in CH2Cl2 (43 mL) were
added PyBOP (2.36 g, 4.54 mmol, 1.05 equiv) and iPr2EtN (1.13 mL,
6.48 mmol, 1.5 equiv). To a separate RBF were added L-tryptophan
methyl ester (8; 1.65 g, 6.48 mmol, 1.5 equiv), iPr2EtN (2.26 mL, 12.96
mmol, 3.0 equiv), and CH2Cl2 (6.5 mL). Both reaction mixtures were
left to stir for 1 h, at which time they were combined and left to stir
overnight at rt. The reaction was quenched with 1 M HCl (1 vol equiv),
and the product was extracted with CH2Cl2 (!2), washed with
NaHCO3(satd), dried over sodium sulfate, and concentrated under
reduced pressure. The crude material was puri!ed via #ash silica gel
chromatography (1:1 EtOAc/hexane) to a"ord 9 (1.81 g, 97% yield):
[%]D
25 +27 (c 0.15, CHCl3); IR (!lm) &max 3418, 3018, 2872, 1739, 1513,
1215 cm!1; 1HNMR (400MHz, DMSO-d6) " 10.85 (s, 1H), 8.06 (d, J =
7.4 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.13 (d, J
= 2.4 Hz, 1H), 7.07!7.02 (m, 1H), 6.96 (td, J = 7.5, 6.9, 1.1 Hz, 1H),
6.82 (d, J = 8.5 Hz, 1H), 4.51 (q, J = 7.1 Hz, 1H), 3.98 (td, J = 8.7, 6.0 Hz,
1H), 3.55 (s, 3H), 3.13!3.05 (m, 2H), 1.53 (dd, J = 13.6, 6.9 Hz, 2H),
1.35 (s, 9H), 1.26 (s, 1H), 0.84 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.5 Hz,
3H); 13C NMR (101 MHz, CDCl3) " 172.99, 172.44, 155.95, 136.45,
127.76, 123.62, 122.15, 119.58, 118.63, 111.71, 109.49, 80.22, 53.46,
53.29, 52.54, 41.55, 28.52, 27.81, 24.92, 23.18, 22.04; HRESIMS m/z
454.2308 [M + Na]+ (calcd for C23H33N3O5Na
+, 454.2312).
N-Boc-L-Ile-L-Pro-OH (10).To a stirring solution of 6 (556 mg, 1.62
mmol, 1.0 equiv) in 1:1 THF/H2O (16 mL) was added LiOH (194 mg,
8.12 mmol, 5.0 equiv). The mixture was left to stir at rt for 5 h. The
reaction was quenched with 1MHCl (1 vol equiv), and the product was
extracted with CH2Cl2, washed with NaHCO3(satd), dried over sodium
sulfate, and concentrated under reduced pressure. The product 10 was
obtained in quantitative yield as an oily residue, which was used without
further puri!cation. IR (!lm) &max 3456, 3304, 2977, 1704, 1314 cm
!1;
1H NMR (400 MHz, CDCl3) " 8.31 (s, 1H), 5.35 (d, J = 9.5 Hz, 1H),
4.57 (t, J = 6.4 Hz, 1H), 4.32!4.25 (m, 1H), 3.82 (dt, J = 9.6, 7.2 Hz,
1H), 3.64 (ddd, J = 9.7, 7.5, 5.4 Hz, 1H), 2.18 (dd, J = 10.0, 3.9 Hz, 2H),
2.07!1.99 (m, 2H), 1.76 (td, J = 7.0, 3.4 Hz, 1H), 1.64!1.48 (m, 2H),
1.41 (d, J = 7.7 Hz, 9H), 0.95 (d, J = 6.7 Hz, 3H), 0.87 (t, J = 7.2 Hz, 3H).
N-Boc-L-Leu-L-Trp-OH (11). To a RBF was added 1 M HCl in
dioxane (4.6 mL), which cooled to 0 °C, at which point 9 (500 mg, 1.16
mmol) was added. The reaction was allowed to stir for 1.5 h. The solvent
was removed under reduced pressure to a"ord a crude white solid (11),
which was used without further puri!cation. IR (!lm) &max 3416, 2879,
1651, 1176 cm!1; 1H NMR (400MHz, DMSO-d6) " 9.04 (d, J = 7.2 Hz,
1H), 8.25 (s, 3H), 7.49 (d, J = 7.8 Hz, 1H), 7.35 (dt, J = 8.1, 1.0 Hz, 1H),
7.24 (d, J = 2.3 Hz, 1H), 7.07 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.00 (ddd, J
= 8.0, 7.0, 1.1 Hz, 1H), 4.63!4.54 (m, 1H), 3.81 (t, J = 7.2 Hz, 1H), 3.58
(s, 3H), 3.21!3.13 (m, 2H), 1.68 (dt, J = 13.3, 6.6 Hz, 2H), 1.57 (s, 2H),
0.90 (dd, J = 7.9, 6.4 Hz, 6H).
N-Boc-L-Ile-L-Pro-L-Leu-L-Trp-OMe (2). Compound 10 (1.32 g,
4.02 mmol, 1 equiv), compound 11 (1.08 g, 2.94 mmol, 1 equiv), and
HOBt (473 mg, 3.09 mmol, 1.05 equiv) were dissolved in dry THF (40
mL) at rt under an argon atmosphere. The solution was cooled to 0 °C
and stirred for 20 min, after which Et3N (1.43 mL, 10.29 mmol, 3.5
equiv) was then added and stirred. Lastly, 20 min later EDC·HCl (592
mg, 3.09 mmol, 1.05 equiv) was added, and the reaction mixture was left
to stir overnight. The reaction was quenched with H2O (1 vol equiv),
and the product was extracted with CH2Cl2, dried over sodium sulfate,
and concentrated under reduced pressure. The crude material was
puri!ed via #ash silica gel chromatography (3:1 EtOAc/hexane) to give
a"ord 2 (2.22 g, 86% yield) as a clear liquid: [%]D
25 +48.1 (c 1.75, CHCl3);
IR (!lm) &max 3305, 3017, 2876, 1741, 1631, 1506, 1392, 1215 cm
!1; 1H
NMR (CDCl3, 400 MHz) " 8.29 (s, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.33
(d, J = 8.0 Hz, 1H), 7.16 (td, J = 8.2, 7.6, 1.3 Hz, 1H), 7.13!7.05 (m,
1H), 7.03 (d, J = 2.4 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.70 (d, J = 7.9
Hz, 1H), 5.20 (d, J = 9.4 Hz, 1H), 4.90 (dt, J = 7.9, 5.5 Hz, 1H), 4.37 (d, J
= 6.0 Hz, 1H), 4.27 (dd, J = 9.3, 7.0 Hz, 1H), 3.71 (d, J = 8.9 Hz, 1H),
3.66 (s, 3H), 3.60!3.51 (m, 1H), 3.30 (d, J = 5.5 Hz, 2H), 2.12!1.87
(m, 3H), 1.73!1.56 (m, 5H), 1.43 (s, 9H), 1.13!1.05 (m, 1H), 0.92 (d,
J = 6.8 Hz, 3H), 0.90!0.80 (m, 11H); 13C NMR (CDCl3, 101 MHz) "
172.86, 172.49, 172.08, 171.74, 156.08, 136.32, 127.75, 123.57, 122.11,
Table 2. Evaluation of Reniochalistatin E and Linear Octapeptides for Cytotoxicity
observed IC50 (!M)
a
cmpd A549 HeLa MiaPaca U937 RPMI-8226 MM.1R
1 >20 16.9 ± 1.9 >20 !M 12.4 ± 2.4 4.5 ± 1.8 >11.2 ± 1.0
17 >20 >20 19.1 ± 1.3 >20 >20 >20
17a >20 >20 >20 9.5 ± 2.1 >20 >20
18 >20 >20 >20 >20 >20 >20
18a >20 18.4 ± 1.7 >20 >20 16.4 ± 3.5 >20
aCytotoxicity evaluated in 384-well plates, 1500 (2000 U937) cells/well, 72 h incubation period, and evaluated via Alamar Blue.
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119.61, 118.60, 111.55, 109.58, 79.89, 60.26, 56.61, 52.95, 52.56, 52.15,
47.99, 41.15, 37.95, 28.60, 25.58, 27.76, 25.31, 24.79, 24.42, 23.10, 23.05,
22.06, 15.65, 11.31; HRESIMS m/z 642.3817 [M + H]+ (calcd for
C34H52N5O7, 642.3822).
N-Boc-L-Pro-L-Val-OMe (14).Compounds 12 (3.0 g, 13.94mmol, 1
equiv) and 13 (2.34 g, 13.94 mmol, 1 equiv) were added to a stirring
solution of HOBt (2.24 g, 14.63 mmol, 1.05 equiv) in dry THF (139
mL) at rt under an argon atmosphere. The solution was then cooled to 0
°C and stirred for 20 min, after which Et3N (6.8 mL, 48.79 mmol, 3.5
equiv) was added. After an additional 20min of stirring EDC·HCl (2.8 g,
14.63 mmol, 1.05 equiv) was added, and the reaction mixture was left to
stir overnight. The reaction was quenched with H2O (1 vol equiv), and
the product was extracted with CH2Cl2, dried over sodium sulfate, and
concentrated under reduced pressure. The crude material was puri!ed
via #ash silica gel chromatography (1:1 EtOAc/hexane) to give 14 (4.45
g, 97% yield) as a clear liquid: [%]D
25 = +80.8 (c 2.05, CHCl3); IR (!lm)
&max 3680, 3323, 3415, 2973, 2879, 1740, 1681, 1216 cm
!1; 1H NMR
(CDCl3, 400MHz) " 4.50 (dd, J = 8.6, 5.1 Hz, 1H), 4.32 (s, 1H), 3.72 (s,
3H), 3.42 (s, 2H), 2.29 (s, 1H), 2.15 (pd, J = 6.9, 5.1 Hz, 2H), 1.95!1.84
(m, 3H), 1.48 (s, 9H), 0.92 (dd, J = 8.3, 6.8 Hz, 6H); 13CNMR (DMSO-
d6, 101 MHz) " 172.71, 78.98, 59.71, 58.16, 52.30, 47.18, 31.67, 30.41,
28.80, 28.68, 23.61, 19.77, 18.99, 14.76; HRESIMS m/z 329.2025 [M +
H]+ (calcd for C16H29N2O5, 329.2032).
N-Boc-L-Pro-L-Val-OH (15). To a stirring solution of 14 (360 mg,
1.1 mmol, 1 equiv) in 1:1 THF/H2O (4.4 mL) was added LiOH (131
mg, 5.5 mmol, 5 equiv), and the mixture was left to stir at rt for 3 h. The
reaction was quenched with 1MHCl (1 vol equiv), and the product was
extracted with CH2Cl2, washed with NaHCO3(satd), dried over sodium
sulfate, and concentrated under reduced pressure. Crude 15 was
obtained in quantitative yield as an oily residue and was used without
further puri!cation: IR (!lm) &max 3410 (b), 1676 cm
!1; 1H NMR
(CDCl3, 400 MHz) " 10.37 (s, 1H), 7.51 (s, 1H), 4.50 (s, 1H), 4.40!
4.19 (m, 1H), 3.50!3.28 (m, 2H), 2.31!2.09 (m, 3H), 1.94!1.79 (m,
2H), 1.43 (s, 9H), 0.91 (dd, J = 9.9, 6.9 Hz, 6H).
H2N-L-Leu-L-Trp-OMe (16). To a RBF containing 6 (857 mg, 2.5
mmol) was added 1.0 M HCl in dioxane (10 mL), and the mixture was
cooled to 0 °C. The reaction mixture was allowed to stir at the same
temperature for 3 h. The solvent was removed under reduced pressure
to a"ord crude 16 in quantitative yield as a white solid, which was used
without further puri!cation. IR (!lm) &max 3416, 2879, 1651, 1454 cm
!1;
1HNMR (CDCl3, 400MHz) " 8.34!8.27 (m, 3H), 4.61 (dd, J = 8.5, 5.3
Hz, 1H), 4.25 (s, 1H), 3.97 (s, 1H), 3.68 (s, 3H), 3.52 (d, J = 9.0 Hz,
1H), 2.28 (s, 1H), 2.05!1.91 (m, 4H), 1.68 (ddd, J = 13.5, 7.5, 3.3 Hz,
1H), 1.35 (ddd, J = 13.3, 10.0, 7.1 Hz, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.94
(t, J = 7.3 Hz, 3H); HSESIMS m/z 243.1658 [M + H]+ (calcd for
C12H23N2O3, 243.1664).
N-Boc-L-Pro-L-Val-L-Ile-L-Pro-OMe (3). Compounds 16 (1.71 g,
7.06mmol, 1 equiv) and 15 (2.24 g, 7.13mmol, 1 equiv) were added to a
stirring solution of HOBt (1.13 g, 7.41 mmol, 1.05 equiv) and dry THF
(71 mL) at rt under an argon atmosphere. The solution was cooled to 0
°C and stirred for 20 min, after which Et3N (3.46 mL, 24.71 mmol, 3.5
equiv) was added. After an additional 20 min of stirring, EDC·HCl (1.42
g, 7.41 mmol, 1.05 equiv) was added, and the mixture was stirred
overnight. The reaction was quenched with H2O (1 vol equiv), and the
product was extracted with CH2Cl2, dried over sodium sulfate, and
concentrated under reduced pressure. The crude material was puri!ed
via #ash silica gel chromatography (7:1 EtOAc/hexane) to give 3 (1.52
g, 78% yield) as a clear liquid: [%]D
25 +72.3 (c 3.21, CHCl3); IR (!lm) &max
3673, 3412, 3306, 2879, 1743, 1632, 1368 cm!1; 1H NMR (CDCl3, 400
MHz) " 7.48 (s, 1H), 6.65 (s, 1H), 6.42 (s, 1H), 4.58 (t, J = 8.2 Hz, 1H),
4.47 (dd, J = 8.6, 4.9 Hz, 1H), 4.31 (s, 1H), 4.26 (dd, J = 8.6, 5.6 Hz, 1H),
3.81 (dt, J = 9.8, 6.3 Hz, 1H), 3.68 (s, 3H), 3.64!3.59 (m, 1H), 3.46!
3.28 (m, 2H), 2.33 (s, 1H), 2.19 (ddq, J = 12.9, 6.8, 3.7 Hz, 2H), 2.02!
1.79 (m, 8H), 1.43 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.89!0.80 (m, 9H);
13C NMR (CDCl3, 101 MHz) " 172.63, 172.40, 171.29, 171.25, 170.63,
80.70, 61.37, 59.96, 59.00, 58.70, 55.04, 52.35, 47.51, 47.25, 37.65, 31.41,
30.58, 29.29, 28.55, 25.17, 24.52, 19.50, 17.45, 15.41, 11.30; HSESIMS
m/z 561.3198 [M + H]+ (calcd for C27H46N4O7Na, 561.3264).
H2N-L-Ile-L-Pro-L-Leu-L-Trp-OMe (Free Amine of Tetrapeptide
2). To a RBF containing 2 (1.03 g, 1.6 mmol) was added 1.0 M HCl in
dioxane (6.4 mL), and the solution was cooled to 0 °C. The reaction
mixture was allowed to stir at the same temperature for 3 h. The solvent
was removed under reduced pressure to a"ord a crude white solid (free
base of 2), which was used without further puri!cation. IR (!lm) &max
3323, 3018, 2879, 1633, 1449, 1216 cm!1; 1HNMR (CDCl3, 400MHz)
" 8.17 (d, J = 44.9 Hz, 2H), 7.51 (d, J = 7.7 Hz, 1H), 7.32 (d, J = 8.0 Hz,
1H), 7.14 (t, J = 7.5 Hz, 1H), 7.10!7.05 (m, 2H), 6.83 (d, J = 8.3 Hz,
1H), 4.96 (d, J = 7.8 Hz, 1H), 4.83!4.63 (m, 4H), 4.42 (q, J = 7.8 Hz,
2H), 3.91 (d, J = 8.3Hz, 1H), 3.79!3.70 (m, 2H), 3.65 (s, 5H), 3.30 (d, J
= 6.0 Hz, 2H), 2.96 (ddt, J = 22.3, 10.3, 6.4 Hz, 2H), 1.95!1.81 (m, 7H),
1.29!1.22 (m, 3H), 0.89!0.76 (m, 22H).
N-Boc-L-Pro-L-Val-L-Ile-L-Pro-OH (Free Acid of Tetrapeptide
3).To a stirring solution of 3 (200 mg, 0.37 mmol, 1 equiv) in 1:1 THF/
H2O (1.5 mL) was added LiOH (45 mg, 1.86 mmol, 5 equiv), and the
solution was left to stir at rt for 3 h. The reaction was quenched with 1M
HCl (1 vol equiv), and the product was extracted with CH2Cl2, washed
with NaHCO3(satd), dried over sodium sulfate, and concentrated under
reduced pressure. The crude material (free acid of 3), obtained in
quantitative yield as an oily residue, was used without further
puri!cation. IR (!lm) &max 3311, 3016, 2965, 1632, 1215 cm
!1; 1H
NMR (CDCl3, 400 MHz) " 7.50 (s, 0H), 4.63 (t, J = 8.9 Hz, 0H), 4.41
(d, J = 65.5 Hz, 4H), 3.88 (d, J = 10.7Hz, 1H), 3.67 (s, 2H), 3.43 (s, 2H),
2.16 (s, 7H), 1.96!1.74 (m, 5H), 1.46 (s, 9H), 1.21!0.74 (m, 12H).
Octapeptide N-Boc-L-Pro-L-Val-L-Ile-L-Pro-L-Ile-L-Pro-L-Leu-L-
Trp-OMe (17). Free base of 2 (915 mg, 1.69 mmol, 1 equiv), free
acid of 3 (784.5 mg, 1.5 mmol, 1 equiv), andHOBt (240mg, 1.56 mmol,
1.05 equiv) were dissolved in dry THF (17 mL) at rt, under an argon
atmosphere. The solution was then cooled to 0 °C and stirred for 20
min, after which Et3N (0.731 mL, 5.25 mmol, 3.5 equiv) was added.
After an additional 20 min of stirring, EDC·HCl (299 mg, 1.56 mmol,
1.05 equiv) was added, and the mixture was left to stir overnight. The
reaction was quenched with H2O (1 vol equiv), and the product was
extracted with CH2Cl2, dried over sodium sulfate, and concentrated
under reduced pressure. The crude material was puri!ed via #ash silica
gel chromatography (1:9 EtOAc/MeOH) to a"ord 17 (605 mg, 34%
yield) as an amber liquid: [%]D
25!26 (c 0.21, MeOH); 1HNMR (CDCl3,
400MHz) " 7.50 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.13 (t, J =
7.2Hz, 1H), 7.10!7.03 (m, 2H), 6.82 (s, 1H), 4.97 (s, 1H), 4.65 (s, 2H),
4.42 (s, 2H), 4.25 (s, 1H), 3.88 (d, J = 9.4 Hz, 1H), 3.69 (s, 2H), 3.66 (s,
3H), 3.30 (d, J = 4.9 Hz, 2H), 2.07 (d, J = 145.9 Hz, 24H), 1.44 (s, 4H),
1.31!1.21 (m, 1H), 0.90!0.75 (m, 25H); 13C NMR (CDCl3, 101
MHz) " 17.38, 172.39, 151.82, 142.80, 140.68, 136.40, 127.78, 122.15,
119.63, 118.69, 111.44, 52.59, 48.15, 28.55, 24.87, 24.87, 23.06, 23.06,
19.62, 19.62, 15.33, 11.24; HRESIMS m/z 1070.6253 [M + H]+ (calcd
for C55H85N9O11Na, 1070.6267).
H2N-L-Pro-L-Val-L-Ile-L-Pro-OMe (Free Amine of Tetrapeptide
3). To an RBF containing 3 (151 mg, 0.28 mmol) was added 1.0 MHCl
in dioxane (1.1 mL), and the solution was cooled to 0 °C. The reaction
was allowed to stir at the same temperature for 3 h. The solvent was
removed under reduced pressure, forming a crude white solid (free base
3), which was used without further puri!cation. IR (!lm) &max 3323,
2878, 1742, 1633, 1216 cm!1; 1H NMR (CDCl3, 400 MHz) " 10.92 (s,
1H), 8.76 (s, 1H), 8.16 (s, 1H), 7.83 (d, J = 9.0 Hz, 1H), 4.92 (s, 1H),
4.76!4.68 (m, 1H), 4.52!4.35 (m, 2H), 3.87 (s, 2H), 3.69 (d, J = 2.2
Hz, 3H), 3.64 (dd, J = 8.5, 5.1 Hz, 1H), 3.44 (s, 3H), 2.63 (s, 1H), 2.46!
2.17 (m, 5H), 2.00 (dd, J = 18.0, 6.0 Hz, 10H), 1.52!1.39 (m, 2H),
1.01!0.79 (m, 13H).
N-Boc-L-Ile-L-Pro-L-Leu-L-Trp-OH (Free Acid of Tetrapeptide
2). To a stirring solution of 14 (100 mg, 0.16 mmol, 1 equiv) in 1:1
THF/H2O (640 mL) was added LiOH (19 mg, 0.78 mmol, 5 equiv),
and the solution was left to stir at rt for 3 h. The reaction was quenched
with 1MHCl (1 vol equiv), and the product was extracted with CH2Cl2,
washed with NaHCO3(satd), dried over sodium sulfate, and concentrated
under reduced pressure. Crude 15 was obtained in quantitative yield as
an oily residue, which was used without further puri!cation. IR (!lm)
&max 3311 (bs), 2965, 1632, 1215 cm
!1; 1H NMR (CDCl3, 400 MHz) "
8.42 (s, 1H), 7.57 (d, J = 7.9Hz, 1H), 7.31 (s, 1H), 7.12 (dq, J = 24.7, 9.6,
7.3 Hz, 3H), 5.22 (s, 1H), 4.83 (d, J = 7.5 Hz, 1H), 4.31 (d, J = 41.9 Hz,
2H), 3.73 (s, 2H), 3.54 (s, 1H), 3.30 (s, 2H), 2.08!1.72 (m, 0H), 1.43
(s, 9H), 1.10!0.57 (m, 12H).
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Octapeptide N-Boc-L-Ile-L-Pro-L-Leu-L-Trp-L-Pro-L-Val-L-Ile-L-
Pro-OMe (18). Free acid of 2 (137 mg, 0.31 mmol, 2.1 equiv) and
free base of 3 (92 mg, 0.15 mmol, 1 equiv) were added to a stirring
solution of HOBt (25 mg, 0.16 mmol, 1.05 equiv) in dry THF (3.1 mL)
at rt under an argon atmosphere. The solution was cooled to 0 °C and
stirred for 20 min, after which Et3N (0.07 mL, 0.53mmol, 3.5 equiv) was
added and stirred. After an additional 20 min of stirring, EDC·HCl (31
mg, 0.16 mmol, 1.05 equiv) was added and the reaction mixture was left
to stir overnight. The reaction was quenched with H2O (1 vol equiv),
and the product was extracted with CH2Cl2, dried over sodium sulfate,
and concentrated under reduced pressure. The crude material was
puri!ed via #ash silica gel chromatography (9:1 EtOAc/MeOH) to
a"ord 18 (198 mg, 61% yield) as an amber liquid: [%]D
25 !29 (c 0.78,
MeOH); IR (!lm) &max 3423, 2925, 1741, 1687, 1612, 1452 cm
!1; 1H
NMR (CDCl3, 400MHz) " 8.67 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.62!
7.27 (m, 4H), 7.20!6.85 (m, 6H), 5.21 (d, J = 9.3 Hz, 1H), 5.01 (q, J =
7.2 Hz, 1H), 4.75!4.00 (m, 10H), 3.80 (dt, J = 35.8, 5.2 Hz, 3H), 3.72!
3.66 (m, 3H), 3.58 (s, 3H), 3.18 (d, J = 7.3 Hz, 1H), 2.36!1.85 (m,
16H), 1.42 (d, J = 4.6 Hz, 9H), 1.04!0.83 (m, 24H); 13C NMR (CDCl3,
101 MHz) " 172.76, 171.84, 171.74, 171.58, 170.90, 156.03, 136.30,
124.14, 123.58, 121.96, 119.58, 118.68, 111.55, 109.77, 79.70, 77.52,
77.04, 60.50, 60.27, 59.34, 59.11, 56.57, 55.13, 55.03, 52.31, 52.26, 52.10,
51.68, 48.01, 47.63, 47.55, 41.19, 37.93, 37.59, 37.53, 30.91, 30.26, 29.26,
28.58, 28.56, 28.11, 27.78, 25.36, 25.18, 24.80, 24.59, 24.53, 23.32, 23.01,
21.92, 19.59, 19.04, 18.36, 15.70, 15.60, 15.39, 11.33, 11.27; HSESIMS
m/z 1070.6253 [M + H]+ (calcd for C55H85N9O11Na, 1070.6267).
Reniochalistatin E (1) via 18. To a stirring solution of 18 (470 mg,
0.45 mmol, 1 equiv) in a 1:1 THF/H2O (1.8 mL) was added LiOH (54
mg, 2.24mmol, 5 equiv), and the solution was left to stir at rt for 3 h. The
reaction was quenched with 1MHCl (1 vol equiv), and the product was
extracted with CH2Cl2, dried with brine, dried over sodium sulfate, and
concentrated under reduced pressure to a"ord the free acid of 18, which
was used without further puri!cation. The free acid of 18 (365 mg, 0.72
mmol) was added to an RBF, and the #ask was cooled to 0 °C, to which
was added 1.0 M HCl in dioxane (2.9 mL). The reaction mixture was
stirred for 3 h at rt. The solvent was removed under reduced pressure to
a"ord the crude material 18a, a white/orange solid that was used
without further puri!cation. Compound 18a (115 mg, 0.12 mmol, 1
equiv) was added to a stirring solution of HOBt (18 mg, 0.12 mmol, 1
equiv) in dry THF (12 mL) at rt under an argon atmosphere. The
solution was cooled to 0 °C and stirred for 20 min, after which Et3N
(0.06 mL, 0.42 mmol, 3.5 equiv) was added. After an additional 20 min
of stirring, EDC·HCl (25 mg, 0.13 mmol, 1.05 equiv) was added and the
reaction mixture was left to stir overnight. The reaction was quenched
with H2O (2 vol equiv), and the product was extracted with CH2Cl2,
dried over sodium sulfate, and concentrated under reduced pressure.
The crude material was puri!ed via #ash silica gel chromatography
(85:15 EtOAc/MeOH) to a"ord 1 (39 mg, 9% yield): [%]D
25 !100 (c
0.16, MeOH); IR (!lm) &max 3290, 2960, 2927, 1670, 1615, 1501, 1445
cm!1; 1H NMR (CDCl3, 500 MHz) " 10.96!10.84 (m, 1H), 8.11!7.78
(m, 1H), 7.52 (dd, J = 24.5, 7.9 Hz, 2H), 7.40 (d, J = 8.2 Hz, 1H), 7.32 (t,
J = 8.7 Hz, 1H), 7.02!6.92 (m, 2H), 4.38!4.33 (m, 1H), 3.36 (s, 23H),
3.33!3.22 (m, 1H), 2.48 (s, 1H), 1.99!1.70 (m, 2H), 1.24 (s, 2H),
0.96!0.75 (m, 8H), 0.83 (s, 27H); 13C NMR (DMSO-d6, 126 MHz) "
172.37, 171.88, 171.81, 171.48, 171.31, 170.58, 170.22, 169.58, 136.59,
127.36, 124.18, 121.21, 118.60, 118.38, 111.71, 111.57, 61.20, 60.67,
59.59, 56.74, 55.85, 54.61, 54.39, 54.22, 47.81, 47.55, 47.41, 38.21, 37.49,
35.09, 33.21, 30.01, 23.92, 29.31, 29.28, 25.22, 25.12, 24.95, 24.83, 24.10,
23.77, 22.71, 20.87, 19.21, 18.88, 15.69, 15.10, 11.50, 9.81; HRESIMS
m/z 938.5475 [M + H]+ (calcd for C49H73N9O8Na, 938.5473).
Reniochalistatin E via 17. To a stirring solution of 17 (249 mg,
0.24 mmol, 1 equiv) in 1:1 THF/H2O (1 mL) was added LiOH (29 mg,
1.2 mmol, 5 equiv), and the mixture was left to stir at rt for 3 h. The
reaction was quenched with 1MHCl (1 vol equiv), and the product was
extracted with CH2Cl2, washed with brine, dried over sodium sulfate,
and concentrated under reduced pressure. The crude material (free acid
of 17) was obtained in 68% yield as a white powder, which was used
without further puri!cation. The free acid of 17 (167 mg, 0.16 mmol)
was added to an RBF, and the #ask was cooled to 0 °C, to which 1.0 M
HCl in dioxane (0.64 mL) and 1 mL of dioxane were added. The
reaction mixture was stirred for 3 h at the same temperature, then
allowed to warm to rt overnight. The solvent was removed under
reduced pressure to a"ord the crude material 17a, a white/orange solid
that was used without further puri!cation. Compound 17a (152 mg,
0.16 mmol, 1 equiv) was added to the stirring solution of HOBt (25 mg,
0.16 mmol, 1 equiv) in dry THF (16 mL) at rt under an argon
atmosphere. The solution was cooled to 0 °C and stirred for 20 min,
after which Et3N (0.08 mL, 0.56 mmol, 3.5 equiv) was added. After an
additional 20 min of stirring, EDC·HCl (32 mg, 0.17 mmol, 1.05 equiv)
was added, and the reaction mixture was left to stir overnight. The
reaction was quenched with H2O (1.5 vol equiv), and the product was
extracted with CH2Cl2, washed with brine, dried over sodium sulfate,
and concentrated under reduced pressure. The crude material was
puri!ed via #ash silica gel chromatography with a gradient solvent
system (9:1 EtOAc/MeOH; 7:3 EtOAc/MeOH) to a"ord 1 (8.6 mg,
6% yield). All NMR and MS data matched those of 1 accessed via 18.
Biological Assays. Cell Culture Information. Cells were grown in
media supplemented with fetal bovine serum (FBS) and antibiotics (100
!g/mL penicillin and 100 U/mL streptomycin). Speci!cally, experi-
ments were performed using the following cell lines and media
compositions: HeLa, A549, RPMI-8226, MM.1R, and U-937 (RPMI-
1640 + 10% FBS) and Mia PaCa-2 (DMEM + 10% FBS). Cells were
incubated at 37 °C in a 5% CO2, 95% humidity atmosphere for all
experiments.
IC50 Value Determination for Adherent Cells Using Alamar Blue.
Adherent cells were added to a 384-well plate (1500 cells/well) in 10 !L
of media and were allowed to adhere for 2!3 h. Compounds were
solubilized in DMSO (10 !M stock solutions) and added to a 96-well
plate over a range of concentrations (31.6 nM to 200 !M) with media,
and 40 !L was added to the 384-well plate in triplicate for each
concentration of compound. After 69 h of continuous exposure, 5 !L of
Alamar Blue was added to each well, and the cells were allowed to
incubate for an additional 3 h. The plates were then read for #uorescence
intensity with an excitation of 560 nm and emission of 590 nm on a
BioTek Synergy H1 plate reader. Doxorubin and etoposide were both
used as positive death controls, and wells with no compounds added as
negative death controls. IC50 values were determined from three ormore
independent experiments using GraphPad Prism 7.0. (LaJolla, CA,
USA)
IC50 Value Determination for Nonadherent Cells Using Alamar
Blue.The same procedure for adherent cells was used, with the following
modi!cations. Cells (2000 cell/well) in media (10 !L) were added after
40 !L of compound in media was added to the 384-well plate. No time
was given to allow cells to adhere.
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6-Thiopurine (6TP) is a currently prescribed drug in the treatment of diseases ranging from 
Crohn’s disease to acute lymphocytic leukemia. While its potent mode of action is through 
incorporation into DNA as a thiol mimic of deoxyguanosine, severe toxicities are associated with 
its administration which hinder the potential therapeutic application. We have previously reported 
in vitro that the oxidative metabolites of 6TP, specifically 6-thiouric acid (6TU, Ki 7 M), are 
potent inhibitors of UDP-glucose dehydrogenase (UDPGDH), an enzyme that is responsible for 
the formation of UDP-glucuronic acid (UDPGA), an essential substrate that is used in 
detoxification processes in the liver. An in vivo investigation was undertaken to probe if 6TU 
inhibits UDPGDH in rat hepatocytes, and it was observed that 6TU does greatly suppress the 
conjugation of bilirubin with UDPGA. The failed excretion of bilirubin is linked to a majority of 
the reported toxicities associated with 6TP administration. Efforts were undertaken for the 
construction of 6TP analogs, substituted at the C8 position, to reduce inhibition of UDPGDH while 
retaining therapeutic efficacy. Three new 6TP analogs bearing a halogen (Br, Cl, and F) at the C8 
position have been achieved over five-synthetic steps in overall yields of 16 to 32%. Each of these 
analogs were shown to have reduced inhibition towards UDPGDH, with Ki values of 192, 163, 
215 M, respectively. In addition, the bromine, chlorine, and fluorine analogs were shown to 
possess cytotoxicity towards the REH cell line (acute lymphocytic leukemia) having IC50 values 
of 9.54 M (±0.97), 3.95 M (±1.94), and 4.71 M (±1.40), respectively. These three new 6TP 
analogs represent the first steps in the redesign of this potent anticancer agent into a better drug 
that possesses reduced toxic side effects while retaining therapeutic potency.






































































   6-Thiopurine (6TP, 1) has been a continuously prescribed therapeutic since its FDA approval in 
1952, shortly after its discovery in 1950 by Gertrude Elion and George Hitchings at Burroughs 
Wellcome.1 This potent therapeutic serves as a treatment option for numerous diseases, such as, 
but not limited to: acute lymphocytic leukemia (ALL),2, 3 non-Hodgkin’s leukemia,4, 5 Crohn’s 
disease,6-8 and inflammatory bowel disease.9, 10 6TP has no therapeutic properties itself, however, 
it is metabolized into a therapeutic form, a deoxyguanosine nucleotide mimic, commencing with 
the phosphoribosylation by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) forming 
the nucleotide mimic 6-thioinosinic acid monophosphate (TIMP, 2). HGPRT is an enzyme that 
usually catalyzes phosphoribosylation of hypoxanthine (C6 hydroxyl) to inosinic acid (IMP).11 
Oxidation of the C2 position of 6TP is accomplished by inosine-5’-monophosphate dehydrogenase 
(IMPD), an enzyme that is overexpressed in the presence of 6TP, followed by C2 amine 
installation by guanine monophosphate synthase (GMPS) giving rise to either thioguanosine mono 
phosphate (TGMP or dTGMP, 3).11-13 Multiple kinase transformations then afford dTGTP (4), 
which gets incorporated into DNA in place of dGTP. However, incorporation of dTGTP does not 
immediately result in apoptosis, via base pair mismatching, but requires multiple passages through 
the S-phase allowing for sufficient dTGTP incorporation into DNA.14 It has also been shown that 
6-thioguanine (6TG, 5) can be used in conjunction with 6TP and is acted upon by HGPRT 
accessing the monophosophate nucleotide formed via 6TP metabolism. 
   Checkpoint activation is required for recognition of the mismatched base pairing within DNA 
post 4 incorporation; a process commonly suppressed within cancer cells.15-17 Mutually 6TP and 
6TG can be methylated to form the corresponding thiol ethers by thiopurine methyltransferase 
(TPMT), neither possessing any cytotoxic properties, but do induce checkpoint activation.18 





































































Additionally, TIMP (2) can be transformed into its corresponding methyl thiol ether, but rather 
than activating checkpoints this species has been proven to inhibit de novo purine biosynthesis.19 
This inhibition allows for the cellular uptake of purines to increase, including 6TP, which 
corresponds to a higher probability of dTGTP incorporation into DNA that can then lead to 
apoptosis, via base pair mismatching. 
Fig. 1 Metabolism of 6-Thiopurine: 1) Therapeutic pathway forming dTGTP, a dGTP mimic, 
which incorporates into DNA resulting in apoptosis, and 2) the excretion pathway allowing for the 
removal of 6-thiopurine and its biosynthetic metabolites.
   In parallel to 6TP’s therapeutic metabolism, efficient oxidative pathways remove 6TP from the 
body, thereby decreasing its therapeutic potential. Xanthine oxidase (XO) can directly oxidize the 
C8 position of 6TP forming 8-OH-6TP (6), a species that is not a substrate for HGPRT, thus, 
eliminating any therapeutic potential.20 Moreover, 6 can be further oxidized at the C2 position 
forming 6-thiouric acid (6TU, 7), which is the terminal excretion metabolite. This highly efficient 
oxidation by XO limits the bioavailability of 6TP. In route to dTGTP (4), dTGMP (3) can be 
formed into 6TG, which is rapidly oxidized to 6-thioxanthine (6TX, 8), a species that is further 





































































oxidized by XO to 6TU. Once 6TU is formed, it is well retained by the body beyond 24-hours 
post-6TP administration.20 
   As with nearly all therapeutic drugs, the benefits come with side effects that limit effectiveness 
and general applications. 6TP is not immune to this trend, with multiple toxicities associated with 
its use including, but not limited to: pulmonary lesions, myocarditis, reticulocytopenia, depletion 
of cellularity in bone marrow, intestinal ulcerations, jaundice, hepatotoxicity, and even death.13, 15 
Of these, the most predominate toxic side effects are jaundice and hepatotoxicity, corresponding 
to the reported increase in bilirubin levels within patients taking 6TP. In addition to the toxicities 
listed above, increased bilirubin levels within the body can cause hyperbilirubinemia, kernicterus, 
Crigler-Najjar syndrome, Gilbert’s syndrome, liver failure, and death.21-23 While 6TP is a currently 
prescribed anticancer agent, its toxic side effects are so potent and prevalent that the administration 
of 6TP is given in an on/off strategy, allowing time for the toxic species to be cleared by the body. 
Unfortunately, this greatly reduces its therapeutic efficacy, restricts the quality of life of the 
patients taking the drug, and has ultimately limited its use as an anticancer therapy. Our laboratory 
is interested in repurposing dismissed or under-utilized anticancer therapies, such as 6TP. Noting 
the common connection between the predominate toxic side effects possibly originating in the 
bilirubin pathway, this prompted us to begin a systematic study to explore the effects of 6TP and 
its oxidative metabolites.
   The bilirubin pathway refers to the excretion of bilirubin from the body through detoxification 
in the liver.24-26 Heme groups are released when red blood cells undergo senescence, which in the 
presence of oxygen and NADPH, reduces the heme to bilirubin (11, also referred to as 
unconjugated bilirubin, UCB).24 Bilirubin is a relatively large non-polar compound that is not 
easily excreted by the body  (Figure 2A).27 The excretion of bilirubin is achieved through 





































































conjugation by UDP-glucuronyl transferase (UGT-1A) with two UDP-glucuronic acids (UDPGA, 
10) forming bilirubin diglucuronide (BDG, 12), a water-soluble and excretable compound.28, 29 
Physiologically, UDPGA (10) is formed from the oxidation of UDP-glucose (UDPG, 9) via UDP-
glucose dehydrogenase (UDPGDH).30 We have reported that 6TP and its excretion/oxidative 
metabolites inhibit UDPGDH, but not UGT-1A (Figure 2B).31 Furthermore, in vitro investigations 
revealed that 6TP and its excretion metabolites resulted in an increase in bilirubin and a decrease 
in conjugated bilirubin levels, relative to controls. While 6TP was shown to have low inhibition 
towards UDPGDH, its main excretion metabolite 6TU has a 41-fold increase in inhibition. Noting 
that the formation of 6TU via XO is rapid, we were led to investigate the other oxidative 
metabolites. Investigations of 6-thioxanthine (8, C2 hydroxyl) revealed a five-fold increase in 
inhibition towards UDPGDH and 8-OH-6TP a 20-fold increase in inhibition, relative to 6TP. From 
this, it is suggested that the C8 position is critical in the inhibition properties towards UDPGDH.31 
As such, we propose that analogs that block the C8 position of 6TP, thereby preventing oxidation 
by XO to the C8-OH, will limit, if not eliminate, inhibition of UDPGDH. We speculate that the 
reduced inhibition of UDPGDH will result in a higher concentration of the UDPGA liable pool to 
allow for conjugation of bilirubin and its excretion, thereby reducing one of the predominate toxic 
side-effects of 6TP administration. 





































































Fig. 2 (Upper) Biosynthesis of UDPGA from the oxidation of UDPG by UDPGDH and 
conjugation of bilirubin with UDPGA by UGT-1A forming the excretable bilirubin diglucuronide. 
(Lower) Inhibition profiles of 6TP and its excretion metabolites towards UDPGDH and UGT-1A.
2. Results and discussion
2.1 Hepatotoxicity Evaluation of 6-Thiopurine and 6-Thiouric acid
   Previously, our lab has shown that the excretion metabolites of 6TP, specifically those 
hydroxylated at both, or either, C2/8, possess inhibition towards UDPGDH but not UGT-1A, when 
both enzymes were screened independently in vitro .31 To further corroborate these findings and 
to give a potential correlation to in vivo effects, we set forth to investigate our initial claim that 
6TP and 6TU inhibit UDPGDH in a bio-mimic in vivo assay, via isolated perfused livers of rat 





































































hepatocytes. While it is difficult to correlate the exact enzyme being inhibited by a small molecule 
in a whole cell experiment, we decided to explore UDPGDH inhibition with regards to these two 
steps through quantification of the glucuronidated bilirubin species. Full glucuronidation of UCB 
leads to the formation of BDG (12, Figure 2), however monoglucuronidation results in two 
different monoglucuronidated bilirubin species (BMG1 and 2); in this work, both BMG1 and 2 
were quantified together (herein refered to as BMG). Rat liver hepatocytes were used for the 
assessment of formation of BMG and BDG in the presence of 6TP and 6TU at high and low 
concentrations. Table 1 shows the quantification of UCB, BMG, and BDG in hepatocytes. 
Quantification of the bilirubin species throughout this study is normalized to the BMG levels of 
the control set. 
Table 1 Hepatocyte studies with 25 and 50 M of 6TP and 5 and 10 M of 6TU. Each group is 
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Unconjugated Bilirubin Bilirubin Monoglucuronide Bilirubin Diglucuronide
   Subjecting the harvested hepatocytes to 25 M 6TP showed an overall decrease in the 
conjugation of UCB and formation of BDG; relative to the control set, UCB levels increased by 
19%, and both BMG and BDG levels were decreased by 19% and 12%, respectively. Based upon 
our previous conducted in vitro assays, this finding was not unexpected and further supports that 





































































inhibition of UDPGDH is responsible for the decrease in bilirubin conjugation and subsequent 
toxicity. Increasing the dosage of 6TP to 50 M revealed greater decrease in BMG and BDG levels, 
28% and 26%, respectively, relative to controls. The observed decrease in BMG and BDG levels 
is assumed to arise from the increased conversion of 6TP to 6TU via XO, thereby inhibiting 
UDPGDH. Treatment with 5 and 10 M of 6TU revealed potent inhibition of BMG and BDG 
formation, far greater than when 6TP was administered. When 5 M of 6TU was employed an 
increase of 31% in UCB levels was observed, relative to the controls. Furthermore, BMG and 
BDG levels decreased by 71% and 76, respectively. The levels of BMG formation decreased by 
81% and BDG levels by 86% when 10 M of 6TU was used, with an increase in UCB levels by 
42%, all relative to the controls. If the reduced BDG formation does originate from the decrease 
in the liable pool of UDPGA, addition of UDPGA to the system should allow recovery of the 
system similar to the controls. The addition of 15 M of UDPGA along with 10 M of 6TU 
resulted in the production of BDG levels similar to that of the control group, suggesting that 6TU 
does suppresses the formation of UDPGA via inhibition of UDPGDH in vivo but does not inhibit 
UGT-1A, but does require further investigations into UGT-1A itself is required to substantiate this 
claim. 
   Treatment with 10 M regorafenib, a known inhibitor of UGT-1A and proven non-inhibitor of 
UDPGDH by our group (see Supplementary Information), resulted in strong inhibition in the 
formation of both BMG (89% decrease) and BDG (96% decrease) is observed, both greater than 
6TU. When treated with 10 M regorafenib and 15 M of UDPGA a similar pattern of reduced 
BMG and BDG formation is observed. Furthermore, treatment with 10 M of regorafenib, 10 M 
6TU, and 15 M of UDPGA also showed the same profile of BMG and BDG levels. Thus, the 





































































decrease in BMG and BDG levels from regorafenib are from UGT-1A inhibition, which can be 
translated into confirming that the effects of 6TP and 6TU are upon UDPGDH and not UGT-1A. 
   With the confirmation of in vivo inhibition of UDPGDH by 6TP and 6TU, the latter being more 
potent with regards to suppressing BDG formation, the construction of 6TP analogs was 
considered the next logical step. From previously conducted in vitro investigations, it was observed 
that hydroxylation upon the C2 and C8 positions does translate into inhibition of UDPGDH.31 The 
C2 position of 6TP cannot be modified as amine installation post phosphoribosylation is required 
to form its therapeutically active form; therefore, modification of the C8 position is considered the 
only viable strategy for analog construction.
2.2 Chemistry
   Construction of C8-substituted purine systems is reported in the literature,32, 33 however the 
inclusion of the C6 thiol with C8 substitution, restricted to alkyl and phenyl analogs, is limited. In 
the efforts to construct analogs that block the C8 position from oxidation by XO, we set forth to 
construct analogs that bear halogens about the C8 position in hopes of retaining the therapeutic 
character of 6TP. Halogens were chosen for the C8 substitution, rather than alkyl or aryl 
substituents, to decrease the probability of failed DNA incorporation due to sterics about the C8 
position. Starting from the commercially available 6-chloropurine (13), protection of the N9 
nitrogen was successfully accomplished with potassium carbonate and para-methoxybenzyl 
chloride (PMBCl) to access 14 in 58% yield (Scheme 1), matching reported characterization found 
in the literature.34-36 In addition to obtaining pure 14, these conditions also allow access to the N7 
PMB protected compound (15) in 34% yield. Further synthetic elaborations were conducted upon 
14 but not 15. While 15 can be employed in the efforts of accessing C8 halogen 6TP analogs in 
the same route as 14, there is a decrease in yields using this material and will be discussed below. 





































































With 14 in hand, efforts towards the installation of halogens (bromine,37, 38 chlorine,34 and 
fluorine39) at the C8 position were undertaken through modifications of reported procedures. 
Deprotonation of the C8 hydrogen of 14 was accomplished with freshly prepared LDA; the 
lithiated species was then treated with 1,2-dibromotetrachloroethane to access the C8-bromo 
compound (16a) in 75% yield. The substitution of the 6-chloro group upon purines has precedent 
in the literature,40, 41 following these reported procedures, thiol installation with thiourea and 
ethanol reflux, afforded 17a in 92% yield over two-steps. Deprotection of the PMB protecting 
group was performed by refluxing sulfuric acid, thus, gaining access to the 8-bromo-6TP (18a) in 
81% yield, with an overall 32% yield over five synthetic transformations from 13. Additional 8-
Br-6TP (18a) was accessed from 15 by subjecting it to the same conditions with comparable yields, 
except about the thiol installation step. From the N7-PMB variant of 16a, subjection to thiol 
installation provided a 58% yield. It is thought that the additional steric congestion brought from 
the N7 PMB is the cause for the decrease in yields, as nearly 34% of starting material is recovered.
 
Scheme 1 Synthetic route accessing the bromo-, chloro-, and fluoro-C8-substituted 6TP analogs 
from 6-chloropurine.
   Following the same approach described in Scheme 1, accessing the C8 chloride and fluoride 
analogs were undertaken. Deprotonation of the C8 hydrogen of 14 was accomplished with LDA 
and subsequent treatment with hexachloroethane afforded 6,8-dichloro-N-





































































paramethoxbenzylpurine (16b) in 70% yield. In an analogous fashion, treatment with N-
fluorobenzenesulfonimide (NFSI) afforded 16c in 71% yield, with 19% of starting material 
recovered. Thiol installation was performed upon 16b and 16c accessing 17b and 17c in 89% and 
92% yields, respectively. When the same transformation was attempted upon the N7 variants, a 
suppression in yields were obtained similar to the bromine analog described previously. Removal 
of the PMB group was performed under refluxing sulfuric acid to give access to 18b and 18c in 
62% and 41% yields. The chloro- and fluoro-analogs were constructed over five-steps in overall 
yields of 22% and 16%, respectively. 
2.3 Biological evaluation of 6TP analogs
   Inhibition assessment of the synthesized C8-halogenated 6TP analogs was performed 
independently against the two enzymatic steps of the bilirubin pathway, UPDGDH and UGT-1A. 
A cytotoxicity assessment was performed against the acute lymphocytic leukemia cell line REH 
as well.
2.3.1 Inhibition Evaluation Towards UDPGDH
   To investigate the inhibition properties of the analogs towards UDPGDH, a previously disclosed 
and employed UV/Vis method was used.31 Recalling the potent inhibitory properties of the C2 
and/or C8 hydroxylated 6TP excretion metabolites towards UDPGDH, we were surprised to find 
that each of the analogs possess minimal inhibition (Table 2-D). The C8 bromine analog was 
observed to inhibit UDPGDH with a Ki of 192 M, the C8 chlorine analog was shown to have the 
strongest inhibition of the C8 halogenated 6TP analogs with a Ki of 163 M, and the C8 fluorine 
analog the weakest inhibition with an observed Ki of 215 M (Table 2 A-C). Previously, we 
reported a Ki of 288 M for 6TP towards UDPGDH, and relative to the analogs synthesized a 
similar weak inhibition profiles were observed. While the minimal inhibition possessed by the 





































































three newly constructed analogs towards UDPGDH represent a positive step in eliminating the 
toxicity associated with 6TP, further evaluation towards UGT-1A is required, as is assessment on 
whether these analogs retain a similar cytotoxicity comparable to 6TP.
Table 2 Inhibitor assessment towards UDP-glucose dehydrogenase in vitro by C8-halogenated 
6TP analogs through Lineweaver-Burk plot analysis under UDPG varying NAD+ saturating 
conditions. A) Concentration of 8-Br-6TP, varying UDPG, screened were 0, 50, 75, 100 M with 
the calculated slopes of each line equaling 0.098, 0.121, 0.132, 0.153, respectively. Plotting slopes 
versus concentration gave a regression line of y=0.0005x+0.096. B) Concentration of 8-Cl-6TP, 
varying UDPG, screened were 0, 50, 75, 100 M with the calculated slopes of each line equaling 
0.097, 0.129, 0.137, 0.156, respectively. Plotting slopes versus concentration gave a regression 
line of y=0.0006x+0.098. C) Concentration of 8-F-6TP, varying UDPG, screened were 0, 50, 75, 
100 M with the calculated slopes of each line equaling 0.106, 0.132, 0.145, 0.152, respectively. 
Plotting slopes versus concentration gave a regression line of y=0.0005x+0.108. D) Summary of 
previously determined Ki values towards UDPGDH for 6TP and its excretion metabolites; 
summary of the found Ki of synthesized analogs. Each group is an average of three independent 
runs with standard error bars shown.







































































2.3.2 Inhibition Evaluation Towards UGT-1A
  While neither 6TP or any of its oxidative metabolites were shown to have inhibition properties 
toward UGT-1A, the same cannot be assumed for the constructed analogs and, as such, assessment 
is required. To accomplish this, we employed our previously reported in vitro HPLC method for 
the assessment of UGT-1A inhibition.31 In this method, the levels of BDG formation is lower than 
physiological levels given the incubation time (45-minutes). The control showed expected 
production of BMG exceeding that of BDG. The evaluation of conjugation in the presence of 75 
M 6TP and 75 M 6TU, independently, showed similar patterns of UCB, BMG, BDG levels with 
respect to the control group, thus, indicating no inhibition by either purine towards UGT-1A, 
similar to what was previously reported and observed (Table 3). Similar to the control group and 
both 6TP and 6TU, each of the analogs were observed to have the same pattern of bilirubin levels. 
As such, no inhibition towards UGT-1A was observed with any of the 6TP analogs constructed in 





































































this study. Validation of UGT-1A activity was accomplished with the use of regorafenib, 
previously mentioned as a selective inhibitor of UGT-1A, which showed nearly full inhibition of 
UGT-1A. 
Table 3 Inhibition studies of UGT-1A by 6TP, 6TU, regorafenib, and the three C8-halogenated 
6TP analogs. Quantification of unconjugated bilirubin (UCB), monoglucuronide bilirubin (BMG, 
sum of BMG1 and 2), and diglucuronide bilirubin (BDG) accomplished via the bilirubin standard 
curve (see supplemental information). Each group is an average of three independent runs with 








































Unconjugated Bilirubin Bilirubin Monoglucuronide Bilirubin Diglucuronide
2.3.4 Cytotoxicity Evaluation against REH
   While the C8-halogenated analogs were shown to possess weak inhibition towards UDPGDH 
and no inhibition towards UGT-1A, investigations into the possible retention of cytotoxicity was 
undertaken. To explore the analogs cytotoxic properties, each analog, 6TP, 6TX, 8-OH-6TP, 6TU, 
and doxorubicin (control) was evaluated towards the acute lymphocytic leukemia cell line, REH, 
over a 48-hour period. Cytotoxicity was assessed via cellular viability, Alamar blue quantification, 
over 48 h and data was analyzed via Prism 7.0 by GraphPad Pro. 6TP was shown to have an IC50 





































































of 2.94 M (±0.48) and doxorubicin of 0.285 (±0.008) as shown in Table 4. Neither 6TU nor 6TX, 
both C2 hydroxylated purines, were observed to have cytotoxicity below 10 M in the REH 
cancerous cell line. It is thought that the lack of cytotoxicity by these two oxidative metabolites 
arises from the hydroxyl at the C2 position, thus preventing phosphoribosylation by HGPRT and 
ultimate formation of dTGTP (4). While the C2 position of TIMP does undergo C2 hydroxylation 
followed by amine installation, these steps are performed upon the nucleotide variant of 6TP and 
not the free 6TP nitrogenous base form. Furthermore, the affinity of 6TU and 6TX towards 
UDPGDH could be stronger than that of HGPRT, thus preventing formation of 4. In comparison, 
the C8 hydroxyl of 8-OH-6TP was observed to be cytotoxic, possessing an IC50 value of 9.91 M 
(±2.36). This suggests that substitution about the C8 position is tolerable, and, most importantly, 
could translate into retention of cytotoxicity. Each of the analogs were shown to possess 
cytotoxicity, with IC50 values of: 18a (C8 Br) 9.54 M (±0.97), 18b (C8 Cl) 3.95 M (±1.94), and 
18c (C8 F) 4.71 M (±1.40). 
   It is assumed that the cytotoxicity of these analogs arise from their incorporation into DNA, in a 
similar pathway and sequence to that of 6TP, but this has not been proven in this study. Assuming 
the same mode of action as 6TP, the observed lower potency of the bromine compared to the 
chlorine and fluorine analogs is thought to arise from its size. The size of bromine upon the C8 
position of the purine within the deoxyguanosine mimic could hinder DNA incorporation. 
Similarly, the increase bulk of the bromine upon the C8 position could prevent enzymatic 
recognition by the HGPRT, as well as, the other enzymatic steps leading to the formation of 4. The 
increased cytotoxicity observed by both the chlorine and fluorine analogs lend further support to 
the possible role of size in the observed trend of cytotoxicity. However, the greater cytotoxicity 
exhibited by the chlorine analog versus the fluorine analog contradicts the argument of size as a 





































































function of activity, but could also lead to an electronic argument for activity. Further 
investigations are required to fully understand the observed trend. Most importantly, through these 
analogs it was shown that substitution of the C8 position is not only tolerated, but does give access 
to 6TP analogs that retain cytotoxicity.
Table 4 Evaluation of 6TP, excretion metabolites, and synthesized 8-substituted analogs towards 
inhibition of UDPGDH and UGT-1A and cytotoxicity towards REH (acute lymphocytic leukemia) 
cancerous cell lines. All experiments were carried out in triplicate and standard error is reported.





18a (Br) 9.54 (±0.97)
18b (Cl) 3.95 (±1.94)
18c (F) 4.71 (±1.40)
Doxorubicin 0.285  (±0.08)
3. Conclusions
   Through this study, further investigations into the mode of toxicity associated with the 
therapeutic application of 6-thiopurine has been accomplished. It has been found that inhibition of 
UDPGDH, one of two critical steps in the bilirubin pathway, is highly inhibited by 6TU, the 
primary excretion metabolite of 6TP. Based upon previous structure-activity relationships of the 
excretion metabolites of 6TP, it was postulated that substitution about the C8 position could 
decrease inhibition towards UDPGDH while retaining its cytotoxic character. The synthesis of the 
C8 substituted bromine, chlorine, and fluorine analogs were successfully accomplished from 6-
chloropurine in 32%, 22%, and 16% yields, respectively, all over five synthetic steps. Each of the 





































































analogs were shown to have low inhibition (192, 163, 215 M, respectively) towards UDPGDH, 
similar to 6TP (288 M) and no inhibition towards UGT-1A. The C8-bromo analog had limited 
cytotoxicity towards the acute lymphocytic leukemia cell line REH, IC50 of 9.54 M, however the 
chloro- and fluoro-6TP analogs were shown to retain cytotoxicity with IC50 values of 3.95 and 4.71 
M, respectively. These results have effectively shown that structural modifications of 6-
thiopurine will not only retain cytotoxicity, but also decrease inhibition towards UDPGDH, a 
critical step found to be responsible for the most predominate toxic side effects of 6TP 
administration. It is anticipated that with a decrease in toxicity of new 6TP analogs, an increase in 
dosage can be administered, resulting in further increase of therapeutic properties of 6TP 
treatment. As such, newly constructed analogs of 6TP will lead to a more potent anti-leukemic 
drug that can help maintain the quality of life for patients through decreased associated toxicities.
4. Experimental Section
4.1 Chemistry
All reagents were commercially available and used without purification unless otherwise stated. 
NMR spectra were recorded with a Varian 400 MHz instrument. The chemical shifts are given in 
parts per million (ppm) relative to residual CHCl3 at  7.26 ppm or DMSO  2.50 ppm for proton 
spectra and relative to CDCl3 at  77.23 ppm or DMSO  39.52 ppm for carbon spectra, unless 
otherwise noted. Low-resolution mass spectra were obtained using a Waters Xevo-TQD via direct 
injection; samples were dissolved in methanol, filtered, and the supernatant injected. Flash column 
chromatography was performed with silica gel grade 60 (230-400 mesh). Dichloromethane 
(CH2Cl2), tetrahydrofuran (THF), toluene (PhMe), N,N-dimethylformamide (DMF), and 





































































acetonitrile (CH3CN) were all degassed with argon and passed through a solvent purification 
system containing alumina or molecular sieves. All commercially available reagents were used as 
received. All procedures including anhydrous solvents were performed with rigorously dried 
glassware under inert atmosphere.
     4.1.1. Synthesis of 6-chloro-9-(4-methoxybenzyl)-9H-purine (14). To a stirring solution of 
6-chloropurine (13; 1.5 g, 9.6 mmol, 1.0 eq.) in DMF (30 mL) was added K2CO3 (2.7 g, 19.2 
mmol, 2.0 eq.) and para-methoxybenzyl chloride (1.44 g, 10.6 mmol, 1.1 eq.) and left to stir for 
20 h. The reaction was quenched with the addition of water (1 vol. eq.) and the product was 
extracted with EtOAc (x3). The organic layers were combined, wash with brine, dried over sodium 
sulfate, and concentrated under reduced pressure. The crude material was purified via flash silica 
gel chromatography (gradient elution EtOAc:hexane of 1:2 to 9:1) to afford 14 (1.55 g, 58% yield) 
and 15 (0.9 g, 34% yield). 1H NMR (DMSO, 400 MHz)  (ppm): 8.81 (s, 1H), 8.78 (s, 1H), 7.33 
(d, J = 8.0 Hz, 2H), 6.89 (d, J = 8.1 Hz, 2H), 5.43 (s, 2H), 3.70 (s, 3H). 13C NMR (DMSO, 101 
MHz)  (ppm): 159.8, 152.3, 149.8, 148.0, 145.3, 131.5, 130.1, 128.6, 114.8, 55.8, 47.3. LRMS 
(ESI): m/z calcd for C13H11ClN4NaO:  [M+ Na]+ 297.05, found 297.12.
     4.1.2. General procedure for the synthesis of 8-substituted 6-chloro-9-(4-methoxybenzyl)-
9H-purine analogs (16a-c). To a mixture of anhydrous diisopropyl amine (1.3 eq.) in THF (0.3 
M) at -78 °C, under an argon atmosphere, was slowly added n-BuLi (1.6 M, 1.3 eq.) over 5 min. 
After 45 min of stirring at -78 °C purine 14 (1 eq.) in THF (0.1 M) was added slowly, followed by 
2.5 eq. of a prepared 1 M anhydrous solution of halogenating reagent in THF over 15 min. The 
mixture was allowed to room temperature slowly, and was then quenched with saturated 
ammonium chloride, and the product was extracted with CH2Cl2 (x3). The organic layers were 





































































combined, dried over sodium sulfate, and concentrated under reduced pressure. Product 
purification is described below. 
     4.1.2.1. 8-Bromo-6-chloro-9-(4-methoxybenzyl)-9H-purine (16a): The crude material was 
purified via flash silica gel chromatography (Et2O:hexane 1:1) to afford 16a in 75% as a yellowish 
amorphous solid (mp: 115-117). 1H NMR (DMSO, 400 MHz)  (ppm): 8.81 (s, 1H), 7.23 (d, J=8.4 
Hz, 2H), 6.88 (d, J=8.4 Hz, 2H), 5.41 (s, 2H), 3.70 (s, 3H). 13C NMR (DMSO, 101 MHz)  (ppm): 
159.7, 153.6, 152.7, 148.3, 136.2, 131.8, 129.6, 127.6, 114.9, 55.8, 47.9. LRMS (ESI): m/z calcd 
for C13H10ClBrN4NaO+:  [M+Na+] 374.96, found 375.08. 
     4.1.2.2. 6,8-Dichloro-9-(4-methoxybenzyl)-9H-purine (16b): The crude material was purified 
via flash silica gel chromatography (Et2O:hexane 3:1) to afford 16b in 70% yield as a white 
amorphous solid (mp: 111-113 °C). 1H NMR (DMSO, 400 MHz)  (ppm): 8.84 (s, 1H), 7.26 (d, J 
= 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.42 (s, 2H), 3.70 (s, 3H). 13C NMR (DMSO, 101 MHz) 
 (ppm): 159.5, 152.2, 152.1, 149.6, 147.8, 131.3, 129.9, 128.4, 114.6, 55.6, 47.1. LRMS (ESI): 
m/z calcd for C13H10Cl2N4NaO+:  [M+Na+] 331.01, found 331.04. 
     4.1.2.3. 8-Fluoro-6-chloro-9-(4-methoxybenzyl)-9H-purine (16c): The crude material was 
triturated in diethyl ether and filtered (x2) to afford 16c in 71% yield as a white apmorphous solid 
(mp: 110-112). 1H NMR (DMSO, 400 MHz)  (ppm): 8.99 (s, 1H), 7.23 (d, J = 8.5 Hz, 2H), 6.72 
(d, J = 8.5 Hz, 2H), 6.06 (s, 2H), 3.63 (s, 3H). 13C NMR (DMSO, 101 MHz)  (ppm):159.7, 152.7, 
146.5, 139.2 & 136.26 (C8), 131.8, 127.6, 114.9, 105.0, 55.8, 47.9. LRMS (ESI): m/z calcd for 
C13H10ClFN4NaO+:  [M+Na+] 315.04, found 315.03.
     4.1.3. General procedure for thiol installation (17a-c). To a stirring solution of 16 (1 eq.) in 
MeCN (0.15 M) under an argon atmosphere was added thiourea (2 eq.) and brought to reflux for 
2 h. The solvent was removed under reduced pressure to afford the thiourea purine, to which was 





































































added ethanol (1.5 volume equivalents) and refluxed. After 2 h, the reaction mixture was allowed 
to cool to room temperature, and purification for each compound is described below.
     4.1.3.1. 8-Bromo-9-(4-methoxybenzyl)-9H-purine-6-thiol (17a): Once at room temperature, the 
resulting yellow crystals were filtered via vacuum filtration, washed with diethyl ether, and left to 
dry over night to afford 17a (181 mg 92% yield) as a white amorphous solid. 1H NMR (DMSO, 
400 MHz)  (ppm): 13.52 (bs, 1H), 8.23 (s, 1H), 7.31 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 
5.26 (s, 2H), 3.70 (s, 3H). 13C NMR (DMSO, 101 MHz)  (ppm): 169.5, 164.5, 159.4, 147.1, 
144.0, 130.1, 128.5, 125.9, 114.5, 55.8, 45.6. LRMS (ESI): m/z calcd for C13H11BrN4NaOS+:  [M+ 
Na+] 372.97, found 372.95.
     4.1.3.2. 8-Chloro-9-(4-methoxybenzyl)-9H-purine-6-thiol (17b): Once at room temperature, the 
resulting yellow crystals were filtered via vacuum filtration, washed with diethyl ether, and left to 
dry over night to afford 17b (177 mg 89% yield) as a white amorphous solid. 1H NMR (DMSO, 
400 MHz)  (ppm): 13.51 (s, 1H), 8.23 (s, 1H), 7.31 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 
5.26 (s, 2H), 3.69 (s, 3H). 13C NMR (DMSO, 101 MHz)  (ppm): 169.3, 164.2, 159.2, 147.0, 
143.8, 129.8, 128.3, 125.6, 114.3, 55.5, 45.4. LRMS (ESI): m/z calcd for C13H11ClN4NaOS+:  [M+ 
Na+] 329.02, found 328.99. 
     4.1.3.3. 8-Fluoro-9-(4-methoxybenzyl)-9H-purine-6-thiol (17c): Once at room temperature, the 
resulting yellow crystals were filtered via vacuum filtration, washed with methanol, and left to dry 
over night to afford 17c (181 mg 92% yield) as a white amorphous solid. 1H NMR (DMSO, 400 
MHz)  (ppm): 13.51 (s, 1H), 8.27 (s, 1H), 7.25 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 5.26 
(s, 2H), 3.61 (s, 3H). 13C NMR (DMSO, 101 MHz)  (ppm): 176.5, 159.1, 149.9, 145.9, 140.5 & 
134.9 (C8), 130.1, 128.9, 114.1, 110.0, 55.4, 47.2. LRMS (ESI): m/z calcd for C13H11FN4NaOS+:  
[M+ Na+] 313.05, found 313.05.





































































     4.1.4. General procedure for PMB deprotection. Under the protection of an argon 
atmosphere, concentrated sulfuric acid (2 eq.) was added drop wise to a stirring solution of 17 (1 
eq.) in PhMe (0.085 M) and allowed to stir. After 2.5 h, the reactions were purified via the 
procedures described below.
     4.1.4.1. 8-Bromo-9H-purine-6-thiol (18a): The PhMe was decanted off, and the residue was 
triturated with Et2O and filtered via vacuum filtration to obtain red/orange crude crystals. The 
water-soluble impurities were removed by partially dissolving the material in water, gently heating 
the mixture, and then allowed to cool to room temperature. The resulting yellow crystals that 
formed were collected by vacuum filtration and washing with Et2O to obtain 18a in 81% yield. 1H 
NMR (DMSO, 400 MHz)  (ppm): 13.70 (bs, 1H), 8.50 (s, 1H). 13C NMR (DMSO, 101 MHz)  
(ppm): 176.2, 165.0, 148.7, 137.4, 133.1. LRMS (ESI): m/z calcd for C5H3BrN4NaS+:  [M+ Na]+ 
252.92, found 252.92. 
     4.1.4.2. 8-Chloro-9H-purine-6-thiol (18b): The PhMe was decanted off, and the residue was 
triturated with Et2O and filtered via vacuum filtration to obtain the crude crystals. The water-
soluble impurities were removed by partially dissolving the material in water, gently heating the 
mixture, and then allowed to cool to room temperature. The resulting white crystals that formed 
were collected by vacuum filtration and washing with Et2O to obtain 18b in 62% yield. 1H NMR 
(DMSO, 400 MHz)  (ppm): 13.71 (bs, 1H), 13.51 (bs, 1H), 8.52 (s, 1H). 13C NMR (DMSO, 101 
MHz)  (ppm): 177.5, 165.3, 148.5, 135.1, 131.9. LCMS (ESI): m/z calcd for C5H3ClN4NaS+:  
[M+ Na]+ 208.97, found 208.91. 
     4.1.4.3. 8-Fluoro-9H-purine-6-thiol (18c): The PhMe was decanted off, and the residue was 
triturated with Et2O and filtered via vacuum filtration to obtain the crude crystals. The resulting 
solid was then dissolved in a minimum amount of warm ethanol, followed by a slow addition of 





































































NaHCO3 (aq) forming a pale-yellow cloudy solution. Dropwise addition of 1 M HCl (aq) to a pH of 
2.5 gave a transparent solution that upon cooling to 0 °C afforded yellow/orange crystals, which 
were filtered and rinsed with cold ethanol (x3) and left to dry to obtain 18c in 41% yield. 1H NMR 
(DMSO3, 400 MHz)  (ppm): 13.68 (bs, 1H), 12.42 (bs, 1H), 8.28 (s, 1H). 13C NMR (DMSO, 101 
MHz)  (ppm): 177.1, 168.9, 159.2, 153.1 & 149.9 (C8), 133.7. LCMS (ESI): m/z calcd for 
C5H3FN4NaS+:  [M+ Na]+ 193.00, found 192.97.
4.2. Biological
4.2.1. UDP-Glucose Dehydrogenase Inhibition Assay
   Inhibitor Assessment – General Procedure: Spectrometric analysis was performed on a Hewlett-
Packard 8452 Diode Array UV/Vis spectrometer equipped with a Lauda Brinkman Ecocline RE 
106 E100 circulating water bath. The water bath was maintained at 25 °C and the diode array was 
set at 340 nm, both were allowed to warm up 10-minutes prior to analysis. To a 1 mL cuvette, 300 
mL of 0.5 M Gly-Gly (0.15 M final concentration), nanopure water, varying NAD+ and UDPG 
concentration in varying inhibitor concentrations were added and placed in the diode array for a 2 
min thermal equilibration. Once 1.5 minutes elapsed, the instrument was zeroed to obtain an initial 
rate change in absorbance versus time. The reaction was initiated by addition of 20 L of the 
UDPGDH solution. Thorough mixing by inversion of the cuvette was performed as quickly as 
possible and then placed in the holder for analysis. The reaction was monitored from 20 to 120 
seconds after enzyme addition, and the slope was calculated from 20 to 40 seconds using the diode 
array software. 
   4.2.1.1 Inhibitor Assessment – Saturating NAD+ varying UDPG concentration: For each 
analysis, the cuvette was prepared in the same fashion as outlined above. The final concentration 





































































of the components of the mixture were 150 mM Gly-Gly, 0.1 unit/mL UDPGDH, 3 mM NAD+ 
and varied concentrations of 0.1, 0.05, 0.025 and 0.02 mM of UDPG, obtained from stock solution 
addition. Nanopure water was used as a variable component to ensure that a final volume of 1 mL 
was obtained. Inhibitor analysis of the four purines was performed at two concentrations: 50 and 
100 M for 6TP, 20 and 50 M for 6TX and 8OH-6TP, and 5 and 10 M for 6TU, obtained from 
their corresponding stock solutions. Each assessment was performed in triplicate. The average of 
the three were plotted and the slopes were used to determined inhibition values. 
4.2.2. UDP-glucuronosyltransferase activity assay
   4.2.2.1. Quantification of Bilirubin, and Mono/Di-glucuronide Levels: Bilirubin was quantified 
directly from the generated standard curve (see Supplementary Information). A total of ten peaks 
for the glucuronide species, including their isomers were detected in the incubation samples. Peak 
assignment and identification of UCB, BMG1, BMG2, BDG and their isomers were based on their 
lipophilicity and polarity, as well as the elution pattern, chromatographic peak position and relative 
retention time from previous reports.21-23, 42 The calibration curves for bilirubin were used to 
determine the concentration of the mono- and di-glucuronide species employing the gradient 
HPLC bilirubin method described above. Quantification of UDPGA levels was determined 
through the use of the constructed standard curve within the isocratic HPLC method developed for 
UDGPA. 
   Bilirubin Glucuronide Formation: Bilirubin glucuronidation was performed at 37 °C in a 
shaking water bath. All steps taken were performed in the lowest light conditions possible; the 
glucuronide formed was found to be unstable to ambient lighting. The following was added to an 
Eppendorf tube to achieve the final concentrations indicated, final volume 200 L: potassium 
phosphate buffer (50 mM, pH 7.4), bilirubin (10 M), MgCl2•6H2O (0.88 mM), rat liver 





































































microsomes (RLM, 100 g of protein/mL), alamethicin (22 g/mL), and allowed to pre-incubated 
for 2 min. Addition of UDPGA (3.5 mM), referred to as the zero-time point, initiated the reaction. 
The mixture was allowed to shake at 37 °C for each of the time course experiments. To each 
reaction 600 L of ice-cold methanol containing 200 mM ascorbic acid was added to terminate 
the enzymatic reaction, vortexed for 2 min, and then centrifuged at 12,000 rpm for 10 min. The 
supernatant was then analyzed by the developed gradient HPLC protocol for separation and 
quantification of UCB, BMG1, BMG2, and BDGs.
   Validation of Bilirubin Glucuronide Formation: Quantification of UCB, BMG1&2 and BDGs 
were performed post the quenching of UGT1A1, which was performed by immersing the 
Eppendorf tube with the reaction mixture in a cold-water bath for two min. No ascorbic acid was 
used, as the residual material would quench the glucuronidase enzyme to be added. To this sample 
0.1 mg/mL glucuronidase enzyme was added, inverted (x3), and then analyzed by the HPLC 
protocol developed to quantify the levels of bilirubin and BMG1&2 and BDGs for formation 
confirmation.
   4.2.2.2. Inhibitor Assessment of Bilirubin Glucuronide Formation: Employing the same protocol 
delineated above for the formation of the bilirubin glucuronide species, inhibitor assessment was 
performed. To the Eppendorf tube, the purine (50 and 75 M final concentrations) was added 
alongside a control (no purine added) and allowed to pre-incubate for 2 min. Addition of UDPGA 
initiated the reaction for each of the time course experiments. The gradient HPLC method was 
employed for the 45-min time course experiments for the quantification of the glucuronide species. 
4.2.3. IC50 Value Determination in REH using Alamar Blue Quantification





































































   The acute lymphocytic leukemia cell line REH was grown in media supplemented with fetal 
bovine serum (FBS) and antibiotics (100 g/mL penicillin and 100 U/mL streptomycin). Cells 
were incubated at 37 °C in a 5% CO2, 95% humidity atmosphere. Cellular viability was determined 
by quantification via Alamar blue. 
   General Procedure: Compounds were solubilized in DMSO (10 M stock solutions) and added 
to a 96-well plate over a range of concentrations (31.6 nM to 200 M) with media, and 40 L was 
added to the 384-well plate in triplicate for each concentration of compound. Cells were then added 
to the plate (2,000 cells/well) in 10 L of media. After 69 h of continuous exposure, 5 L of Alamar 
Blue was added to each well, and the cells were allowed to incubate for an additional 3 h. The 
plates were then read for fluorescence intensity with an excitation of 560 nm and emission of 590 
nm on a BioTek Synergy H1 plate reader. Doxorubin and etoposide were both used as positive 
death controls, and wells with no compounds added as negative death controls. IC50 values were 
determined from three or more independent experiments using GraphPad Prism 7.0. (LaJolla, CA, 
USA) 
4.2.4 Investigations into UDPGDH Inhibition by 6TP and 6TU in Hepatocytes
   A male Sprague-Dawley rat was housed in an animal care room, kept at 25 °C with a 12 h 
light/dark cycle, and had free access to food and water. The rat was anesthetized by IP injection of 
ketamine/xylazine mixture (ketamine 100 mg/kg and xylazine at 15 mg/kg). Rat hepatocytes were 
isolated through the procedure outlined by Ogimura43 and Ito.44 Through the portal vein and 
inferior vena cava was inserted an IV cannula. The liver was washed with a perfusion solution 
(Ca2+ free, EDTA-containing perfusion buffer) for 10 min, followed by a perfusion with a 
collagenase containing buffer. Hepatocytes were isolated, filtered through a sterile nylon mesh, 
and purified via a Percoll solution, and washed with WME media (comprised of 10% FBS, 5% 





































































penicillin and streptomycin, and 22 g/mL alamethicin). Hepatocyte viability was assessed by 
Trypan blue exclusion, and cells with viabilities of >90% were used for the study. Cells were 
seeded onto a collagen-coated tissue culture plate, density of 500,000 cells/well, in 1 mL of WME 
media in a 12-well plate and incubated at 37 °C in a 5% CO2, 95% humidity atmosphere. Following 
the procedure established by Ito,44 cell media was exchanged and the hepatocytes were left to grow 
for 5 days. 
   Assessment: Hepatocytes were transferred to a 24-well plate (20,000 cells/well) in 500 of HWE 
media and allowed to adhere for 24 h. The media was removed and replaced with 1 mL of a buffer 
solution comprised of: HWE, bilirubin (10 M), MgCl2•6H2O (0.88 mM), alamethicin (22 
g/mL), and 15 M UDPG and left to incubate. To this buffered solution was added the purines 
of interest, as well 15 M UDPGA and 10 M of regorafenib. The addition of the buffered solution 
was considered the 0-min time point. After 24 h, the liquid mixture was transferred to labelled 
Eppendorf tubes and 2 mL of trypsin was added to well and left to incubate for 20 min at which 4 
mL of WME media was added. The 6 mL of the cell mixture was then centrifuged (10,000 g, 2 
min), the supernatant removed, washed three times with PBS buffer via gentle resuspension and 
centrifugation. The pellet was treated with 0.7 mL of a lysis solution (ETA, SDS, Tris HCl at pH 
8.00) and 600 L of ice-cold methanol containing 200 mM ascorbic acid was added to terminate 
the enzymatic reaction, vortexed for 2 min, centrifuge at 20,0000 x g for 15 min (pellet large 
cellular debris), the supernatant was added to the original liquid and assessed for UCB, BMG, and 
BDG levels via the HPLC previously described.
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